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General introduction
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General introduction
Osteoarthritis (OA) is a common, chronic joint disease occurring (mostly) in middle-aged and 
elderly persons, and characterized by pain and disability. Knee, hand and hip are the joints 
most commonly affected by OA and registered in general practice.[1, 2] Although OA is not a 
life-threatening disease, the symptoms of pain and disability can have considerable impact 
on a person’s activities of daily living. The global burden of knee and hip OA has recently been 
compared to other diseases in which the burden of the diseases was measured by means 
of Years Lived with Disability (YLD).[3] Hip and knee OA were ranked as the 11th highest 
contributor to global disability (of the 291 diseases studied); from 1990 to 2010 the YLD for 
hip and knee OA increased from 10.5 million to 17.1 million and was the fastest increasing 
contributor.[3] In the last 20 years the prevalence of OA has risen by 24% in males and by 17% 
in females.[4] Moreover, healthcare costs in the Netherlands have almost doubled from 530.5 
million in 2003 to 1.1 billion in 2011. Hospital care, including joint replacement, accounts for 
most of these costs (54%).[5] Due to an aging society and an increase in obesity the incidence 
of OA will further increase, with an estimated rise of almost 40% between 2011 and 2030.[6]
OA is characterized by a slowly progressive change of synovial joint tissues, including 
cartilage destruction and alterations of the bone and synovial tissue. The main characteristics 
of OA are cartilage loss, formation of new bone at the joint margins (osteophytes), increased 
thickening of the bone structure (subchondral sclerosis) and cyst formation.[7] Patients with 
OA generally suffer from joint pain, tenderness, limited joint motion, disability, crepitus, and 
swelling of the affected joint.[7]
Hip osteoarthritis
Hip OA is a common musculoskeletal disease in the Netherlands with a prevalence of 9.6/1000 
in males and 19.6/1000 in females, and an incidence of 0.9 in males and 1.6 in females.[8] 
Currently, because no treatment is available that can cure OA, the treatment of OA consists 
of the management of symptoms. In the Netherlands, the treatment of symptomatic hip OA 
begins in primary care. When symptoms progress and joint arthroplasty becomes an option, 
patients are usually referred to an orthopaedist. Patients with incident hip OA remain in pri-
mary care for (on average) 7 years until referral to an orthopaedic specialist.[9] Many patients 
with end-stage hip OA undergo total hip replacement (THR); in 2014 in the Netherlands a 
total of 28,026 THR procedures were performed.[10]
10
Diagnosis
Hip OA can usually be diagnosed based on clinical fi ndings.[8, 11] For research and inclusion 
of patients in clinical trials, it is advised to use the established criteria for the classifi cation of 
OA.[12] For hip OA the American College for Rheumatology classifi cation tree is most often 
used (Figure 1).[13]
 
 
 
Pain in the hip 
AND 
Internal hip rotation <15o 
ESR ≤ 45mm/hour or 
Hip flexion ≤115o if ESR unavailable 
AND 
Internal hip rotation ≥15o 
Pain associated with internal hip rotation 
Morning stiffness of the hip ≤60 minutes 
Over 50 years of age 
AND 
AND 
AND 
OR 
Figure 1 Classifi cation tree for hip OA according to the American College for Rheumatology.[13]
ESR = Erythrocyte Sedimentation Rate
Radiographic hip OA can be graded with the Kellgren and Lawrence (KL) score, ranging from 
0 to 4.[14] On radiography, a hip joint without OA features scores KL 0 and a hip joint with 
severe OA scores KL 4. This KL score is often dichotomized between the absence of radio-
graphic OA (KL 0 and 1) and the presence of radiographic OA (KL ≥2). However, although the 
severity of radiographic hip OA usually correlates well with the patient’s reported symptoms, 
this relationship cannot be used for diagnostic purposes.[15-17]
Hip pain can also occur due to pathology other than OA in the hip joint, e.g. labral pathol-
ogy, femoral head osteonecrosis, bone tumors, inguinal hernia, greater trochanter pain syn-
drome (GTPS), and radiating/radicular pain from the lumbosacral spine and sacroiliac joints.
Careful history taking and physical examination can often diff erentiate between hip OA 
and other sources.[13] However, when signs, symptoms and radiographs are atypical for hip 
OA, this can cause a diagnostic dilemma.[18]
To exclude or confi rm an intra-articular source of hip pain, an intra-articular anesthetic hip 
injection can be performed as an additional diagnostic test.[19-22] Under fl uoroscopic or 
ultrasound guidance the hip joint is injected with an anesthetic and the patient is asked to 
report the course of the severity of pain after injection. In case of an intra-articular cause of 
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hip pain, the pain should diminish or be absent after this injection for (at least) some hours. 
Although this diagnostic injection is widely used in orthopaedic practice, the diagnostic 
value of this injection is still debated. The studies that investigated the diagnostic value of 
this test included a small number of participants. Also, the results of these studies may be 
difficult to interpret because of problems related to the reference test used.[19-27]
Course of pain in hip OA
Patients with hip OA often show fluctuating pain levels. Periods of relatively mild pain are 
alternated with periods of pain flairs.[28, 29] Moreover, little is known about the mechanism 
behind these fluctuations in pain severity.[30]
Recently, biochemical markers have become a topic of research in OA. Biochemical mark-
ers, or biomarkers, are characteristics that are objectively measured and evaluated as an 
indicator of biologic or pathologic processes.[31] Biomarkers in OA originate from bone, 
synovial tissue, and articular cartilage and can be measured in serum, urine or synovial fluid.
[32] Although much work has focused on biomarkers in knee OA, limited data are available 
for hip OA.[33] In fact, no biomarker has been found that can be used as a prognostic factor 
in hip OA.[33]
A study reported that, in a longitudinal dataset of patients with hip OA, five different pain 
trajectories could be discriminated.[28] These trajectories varied from ‘highly progressive 
pain’ to ‘mild pain’. If it could be established that specific biomarkers are associated with par-
ticular trajectories, clinicians could classify patients using these biomarkers. Particularly those 
patients that are at high risk of progression could be monitored more closely and treated 
accordingly.
Patients with OA often report that their clinical symptoms are changed by weather condi-
tions such as precipitation and temperature.[34] Moreover, about 62% of patients with OA 
report being weather sensitive.[35] Temperature, barometric pressure, precipitation and 
relative humidity have been studied in patients with OA; however, in these studies none of 
the meteorological variables showed a consistent correlation with patients’ perceived pain in 
OA.[34-44] This inconsistency might be caused by differences in data collection and/or the 
definition of weather variables; e.g. some studies used multiple data per day, whereas others 
averaged the data over 24 hours.[35, 36, 41]
Hip OA and comorbidities
Another factor possibly influencing clinical symptoms in hip OA is the greater trochanter 
pain syndrome (GTPS). GTPS is a common tendinitis and/or bursitis in the hip region with an 
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incidence in general practice of 1.8 patients per 1000 per year.[45] It is defined as a tendinitis 
of the insertion of the gluteus medius or minimus muscle, or a trochanteric bursitis, or a 
combination of both.[46, 47] About 30% of patients with GTPS have concurrent low-back 
pain or hip OA.[48] In patients with hip OA the prevalence of GTPS is unknown, and it is also 
unknown whether the presence of GTPS influences the perceived pain in these patients.
Non-operative treatment
Because disease-modifying options for OA are still lacking, this has resulted in symptomatic 
treatment.[49] Non-operative treatment for hip OA consists of non-pharmacological and 
pharmacological therapies. Both focus on pain relief, maintenance of function in daily activi-
ties, and improving quality of life. If non-operative treatment fails, a total joint replacement 
can be considered; however, this is a costly operation with an intensive period of rehabilita-
tion.
International guidelines advise to begin treatment with non-pharmacological manage-
ment such as education, exercise and weight loss, and assistive devices.[50] These therapies 
can be combined with pain medication. In symptomatic OA, the first step as a first-line 
therapy is use of acetaminophen. Although this analgesic has few adverse reactions, it also 
has a small effect size (0.14) regarding pain reduction.[51] The following step is use of a non-
steroidal anti-inflammatory agent; this type of analgesic has a small-to-moderate effect size 
for pain reduction (0.29) but is known for its adverse drug reaction, particularly gastrointesti-
nal problems.[51] As a third step, opioids such as tramadol are advised.[50, 51]
When patients suffer pain despite these oral analgesics, several national and international 
guidelines recommend intra-articular corticosteroid injections for individuals with knee and 
hip OA.[50-52] In knee OA the effect of corticosteroid injections on pain reduction has been 
studied extensively. A Cochrane review of 27 trials with 1,767 participants showed moderate 
effect at 1-2 weeks (effect size 0.48) and small-to-moderate effect at 4-6 weeks (effect size 
0.41). The quality of this evidence was graded as low because most of the trials had a high 
(or unclear) risk of bias.[53] Regarding hip OA, 5 randomized controlled trials on this subject 
were published.[54-58] A recent systematic review on the efficacy of intra-articular steroids 
in hip OA included these 5 randomized controlled trials and the quality of these studies was 
judged to be high.[59] The treatment effect was strong at one-week post-injection, but de-
clined thereafter. At the 8-week follow-up, only two trials reported a reduction in pain (with 
moderate effect size).[59]
Injection into the hip joint is challenging, as the joint cannot be palpated and is adjacent to 
important neurovascular structures. An intra-articular hip injection is best performed under 
fluoroscopic or ultrasound guidance. Moreover, an intra-articular injection can lead to septic 
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arthritis and may increase the risk of prosthesis infection when shortly followed by total hip 
replacement.[60]
The systemic effect of corticosteroids had been indicated in a double-blind randomized 
controlled trial in patients with impingement shoulder pain.[61] A clinically relevant effect of 
an intramuscular corticosteroid injection might offer a less complex alternative treatment for 
patients with episodes of increased pain in hip OA.
Aims and contents of this thesis
This thesis focuses on diagnosing hip OA, the non-interventional factors associated with 
influencing the symptoms of hip OA, and the treatment effects of an intramuscular cortico-
steroid injection in patients with hip OA.
Chapter 2 presents the study protocol of our randomized controlled trial on the effective-
ness of an intramuscular corticosteroid injection versus a placebo injection on hip pain in 
patients with hip OA from general practices and orthopaedic outpatient clinics. Chapter 3 
presents and discusses the results of that trial.
Chapter 4 describes a systematic review on the usefulness of an anesthetic hip joint injec-
tion in diagnosing hip OA.
Chapter 5 reports on the associations between biochemical cartilage markers and clinical 
symptoms over a two-year period in patients with hip OA.
To gain further insight into the influence of weather conditions on clinical symptoms in 
hip OA a review was performed and is reported in Chapter 6. This chapter also describes the 
associations between weather conditions and clinical symptoms in patients with hip OA in a 
cohort study with a two-year follow-up.
Chapter 7 describes the prevalence of greater trochanter pain syndrome in patients with 
hip OA, as well as the influence of this syndrome on patients’ perceived hip pain.
Chapter 8 discusses the main findings, addresses the study limitations, and considers vari-
ous implications for daily practice and future research.
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CHAPTER 2
Effectiveness of intramuscular 
corticosteroid injection versus 
placebo injection in patients with hip 
osteoarthritis: design of a randomized 
double-blinded controlled trial
DMJ Dorleijn, PAJ Luijsterburg, M Reijman,  
M Kloppenburg, JAN Verhaar, PJE Bindels, PK Bos,  
SMA Bierma-Zeinstra
BMC Musculoskeletal Disorders 2011, 12:280
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Abstract
Background: Recent international guidelines recommend intra-articular corticosteroid 
injections for patients with hip osteoarthritis who have moderate to severe pain and do 
not respond satisfactorily to oral analgesic/anti-inflammatory agents. Of the five available 
randomized controlled trials, four showed positive effects with respect to pain reduction. 
However, intra-articular injection in the hip is complex because the joint is adjacent to impor-
tant neurovascular structures and cannot be palpated. Therefore fluoroscopic or ultrasound 
guidance is needed. The systemic effect of corticosteroids has been studied in patients 
with impingement shoulder pain. Gluteal corticosteroid injection was almost as effective as 
ultrasound-guided subacromial corticosteroid injection. Such a clinically relevant effect of a 
systemic corticosteroid injection offers a less complex alternative for treatment of patients 
with hip osteoarthritis not responsive to oral pain medication.
Methods/Design: This is a double-blinded, randomized controlled trial. A total of 135 patients 
(aged > 40 years) with hip osteoarthritis and persistent pain despite oral analgesics visiting 
a general practitioner or orthopaedic surgeon will be included. They will be randomized to 
a gluteal intramuscular corticosteroid injection or a gluteal intramuscular placebo (saline) 
injection. The randomization will be stratified for setting (general practitioner and outpatient 
clinics of department of orthopaedics). Treatment effect will be evaluated by questionnaires 
at 2, 4, 6, and 12 weeks follow-up and a physical examination at 12 weeks. Primary outcome is 
severity of hip pain reported by the patients at 2-week follow-up. Statistical analyses will be 
based on the intention-to-treat principle.
Discussion: This study will evaluate the effectiveness of an intramuscular corticosteroid 
injection on pain in patients with hip osteoarthritis.
Trial Registration: This trial is registered in the Dutch Trial Registry: number NTR2966.
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Background
Recent international guidelines recommend intra-articular (IA) corticosteroid injections for 
patients with hip osteoarthritis (OA) who have moderate to severe pain and no satisfactory 
response to oral analgesic/anti-inflammatory agents.[1] Of the five randomized controlled 
trials (RCTs) on this subject [2-6], four showed clinically significant positive effects with 
respect to pain reduction (effect size up to 1.5 at 1 week follow-up) [2, 4-6] and one showed 
no clinical benefit of an IA injection.[3] In the RCT that showed no clinical benefit of an IA 
injection, patients were biased towards a negative result having been informed they would 
receive priority for surgery if their pain worsened after injection.[3]
Because the hip joint is adjacent to important neurovascular structures and cannot be 
palpated, IA injection under fluoroscopic or ultrasound guidance is advised. However, these 
techniques are not always available, especially in a primary care setting. Moreover, apart 
from being complex, an IA hip injection can be painful for the patient and can lead to septic 
arthritis. An effective but simpler administration technique would be a welcome addition to 
the current methods to treat episodes of increased pain in hip OA.
A double-blind RCT in patients with subacromial impingement shoulder pain showed 
almost equal effectiveness of ultrasound-guided subacromial corticosteroid injection com-
pared to gluteal (systemic) injection[7]; this effect was also reported in an earlier study.[8] 
In addition, an equal or even more pronounced pain decrease was found in patients with 
concurrent hip OA or chronic low back pain in an RCT assessing the effectiveness of a local 
corticosteroid injection in patients with greater trochanteric pain syndrome.[9, 10] These 
results indicate a systemic effect of corticosteroids on pain in OA.
A clinically relevant effect of a systemic corticosteroid injection, offers a less complex alter-
native for treatment of patients with hip OA who are not responsive to oral pain medication. 
Since IA hip injection is not standard care in the Netherlands, we decided to conduct a trial 
comparing intramuscular (IM) corticosteroid injection versus IM placebo injection.
Primary objective
This RCT will assess the effectiveness of an IM gluteal corticosteroid injection versus an IM glu-
teal placebo injection for pain in patients with hip OA who have moderate to severe pain and no 
satisfactory response to oral analgesic/anti-inflammatory agents during 12-weeks follow-up.
Secondary objectives
The study will assess the effectiveness of an IM gluteal corticosteroid injection versus an 
IM gluteal placebo injection in patients with hip OA with regard to function, mobility and 
patients’ perceived improvement. Adverse reactions will be registered and an explorative 
subgroup analysis will be performed stratified for setting (general practitioner and outpa-
tient clinics of department of orthopaedics).
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Methods
Design
This is a double-blinded RCT. The Medical Ethics Committee of the Erasmus University Medical 
Center approved the trial (MEC2011-115). All patients will provide written informed consent.
Patient selection
Patients with hip OA will be recruited in primary care (general practices in the Rotterdam 
area) and via hospital referrals (orthopaedic outpatient clinics in the Rotterdam area). Treat-
ing physicians are asked to select patients with hip OA and screen them on the inclusion/
exclusion criteria (Table 1). If a patient has bilateral hip OA, the most painful hip will be 
selected as the study hip.
Procedures
Eligible patients will receive written study information from their treating physician. If they 
show interest, the physician will fax their contact data to the research team. The researcher 
will contact the patient to answer additional questions. If the patient is interested/willing to 
participate, an appointment at the research centre will be made to sign an informed consent 
form and screen on inclusion/exclusion criteria, including assessment of radiologic hip OA. 
Pelvic anteroposterior (AP) X-rays taken within 6 months prior to enrolment are accepted; 
otherwise an AP pelvic X-ray will be taken. Two researchers will independently of each other 
assess grading of hip OA according to Kellgren-Lawrence (KL).[11] If the patient meets the 
radiologic criteria for participation (KL score of ≥ 2), baseline measurement (questionnaire 
and physical examination) follows.
Randomisation
An independent pharmacy assistant will allocate each patient based on computerized 
randomization lists to either receive placebo (saline) injection or triamcinolone acetate 40 
mg injection IM. Randomization is stratified for setting (general practitioner and outpatient 
clinics of department of orthopaedics) and uses random blocks of 2 and 4.
Blinding
To assure blinding with respect to the patient, researcher and treating physician, the trial 
medication will be packed and sealed by the pharmacy of the Erasmus MC, Rotterdam. An 
independent research assistant (who is not otherwise involved in the study) will prepare 
and administer, out of sight of the patient, the injection in the upper lateral quadrant of the 
gluteal musculature. The injection will be administered in the gluteal area ipsilateral of the 
study hip.
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Table 1 Patients’ eligibility criteria.
Inclusion criteria
1. Hip OA* according to clinical ACR** criteria
2. Age > 40 years
3. Symptomatic disease for at least six months prior to enrolment
4. Radiographic evidence of OA* (Kellgren-Lawrence score ≥ 2)
5. Persistent pain despite receiving optimal doses of oral pain medication for at least 3 weeks. Pain severity (in 
rest or on walking) defined as ≥ 3 on an NRS# (0-10 range, 0=no pain)
Exclusion criteria
1. Inability to understand Dutch questionnaires
2. Systemic infection
3. Local infection
4. Systemic arthritis
5. Diabetes mellitus
6. Coagulopathy
7. Gastric ulcer
8. Current use of oral corticosteroids, DMARDs$ or immunosuppressive medication
9. Allergy to corticosteroids
10. Anticoagulant therapy (coumarins)
11. On the waiting list for total hip replacement surgery
12. IA## injection into the hip in the previous 6 months
13. Radiologic signs of osteonecrosis
14. Participation in other medical trial
15. Pregnancy or lactating female
* OA = Osteoarthritis; **ACR = American College of Rheumatology; # NRS = Numerical Rating Scale; 
$ DMARD = disease-modifying antirheumatic drugs; ## IA = intra-articular
Intervention
Patients who participate in the trial are randomized to either an IM triamcinolone acetate 
40 mg injection once or an IM saline injection once. Patients are allowed to continue their 
usual pain medication or physical therapy, but are requested not to start any new therapies 
regarding their hip OA during study follow-up.
Outcomes
Questionnaires at baseline, 2, 4, 6 and 12 weeks
All outcomes are measured at baseline and at 2, 4, 6 and 12 weeks follow-up. The primary 
outcome is severity of hip pain reported by the patient at 2 weeks. This will be measured 
with two validated questionnaires: an 11-point numerical rating scale (NRS) in rest and on 
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walking (0-10, where 0 equals no pain),[12] and the Western Ontario and McMaster Uni-
versity Osteoarthritis Index (WOMAC) pain subscale.[13] The WOMAC pain subscale will be 
converted to a 0-100 score, where 0 equals no symptoms. The WOMAC is recommended by 
the Osteoarthritis Research Society for use in clinical trials in patients with hip OA to measure 
pain and disability.[13]
Secondary outcomes include the primary outcomes at 4, 6, and 12 weeks follow-up. Addi-
tional secondary outcomes are the disease-specific WOMAC function and stiffness subscales.
[13] Both the function and stiffness subscale of the WOMAC will be converted to a 0-100 
score. Data on pain and function will also be obtained with the Hip disability and Osteoarthri-
tis Outcome Score (HOOS),[14] which was developed as an extended version of the WOMAC 
to evaluate the whole domain of patient-relevant outcome in young and active patients and 
is validated in the Dutch language.[15]
For patients’ perceived recovery a 7-point Likert scale will be used (score range 1 = ‘worse 
than ever’ to 7 = ‘major improvement’).[9, 10] Quality of life will be measured with the Euroqol 
(EQ-5D).[16] Constant and intermittent pain will be obtained with the questionnaire Intermit-
tent and Constant Osteoarthritis Pain (ICOAP) taking into account both pain intensity and 
impact on quality of life.[17] Patients’ medical consumption will be registered and adverse 
reactions noted.[9, 10] For this, a questionnaire will be used that covers the known local and 
systemic adverse reactions to corticosteroids. Data on daily pain and pain medication use will 
be obtained with a diary during the first 2-weeks follow-up.
Another secondary outcome is the difference in percentage of responders as defined by 
the OMERACT-OARSI (improvement in at least 2 of the 3 following domains: ≥20% improve-
ment in WOMAC pain, ≥20% improvement in WOMAC function, or markedly improved on the 
patients’ global assessment).[16]
At baseline various patient characteristics (gender, age, height, weight, race, education, 
marital status, occupational situation and co-morbidities) are recorded. Table 2 presents an 
overview of the parameters measured during follow-up.
Physical examination at baseline and 12-weeks follow-up
Both hip joints will be examined for presence of groin pain or peri-trochanteric pain at palpa-
tion, range of motion and pain at/during movement for flexion/extension, abduction, and 
for internal/external rotation. Hip rotations will be examined in sitting position with the hips 
and knees in 90°. Hip flexion/extension and abduction will be examined in supine position. A 
goniometer will be used to measure degrees of range of motion.[18]
To gain insight in knee and lumbar spine co-morbidity both knee joints and lumbar spine 
will be examined. Pain at palpation of the medial or lateral joint space of the knee, hydrops, 
and range of motion of flexion/extension of the knee will be registered. Pain at palpation of 
the spinous processes or sacro-iliac joints and lateroflexion and flexion of the lower spine 
(fingertip-floor distance and classic Schober test) will be examined.[19]
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Table 2 Timing of measurements and outline of primary and secondary outcome measures.
Baseline Daily 
diary for 
2 weeks
2 weeks 4 weeks 6 weeks 12 weeks
Primary outcome measures
Pain score (WOMAC*) x x x x x
Pain Score (NRS**) x x x x x x
Secondary outcome measures
Function score (WOMAC) x x x x x
Stiffness score (WOMAC) x x x x x
HOOS*** x x x x x
Quality of life (EuroQol EQ-5D) x x x x x
Constant and intermittent pain (ICOAP#) x x x x x
Use of medication x x x x x x
Medical consumption x x x x x
Adverse reactions x x x x
Perceived recovery x x x x
Others
Demographic data x
Co-morbidity x
Physical examination hip, knee and 
lumbar spine
x x
Laboratory assessment (ESR##, Hs-CRP###) x
* WOMAC = Western Ontario and McMaster University Osteoarthritis Index; ** NRS = Numerical Rating 
Score; *** HOOS = Hip disability and Osteoarthritis Outcome Score; # ICOAP = Intermittent and Constant 
Osteoarthritis Pain; ## ESR = Erythrocyte Sedimentation Rate; ### Hs-CRP = high sensitive C-reactive protein
Laboratory assessment
At baseline, two blood samples (9 ml) will be collected. One to measure the erythrocyte 
sedimentation rate, which is used for the American College of Rheumatology criteria of hip 
OA.[20] The other for high-sensitive C-reactive protein (hs-CRP) to gain insight in the inflam-
matory processes. The samples will be analyzed at the Trial Laboratory Department of the 
Erasmus MC.
Sample size
Data from the Qvistgaard et al. study (patients with hip OA from primary care and secondary 
care) were used to calculate our sample size.[6] That study showed a baseline standard devia-
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tion (SD) of 20 for pain at rest and at walking (0-100 visual analogue scale; VAS). Assuming a 
minimal clinically relevant difference of 10 points (effect size 0.5), 64 patients per group will be 
needed to show a statistically significantly difference using 80% power and with a 5% alpha.
In that same study [6] the WOMAC total score (0-96) was used with an SD of 15. Standard-
ized to a 0-100 score this SD is almost 16. Assuming an SD of 16 and an 8-point difference as 
clinically relevant (effect size 0.5), the same sample size is needed.
We checked these scores in a Dutch study population with hip OA, i.e. those with a K-L score 
of the hip ≥ 2 and a VAS pain score ≥ 30, participating in the GOAL study.[21] This showed 
they had a mean VAS score of 56.4 with an SD of 19.3, a mean WOMAC pain score of 51.2 with 
a SD of 16.4; these data are very similar to the SDs in the study of Qvistgaard et al. Therefore, 
in the planned trial, we will include 135 patients, anticipating only 5% loss to follow-up based 
on the relatively short follow-up and earlier experience with loss to follow-up.[21, 22]
Data analyses
Data analysis will be performed based on the ‘intention to treat’ principle.
Descriptive statistics will be used to describe patient’s characteristics, items of physical 
examination, and the severity of radiologic hip OA.
Linear mixed models will be used for repeated measures to analyze the continuous out-
come measures. Fixed effects will be time, time by therapy and the covariates we adjust for. 
For patients lost to follow-up, we will include all observed data in the analysis. Adjustment 
will be made for those baseline variables that change the effect estimate by more than 10%. 
Similar analyses with Generalized Estimating Equations techniques for repeated measures 
will be done for dichotomous outcome measures.
Subgroup analyses for setting will be analyzed by assessing interaction effects between 
type of intervention and setting on the primary outcomes; in addition, the estimates will 
be shown for both settings separately. We realize that these subgroup analyses will remain 
solely explorative because our sample size is not directed to powerful subgroup analyses.
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Abstract
Background: Guidelines recommend intra-articular corticosteroid injection in patients with 
painful hip osteoarthritis (OA). However, injection in the hip joint is an invasive procedure 
and best performed under fluoroscopic or ultrasound guidance. The efficacy of systemic 
corticosteroid treatment for pain reduction in hip OA is unknown.
Methods: In this randomized, double-blind, controlled trial we enrolled patients with painful 
hip OA scoring ≥3 on an 11-point numerical rating scale (NRS:0-10;0=no hip pain) despite 
the use of oral analgesics. Patients were randomized to receive either 40 mg of triamcinolone 
acetate or placebo with an intramuscular injection into the ipsilateral gluteus muscle. The 
primary outcome was severity of pain at 2-week follow-up measured with a NRS at rest and 
during walking, and with the WOMAC pain subscale (0-100; 0=no pain). Total follow-up was 
12 weeks. Data analysis was performed based on the intention-to-treat principle using linear 
mixed models for repeated measurements.
Results: Of the 107 patients randomized, 106 could be analyzed (52 in the corticosteroid 
group, 54 in the placebo group). At 2-week follow-up, compared to the placebo injection, the 
intramuscular corticosteroid injection showed a significant and clinically relevant association 
with hip pain reduction at rest (difference -1.3, 95% CI -2.3 to -0.3). Moreover, the effect of 
the corticosteroid injection persisted for the primary outcome measures during the entire 
12-week follow-up.
Conclusions: An intramuscular corticosteroid injection showed clinical effectiveness in 
patients with hip OA during 12 weeks of follow-up.
Funding: Financial support was received from the Dutch Arthritis Foundation and the 
NutsOhra Fund.
Dutch Trial Registry: NTR2966.
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Introduction
Several international guidelines recommend intra-articular (IA) corticosteroid injections for 
patients with hip osteoarthritis (OA) experiencing moderate to severe pain and not respond-
ing to oral analgesics.[1-3] A systematic review on the efficacy of intra-articular steroids in hip 
osteoarthritis included 5 randomized controlled trials (RCT) and assessed quality of the studies 
was high.[4] The treatment effect was large at one week post-injection, but declined afterwards. 
At 8 weeks there were 2 trials that reported a reduction in pain (moderate effect size).[4]
However, injection into the hip joint is challenging because the joint cannot be palpated 
and is adjacent to important neurovascular structures. An IA hip injection is best performed 
under fluoroscopic or ultrasound guidance. Moreover, an IA injection can lead to a septic 
arthritis[5], and an IA corticosteroid injection may increase the risk of prosthesis infection 
when shortly followed by total hip replacement (THR).[6]
A systemic effect of corticosteroids on joint pain has been indicated in patients with subacro-
mial impingement shoulder pain. A double-blinded RCT showed no important differences in 
effectiveness on pain of ultrasound-guided subacromial corticosteroid injection compared to 
gluteal injection.[7] A systemic effect of corticosteroids was also suggested in an RCT reporting 
the effect of local corticosteroid injection for greater trochanteric pain syndrome: patients with 
concurrent hip OA or chronic low back pain had an equal or even more pronounced decrease 
in pain.[6, 8]
If an intramuscular (IM) corticosteroid injection is shown to have a clinically relevant ef-
fect on pain, this would offer a less complex alternative treatment for episodes of increased 
pain in hip OA. Therefore, this study assessed the efficacy of an IM corticosteroid injection 
compared to an IM placebo injection on hip pain severity in patients with hip OA who were 
not responding to oral analgesics.
Methods
Trial design
This was a multicenter, double-blinded, randomized controlled superiority trial with two 
parallel groups and a follow-up period of 12 weeks: details of the study protocol are already 
published.[9] The Medical Ethics Committee of the Erasmus University Medical Center (EMC; 
Rotterdam) approved the study protocol (MEC2011-115) and all included patients provided 
written informed consent.
Patients
Patients with hip OA were invited to participate in the trial by general practitioners and orthopae-
dic surgeons located in the south-west of the Netherlands. Patients (aged >40 years) were eligible 
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for inclusion if they met the American College for Rheumatology (ACR) clinical criteria for hip OA 
during clinical screening and radiologic evidence of hip OA was present [Kellgren & Lawrence 
score (KL) ≥2].[10, 11] Patients were included if they had symptomatic disease for ≥6 months, and 
had a pain score ≥3 (scale 0-10; 0=no pain) despite the use of oral analgesics at time of inclusion.
Radiologic hip OA was scored on an anterior-posterior pelvic radiograph of (at most) 6 
months old. The radiologic grade of hip OA was scored by two researchers (DD, PKB) in-
dependently and the inter-observer reliability was κ=0.7 for KL<2 versus KL≥2. In case of 
disagreement a consensus was formed during a consensus meeting. If a patient had bilateral 
hip OA, the most painful hip was selected as the study hip.
Patients were excluded if they had diabetes mellitus, were using oral corticosteroids, had 
local/systemic infection, had presence of inflammatory rheumatic diseases (e.g. rheumatoid 
arthritis, psoriatica arthritis, spondylartropathies), coagulopathy, use of coumarins, had a 
gastric ulcer, allergy to corticosteroids, radiologic signs of osteonecrosis, had an IA injection 
in the hip in the previous 6 months, were on the waiting list for THR surgery, or were unable 
to complete questionnaires in Dutch.
Interventions
Patients received either 40 mg triamcinolone acetate or 40 mg saline (placebo) with an IM 
injection. At the research center the trial nurse administered the allocated injection in the 
upper lateral quadrant of the gluteal musculature on the ipsilateral side of the study hip.
Randomization
An independent pharmacy assistant allocated each included patient based on a computer-
ized randomization list using random blocks of 2 and 4 to either placebo (saline) injection 
or triamcinolone acetate 40 mg injection. Randomization was stratified for setting (general 
practice and orthopaedic outpatient clinic). After randomization the vials for the injections 
were prepared, packed and sealed in an identical way for both groups by the pharmacy of the 
EMC. The randomization list was available only to the pharmacy assistant.
Blinding
In this trial, the outcome assessors, patients, treating physicians, researchers (including the 
statistical analyses) and research assistants involved in data collection were blinded to the 
content of the injections. To assure blinding, the independent trial nurse not involved with 
follow-up measurements prepared and administered the injection out of sight of the patient, 
assessors, treating physicians, and the researchers. After preparation, and before injection, 
the syringe was covered with an opaque foil to assure blinding of the patient.
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Outcomes
The primary outcome was severity of hip pain at 2 weeks, measured on an 11-point numerical 
rating scale (NRS: 0-10, 0=no pain) at rest and on walking, and with the Western Ontario and 
McMaster University Osteoarthritis Index pain subscale (WOMAC pain: 0-100, 0=no symp-
toms).[12, 13]
Secondary outcomes were the primary outcomes at 4, 6, and 12-week follow-up. Additional 
secondary outcome measures were WOMAC function and stiffness, WOMAC total score, Hip 
disability and Osteoarthritis Outcome Score for pain (HOOS pain), and function in daily living 
(HOOS ADL), quality of life (EQ-5D), Intermittent and Constant Osteoarthritis Pain (ICOAP), 
and patients’ perceived recovery assessed on a 7-point Likert scale.[14-16] At all time points 
the WOMAC and ICOAP scales are presented as normalized scores (0-100, 0= no symptoms). 
The HOOS subscales are presented as normalized scores (0-100, 100= no symptoms). Also 
recorded was patients’ medical consumption, including analgesic use and adverse reactions, 
at all time points. Patients were allowed to use escape pain medication as needed.
Another secondary outcome was the percentage of responders as defined by the 
OMERACT-OARSI criteria (improvement in at least 2 of the 3 following domains: ≥20% im-
provement in WOMAC pain, ≥20% improvement in WOMAC function, or markedly improved 
on patients’ global assessment).[15] For patients’ global assessment the 7-point Likert scale 
for patients’ perceived recovery was dichotomized in ‘improved’ (scores: completely recov-
ered, almost completely recovered, and slightly recovered) and ‘not improved’ (scores: no 
change, slightly worse, significantly worsened, and worse than ever).
At baseline and at 12-week follow-up, patients visited the research center to undergo a 
physical examination of hips, spine and knees by the research assistant. At baseline, blood 
samples were collected to measure the erythrocyte sedimentation rate (ESR), and C-reactive 
protein (CRP) to gain insight in the inflammatory processes. Samples were analyzed at the 
Trial Laboratory Department of the EMC.
Sample size
We based our power calculations on the standard deviation SDs reported for a study popula-
tion with similar inclusion criteria.[17] A 10-point difference (SD 20) on the hip pain at rest and 
during walking [visual analogue scale (VAS): 0-100] was assumed to be the minimal clinically 
important difference between both groups (effect size of 0.5). With a power of 80% and an 
alpha of 5%, 64 patients per group were required (including 5% loss to follow-up=67 patients 
per group). The same sample size was needed when assuming an 8-point difference (SD 16) 
on the standardized WOMAC total score (0-100) as a clinically relevant difference between 
the groups.
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Statistical analysis
Data analysis was performed based on the intention-to-treat principle. Descriptive statistics 
were used to describe patients’ characteristics at baseline, items of physical examination, and 
the severity of radiologic hip OA. Linear mixed models with repeated measures were used for 
continuous outcomes. When patients underwent a THR, data of these patients were included 
up to the date of surgery. To model the covariance of repeated measures by patients, the 
unstructured structure was chosen, because this yielded the lowest Akaike’s information 
criterion. Fixed effects were time, and time by treatment. Analyses were adjusted for baseline 
variables that changed the effect estimate by ≥10%.
Generalized estimating equations analyses (GEE) with repeated measures were performed 
for the dichotomous outcomes perceived improvement, and the OMERACT-OARSI responder. 
Before GEE analyses, multiple imputations were performed for missing values, creating five 
imputed datasets.
The Pearson chi2 test was used to analyze differences between groups concerning medi-
cal consumption, analgesic use, and adverse events. An explorative, pre-defined, subgroup 
analysis was performed assessing the interaction effects between injections and setting 
(general practice and orthopaedic outpatient clinic) on the primary outcomes.[9]
All analyses were performed using SPSS 22 (IBM Corp. Released 2013. IBM SPSS Statistics 
for Windows, Armonk, NY, USA).
Results
Patient flow
A total of 422 invited patients contacted the research center and were screened for eligibil-
ity; of these, 92 refused to participate and 223 did not meet the inclusion criteria (Figure 1). 
Finally, 107 patients provided informed consent: 53 were randomized to the corticosteroid 
injection and 54 to the placebo injection. One patient in the corticosteroid group withdrew 
his consent just before the appointment for baseline physical examination and subsequent 
injection, because his pain had resolved spontaneously. Because this patient did not receive 
the allocated treatment, and was not willing to send us the completed baseline question-
naire or any follow-up questionnaires, he was not included in the analyses.
Recruitment
Recruitment of patients took place between September 2011 and October 2014 and follow-
up measurements were done until January 2015. Of the 107 included patients, general 
practitioners referred 81 patients and orthopaedic surgeons referred 26 patients.
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Lost to follow-up
At 6-week follow-up one patient in the corticosteroid group reported being scheduled for 
a THR; in the placebo group two patients (at 4 and 6-week follow-up, respectively) reported 
being scheduled for a THR. One patient in the placebo group was not willing to participate 
after 6 weeks due to logistical problems.
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Assessed for eligibility (n=422) 
Excluded  (n=315) 
Declined to participate (n=66) 
Do not want to receive placebo (n=26) 
Not meeting inclusion criteria (n=223) 
o No pain medication use (n=101) 
o KL<2 (n=34) 
o Pain score NRS<3 (n=23) 
o Diabetes (n=12) 
o THR / awaiting THR (n=11) 
o Anti-coagulant use (n=9) 
o Recent IA corticosteroid injection (n=6) 
o No osteoarthritis (n=6) 
o Rheumatoid arthritis (n=5) 
o Knee/back pain predominates hip pain 
(n=5) 
o Systemic corticosteroid use (n=2) 
o Inammatory disease (n=2) 
o Duration of complaints <6 months (n=1) 
o Allergy to corticosteroids (n=1) 
o Participation other trial (n=1) 
o Other (n=4) (treatment pain team, not 
Dutch speaking, blindness) 
Analysed  (n=52) 
Lost to follow-up (n=2) 
At baseline (n=1) 
THR after 6 W FU, did not complete 
nale questionnaire (n=1) 
Allocated to corticosteroid (n=53) 
Received allocated intervention (n=52) 
Not received intervention; no outcome data (n=1) 
Lost to follow-up (n=3) 
Not willing to participate after 6 W FU (n=1) 
THR after 4 W FU; not willing to participate 
after 4 weeks (n=1) 
THR after 6 W FU; did not complete nal 
questionnaire (n=1) 
Allocated to placebo (n=54) 
Received allocated intervention (n=54) 
Analysed  (n=54) 
Randomized (n=107) 
Figure 1 Flow diagram of the study participants.
NRS = numerical rating scale (0-10; 0=no pain); THR=total hip replacement; IA=intra-articular; KL=Kellgren 
& Lawrence score for hip osteoarthritis; W=weeks; FU=follow-up
Patient population
Of all patients, 52 received the allocated corticosteroid injection and 54 the allocated placebo 
injection, and were included in the analyses. Baseline characteristics of both patient groups 
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Table 1 Patients’ characteristics at baseline.
Characteristic Corticosteroid
(n= 52)
Placebo
(n = 54)
Women, n (%) 40 (77) 33 (61)
Age in years, mean (SD) 66 (11) 63 (10)
Body mass index, kg/m2, mean (SD) 27 (3.7) 28 (6.4)
Duration of symptoms, n (%) < 1 y 12 (23) 20 (37)
≥ 1 y 40 (77) 34 (63)
Referral to study by, n (%) General practitioner 39 (75) 41 (76)
Orthopedic surgeon 13 (25) 13 (24)
Kellgren & Lawrence score hip OA, n (%) KL 2 42 (81) 38 (70)
KL≥ 3 10 (19) 16 (30)
Ethnicity Dutch, n (%) 51 (98) 47 (87)
Employment, n (%) 17 (33) 23 (43)
Comorbidities (self reported)
Osteoarthritis of knee(s), n (%) 20 (39) 15 (28)
Osteoarthritis of hand(s), n (%) 12 (23) 14 (26)
Low back pain, n (%) 33 (64) 30 (56)
Signs and symptoms
Stiffness of the hip, n (%) Morning stiffness 40 (77) 35 (65)
Severity of hip pain last week NRS 0-10, 
mean (SD)
Pain at rest 4.3 (2.4) 4.2 (2.5)
Pain at walking 5.4 (2.1) 5.1 (2.3)
WOMAC 0-100, mean (SD) Total score 46 (19) 47 (18)
Pain 43 (17) 43 (17)
Impairment 47 (20) 48 (19)
Stiffness 52 (21) 48 (24)
HOOS 0-100, mean (SD) Pain 52 (17) 52 (16)
ADL 53 (20) 52 (19)
ICOAP 0-100, mean (SD) Total score 38 (18) 39 (17)
Intermittent pain 41 (21) 41 (17)
Continuous pain 34 (21) 36 (19)
EQ5D score range, mean (SD) 0.658 (0.234) 0.682(0.264)
Treatment
Frequent pain medication use*, n (%) Acetaminophen 25 (48) 26 (48)
NSAID 14 (27) 14 (26)
Opiates 8 (15) 6 (11)
Visited healthcare giver for hip OA in the 
previous 3 months, n (%)
General practitioner
Number of visits (median, range)
24 (46)
1 (1-5)
22 (41)
1 (1-3)
Physiotherapist
Number of visits (median, range)
14 (27)
6 (1-24)
22 (41)
5.5 (1-25)
Medical specialist
Number of visits (median, range)
16 (31)
1 (1-3)
18 (33)
1 (1-4)
Patients’ expected effect of injection, n (%) Much or very much 36 (69) 29 (54)
Laboratory outcomes
CRP, median (range) 2 (0-11) 1.5 (0-16)
ESR, median (range) 9.5 (2-67) 10 (2-60)
SD = standard deviation; Y = years; KL = Kellgren & Lawrence grading of radiologic hip OA; NRS = numeric 
rating scale (0 = no pain); WOMAC = Western Ontario and McMaster University Osteoarthritis Index (0 = no 
pain); HOOS = Hip disability and Osteoarthritis Outcome Score (0 = extreme problems); ADL = function in 
daily living; ICOAP = Intermittent and Constant Osteoarthritis Pain (0 = no pain); EQ5D = Euroqol; NSAID 
= non-steroidal anti-inflammatory drug; OA = osteoarthritis; CRP = C-reactive protein; ESR = Erythrocyte 
Sedimentation Rate; * Frequent pain medication use = 3-5 times/week or daily use in the past 3 weeks
339
Table 2 Results of multivariable linear mixed model analysis with repeated measurements regarding pri-
mary and secondary outcomes between the corticosteroid and placebo group.
Corticosteroid
(n=52)
Placebo
(n=54)
Difference * (95% CI) p- value
Primary outcome
NRS (rest) (0-10) 2 w 2.6 (2.3) 3.9 (2.5) -1.3 (-2.3 to -0.3) 0.01
NRS (walking) (0-10) 2 w 3.5 (2.4) 4.2 (2.5) -0.9 (-1.9 to 0.1) 0.07
WOMAC pain (0-100) 2 w 35 (18) 39 (17) -6.1 (-13.4 to 1.2) 0.10
Secondary outcome
NRS pain (rest)
(0-10)
4 w 2.8 (2.1) 3.9 (2.5) -1.2 (-2.1 to -0.2) 0.01
6 w 2.6 (2.3) 4.0 (2.6) -1.4 (-2.4 to -0.5) 0.005
12 w 3.2 (2.4) 4.2 (2.8) -1.2 (-2.3 to -0.2) 0.02
NRS pain (walking)
(0-10)
4 w 3.5 (2.2) 4.5 (2.5) -1.1 (-2.0 to -0.2) 0.01
6 w 3.4 (2.2) 4.6 (2.5) -1.4 (-2.3 to -0.4) 0.004
12 w 4.0 (2.5) 5.0 (2.7) -1.3 (-2.2 to -0.3) 0.01
WOMAC pain
(0-100)
4 w 34 (19) 39 (18) -7.0 (-14.4 to 0.4) 0.06
6 w 32 (18) 40 (20) -9.9 (-17.7 to -2.2) 0.01
12 w 33 (18) 40 (23) -9.6 (-18.0 to -1.2) 0.03
WOMAC function
(0-100)
2 w 36 (20) 43 (19) -7.6 (-15.5 to 0.4) 0.06
4 w 36 (19) 44 (21) -9.3 (-17.2 to -1.4) 0.02
6 w 36 (20) 43 (21) -8.2 (-16.5 to 0.1) 0.05
12 w 37 (19) 44 (24) -8.9 (-17.6 to -0.1) 0.05
WOMAC stiffness
(0-100)
2 w 39 (21) 47 (21) -9.4 (-17.2 to -1.6) 0.02
4 w 39 (23) 48 (23) -11.6 (-20.1 to -3.2) 0.008
6 w 38 (23) 46 (25) -10.9 (-20.1 to -1.7) 0.02
12 w 39 (25) 48 (26) -12.2 (-21.7 to -2.8) 0.01
WOMAC total
(0-100)
2 w 36 (19) 42 (18) -7.5 (-15.0 to -0.1) 0.05
4 w 36 (18) 43 (20) -8.9 (-16.4 to -1.4) 0.02
6 w 35 (19) 43 (20) -9.0 (-17.0 to -1.0) 0.03
12 w 37 (19) 44 (24) -9.4 (-17.8 to -0.9) 0.03
HOOS pain
(0-100)
2 w 59 (19) 55 (17) 6.7 (-0.7 to 14.1) 0.08
4 w 60 (18) 56 (17) 6.4 (-0.7 to 13.5) 0.08
6 w 61 (18) 54 (19) 9.0 (1.6 to 16.4) 0.02
12 w 60 (18) 54 (22) 8.7 (0.8 to 16.6) 0.03
HOOS ADL
(0-100)
2 w 64 (20) 57 (19) 7.6 (-0.4 to 15.6) 0.06
4 w 64 (19) 56 (21) 9.3 (1.4 to 17.2) 0.02
6 w 64 (20) 57 (21) 8.2 (-0.1 to 16.5) 0.05
12 w 63 (19) 56 (24) 8.9 (0.1 to 17.6) 0.05
ICOAP intermittent
(0-100)
2 w 30 (19) 37 (20) -8.0 (-16.0 to 0.1) 0.05
4 w 31 (19) 40 (21) -10.0 (-18.0 to -1.9) 0.02
6 w 28 (20) 40 (22) -13.1 (-21.4 to -4.7) 0.002
12 w 30 (20) 40 (23) -11.7 (-20.4 to -2.9) 0.009
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are presented in Table 1. Of the 106 patients, 73 (68%) were female; mean age was 64 (SD 11) 
years, and the duration of hip OA symptoms was ≥1 year for 74 (70%) patients. Of all patients, 
75% was referred to our study by general practitioners.
The estimates for the primary outcome were changed ≥10% by the KL score of hip OA 
at baseline, ethnicity, morning hip stiffness, and patients’ expected effect of the injection. 
Patients in both groups were asked to guess the allocated treatment just after the injection 
was given (corticosteroid/ placebo/ don’t know). Very few patients correctly guessed their 
allocated treatment, i.e. in the corticosteroid group 3 patients (6%) and in the placebo group 
6 patients (11%). In both groups most patients claimed not to know what treatment had 
been given, i.e. in the corticosteroid group 46 patients (89%) and in the placebo group 40 
patients (75%).
Primary outcome
At 2-week follow-up, compared to the placebo injection, the corticosteroid injection showed 
a significant and clinically relevant association with hip pain reduction at rest (between group 
difference -1.3, 95% CI -2.3 to -0.3) (Table 2). Also, at 2-week follow-up, there were no signifi-
Table 2 Results of multivariable linear mixed model analysis with repeated measurements regarding pri-
mary and secondary outcomes between the corticosteroid and placebo group. (continued)
Corticosteroid
(n=52)
Placebo
(n=54)
Difference * (95% CI) p- value
ICOAP constant
(0-100)
2 w 24 (20) 32 (21) -9.8 (-18.2 to -1.4) 0.02
4 w 25 (20) 34 (23) -10.4 (-19.0 to -1.8) 0.02
6 w 23 (21) 33 (23) -11.8 (-20.5 to -3.1) 0.008
12 w 25 (17) 36 (25) -12.2 (-20.7 to -3.8) 0.005
ICOAP total
(0-100)
2 w 27 (18) 35 (20) -8.8 (-16.3 to -1.3) 0.02
4 w 28 (18) 37 (22) -10.2 (-18.1 to -2.3) 0.01
6 w 26 (18) 37 (22) -12.5 (-20.5 to -4.4) 0.003
12 w 28 (17) 38 (23) -11.9 (-20.1 to -3.8) 0.004
quality of life
EQ-5D
2 w 0.772 (0.14) 0.711 (0.21) 0.054 (-0.017 to 
0.126)
0.14
4 w 0.742 (0.20) 0.705 (0.24) 0.029 (-0.058 to 
0.115)
0.51
6 w 0.777 (0.17) 0.712 (0.20) 0.064 (-0.012 to 
0.140)
0.10
12 w 0.757 (0.18) 0.692 (0.26) 0.080 (-0.012 to 
0.017)
0.09
Values in mean (SD); model adjusted for KL-score at baseline, ethnicity, morning stiffness and patients’ ex-
pected effect of injection; * placebo group is reference group; SD = standard deviation; 95%CI = 95% confi-
dence interval; WOMAC = Western Ontario and McMaster Universities Index (0 = no pain); NRS = Numerical 
Rating Scale (0 = no pain); HOOS = Hip disability and Osteoarthritis Outcome Score (0 = extreme problems); 
ICOAP = intermittent and constant osteoarthritis pain (0 = no pain); EQ-5D = Euroqol; w = weeks
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cant associations between corticosteroid injection and hip pain during walking and WOMAC 
pain. The results of the unadjusted linear mixed model analysis were similar (Appendix A).
Secondary outcomes
At 4, 6 and 12-week follow-up the corticosteroid injection was associated with a significant 
and clinically relevant hip pain reduction at rest and during walking (Table 2). Moreover, at 
almost all follow-up measurements, the estimates showed significant and clinically relevant 
differences in favor of the corticosteroid injection on WOMAC pain, function, stiffness, and 
total; HOOS pain and HOOS ADL; and ICOAP total, intermittent and constant. No significant 
differences between groups were found for quality of life (Table 2). At 2-week follow-up, 
perceived improvement and the OMERACT-OARSI responders showed a significant effect in 
favor of corticosteroid injection: OR 2.8 (95% CI 1.3-6.4) and OR 3.0 (95% CI 1.2-7.2), respec-
tively (Table 3).
Table 3 Results of the GEE analyses with repeated measurements regarding recovery and treatment re-
sponders between the corticosteroid and placebo group.
Corticosteroid
(n=52)
Placebo
(n=54)
OR (95% CI) p- value
Perceived 
improvement **
2 w 30 (58) 17 (32) 2.8 (1.3 to 6.4) 0.01
4 w 25 (48) 15 (28) 2.3 (1.0 to 5.3) 0.05
6 w 23 (44) 17 (32) 1.7 (0.7 to 3.8) 0.24
12 w 22 (42) 16 (30) 1.6 (0.7 to 3.6) 0.26
Responder*** 2 w 24 (46) 12 (22) 3.0 (1.3 to 7.2) 0.02
4 w 21 (40) 15 (28) 1.7 (0.7 to 4.1) 0.23
6 w 23 (44) 16 (30) 1.9 (0.8 to 4.5) 0.21
12 w 22 (42) 17 (32) 1.5 (0.6 to 3.4) 0.36
Values are n (%)* analyses adjusted for KL-score at baseline, ethnicity, morning stiffness and patients ex-
pected effect of injection; ** perceived improvement indicates scores completely improved, significantly 
improved and slightly improved; *** according to the OMERACT-OARSI criteria; GEE= Generalized Estimat-
ing Equations; OR = odds ratio; 95%CI = 95% confidence interval; w = weeks
Adverse events and medical consumption
At 2-week follow-up, 27 adverse events were reported in the corticosteroid group versus 
18 in the placebo group (Table 4). Hot flushes, headache and itching were reported most 
frequently in the corticosteroid group. There were no significant differences in medical con-
sumption between the two groups (Appendix B).
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Table 4 Adverse events in the two study groups at 2-week follow-up.
Adverse events* at 2 weeks Corticosteroid
(n= 52)
Placebo
(n= 54)
SOC Reproductive system and breast disorders
Hot flushes 8 (15) 4 (7)
Irregular menstruation 0 0
SOC Immune system disorders
Itching 4 (8) 1 (2)
Urticaria 1 (2) 0
SOC Respiratory, thoracic and mediastinal disorders
Dyspnea 0 1 (2)
Epistaxis 1 (2) 0
SOC Nervous system disorders
Headache 5 (10) 4 (7)
Cramp 2 (4) 0
Paresthesia 0 1 (2)
Sweating 2 (4) 0
SOC Musculoskeletal and connective tissue disorder
Pain in extremity 2 (4) 2 (4)
SOC Gastrointestinal disorders
Bowel complaints 0 1 (2)
Nausea 0 1 (2)
SOC General disorders and administration site condition
Pain 2 (4) 0
Fatigue 0 1 (2)
SOC Psychiatric disorders
Agitation 0 1 (2)
Nervous 0 1 (2)
Values in n (%); SOC = system organ class; * classified according to Common Terminology Criteria for Ad-
verse Events Version 4.0, National Institutes of Health National Cancer Institute
Ancillary analyses
In the explorative subgroup analyses, the effects of hip pain reduction in the corticosteroid 
group were greater for patients from orthopaedic outpatient clinics than for patients from 
general practices [NRS at rest at 2-week follow-up: between-group difference -2.3 (95% CI-
4.4 to -0.2); between-group difference in primary care -0.9 (95% CI -2.0 to 0.2)]. However, 
the results of the analyses of the interaction of setting on injections showed no significant 
interaction differences between the two groups (NRS at rest at 2-week follow-up 1.5; 95% CI 
-0.6 to 3.7).
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Discussion
This study shows that, at 2-week follow-up, compared to an IM placebo injection an IM 
corticosteroid injection is clinically effective in patients with painful hip OA with regard to 
hip pain reduction. Moreover, the clinical effectiveness of the IM corticosteroid injection 
persisted during the entire 12-week follow-up period. Also, the IM corticosteroid injection 
had a positive effect at almost all follow-up moments on other pain measures, function, and 
mobility of the hip in patients with painful hip OA.
The effect of an IA corticosteroid injection for pain reduction in hip OA has been reported 
in several RCTs.[17-20] The present study shows that systemic treatment with an IM cortico-
steroid injection is effective compared to placebo on pain reduction in patients with hip OA. 
There are several advantages of an IM injection compared with an IA hip injection. First, the 
administration is much easier without the need for ultrasound/radiologic guidance and can, 
therefore, be performed in both secondary and primary care.
Another advantage is that an IM injection has no known risk of septic arthritis. Although 
the prevalence of septic arthritis following IA corticosteroid injections is low (4.6 per 100,000 
injections), the implications are far-reaching.[5] There is often a need for operative lavage and 
prolonged antibiotic regimes.[5]
A third advantage of IM injection compared to IA injection is a reduction in the risk of 
prosthesis infection following subsequent THR implantation. An IA hip injection in the year 
preceding THR increases the risk of prosthesis infection (3.3% versus 2.4% for patients who 
did not receive IA injection), leading to early revision surgery.[6]
Strengths and limitations
An important strength of our placebo RCT is that it was blinded for outcome assessors, 
patients, treating physicians, and researchers (including the statistical analyses); also, it was 
performed without financial support from any pharmaceutical company. Secondly, we had 
a high follow-up rate, i.e. 100% at 2 weeks in both groups, which was the primary outcome 
time point. At 12-week follow-up, the follow-up rate was 98% in the corticosteroid injection 
group and 94% in the placebo group.
A limitation is that we were unable to include our pre-calculated sample size of 128 partici-
pants. Nevertheless, the results show that, with the present sample size, we were still able to 
detect significant differences on the score levels of our predefined clinically relevant cutoff 
points.
It was surprising to see that 92 patients (22%) declined to participate after receiving ad-
ditional study information, mostly because they did not want to risk receiving a placebo. 
Similarly, in their placebo-controlled trial with IA corticosteroid injection for hip OA, Lambert 
et al. found that almost 50% of their patients refused to participate to avoid the risk of being 
allocated to placebo treatment.[20] Secondly, although our patients reported moderate to 
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severe pain (NRS ≥3), the main exclusion criterion was that they had not used any analgesics 
during the past 3 weeks. It would be interesting to establish why patients with moderate to 
severe pain do not take analgesics. For hip OA little is known about patients’ preference and 
perceptions on treatment. In knee OA, although about 75% of patients use over-the-counter 
oral analgesics, they do not perceive this treatment as being the most effective; instead, 
patients perceived viscosupplementation (74.1%), narcotics (67.8%) and steroid injection 
(67.6%) as being the most effective.[21]
To exclude patients with other painful hip diseases, we set strict criteria for the presence 
of radiologic hip OA (KL ≥2). These strict criteria led to the exclusion of 8% of the screened 
patients.
A final point was the exclusion of patients with diabetes mellitus, a frequently occurring 
comorbidity in this patient population. It is well known that glucocorticoids can give rise to 
hyperglycemia in diabetic patients; this effect is highest after acute administration during 
the second to fourth week, with remission thereafter.[22] For reasons of patient safety, our 
medical ethics committee stipulated that we exclude diabetic patients from the present trial; 
this means that we cannot extrapolate our results to patients with diabetes and hip OA.
A surprising finding was that, for patients’ perceived improvement and the OMERACT-
OARSI responders, there was a significant association in favor of corticosteroid injection only 
at 2-week follow-up. There are two possible explanations for this. First, for patients’ perceived 
improvement we dichotomized the 7-point Likert scale, which resulted in less power. Sec-
ond, the answer options we provided in the questionnaire were not clearly formulated. For 
example, answer options were ‘completely recovered’, ‘almost completely recovered’ and 
‘slightly recovered’, resulting in a large step between ‘almost completely recovered’ and 
‘slightly recovered’. A better delineation would have been: ‘completely improved’, ‘markedly 
improved’ and ‘slightly improved’.
Another finding is that pain reduction after IM corticosteroid injection was still present 
at a similar degree at 12-week follow-up. Previous studies on IA corticosteroid injections in 
hip OA studies mostly showed a peak effect after 1-3 weeks, but still showed significant pain 
reduction at 8-12 weeks follow-up.[17-20] In a recent Cochrane review on IA corticosteroid 
injections in knee OA, the effects were moderate at 1-2 weeks after treatment (effect size 
0.48), small to moderate at 4-6 weeks (effect size 0.41), and small at 13 weeks after treatment 
(effect size 0.22).[23]
To gain insight into the inflammatory processes that might be present in hip OA, we 
planned to analyze high-sensitive C-reactive protein. However, we only report C-reactive 
protein because the Trial Laboratory stopped supporting measurement of high-sensitive 
CRP during the inclusion period. Nevertheless, another large cohort study (349 patients with 
hip OA and 2806 controls) showed no evidence for an association between serum C-reactive 
protein and incidence or progression of OA.[24]
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In our RCT we gave a single IM corticosteroid injection. In clinical practice, patients are 
sometimes offered multiple IA injections per year. However, there are concerns that even one 
IA corticosteroid injection may cause toxicity to chondrocytes, possibly resulting in progres-
sion of OA. This has been confirmed in in-vitro and in-vivo animal studies and needs further 
study in humans.[25, 26] It is unknown whether a single IM corticosteroid injection has a 
negative effect on chondrocytes.
Intramuscular corticosteroid injection showed to be an additional conservative treatment 
option to reduce hip pain in patients with painful hip OA. However, because it is unknown 
whether IM corticosteroid injection can effectively replace IA corticosteroid injection, more 
investigation is required. Also, future research should explore the possible negative effects 
on chondrocytes in corticosteroid treatment,[25, 26] and the effectiveness of IM injection in 
knee OA.
Based on the present results we conclude that an IM corticosteroid injection, compared to 
IM placebo, shows clinical effectiveness in patients with hip OA for at least 12 weeks follow-
up.
46
References
 1. Nelson AE, Allen KD, Golightly YM, Goode AP, Jordan JM. A systematic review of recommendations 
and guidelines for the management of osteoarthritis: The chronic osteoarthritis management 
initiative of the U.S. bone and joint initiative. Semin Arthritis Rheum 2014; 43: 701-712.
 2. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI recommendations 
for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment 
guidelines and systematic review of current research evidence. Osteoarthritis Cartilage 2007; 15: 
981-1000.
 3. Zhang W, Nuki G, Moskowitz RW, Abramson S, Altman RD, Arden NK, et al. OARSI recommenda-
tions for the management of hip and knee osteoarthritis: part III: Changes in evidence follow-
ing systematic cumulative update of research published through January 2009. Osteoarthritis 
Cartilage 2010; 18: 476-499.
 4. McCabe PS, Maricar N, Parkes MJ, Felson DT, O’Neill TW. The efficacy of intra-articular steroids in 
hip osteoarthritis: A systematic review. Osteoarthritis Cartilage 2016.
 5. Pal B, Morris J. Perceived risks of joint infection following intra-articular corticosteroid injections: 
a survey of rheumatologists. Clinical rheumatology 1999; 18: 264-265.
 6. Ravi B, Escott BG, Wasserstein D, Croxford R, Hollands S, Paterson JM, et al. Intraarticular hip 
injection and early revision surgery following total hip arthroplasty: a retrospective cohort study. 
Arthritis & rheumatology 2015; 67: 162-168.
 7. Ekeberg OM, Bautz-Holter E, Tveita EK, Juel NG, Kvalheim S, Brox JI. Subacromial ultrasound 
guided or systemic steroid injection for rotator cuff disease: randomised double blind study. BMJ 
2009; 338: a3112.
 8. Brinks A, van Rijn RM, Willemsen SP, Bohnen AM, Verhaar JA, Koes BW, et al. Corticosteroid injec-
tions for greater trochanteric pain syndrome: a randomized controlled trial in primary care. Ann 
Fam Med 2011; 9: 226-234.
 9. Dorleijn DM, Luijsterburg PA, Reijman M, Kloppenburg M, Verhaar JA, Bindels PJ, et al. Effective-
ness of intramuscular corticosteroid injection versus placebo injection in patients with hip os-
teoarthritis: design of a randomized double-blinded controlled trial. BMC Musculoskelet Disord 
2011; 12: 280.
 10. Altman R, Alarcon G, Appelrouth D, Bloch D, Borenstein D, Brandt K, et al. The American College 
of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis 
Rheum 1991; 34: 505-514.
 11. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 1957; 16: 
494-502.
 12. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a 
health status instrument for measuring clinically important patient relevant outcomes to anti-
rheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988; 15: 
1833-1840.
 13. Jensen MP, Karoly P, Braver S. The measurement of clinical pain intensity: a comparison of six 
methods. Pain 1986; 27: 117-126.
 14. Brooks R. EuroQol: the current state of play. Health Policy 1996; 37: 53-72.
 15. Hawker GA, Davis AM, French MR, Cibere J, Jordan JM, March L, et al. Development and preliminary 
psychometric testing of a new OA pain measure--an OARSI/OMERACT initiative. Osteoarthritis 
Cartilage 2008; 16: 409-414.
347
 16. Pham T, van der Heijde D, Altman RD, Anderson JJ, Bellamy N, Hochberg M, et al. OMERACT-OARSI 
initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis 
clinical trials revisited. Osteoarthritis Cartilage 2004; 12: 389-399.
 17. Qvistgaard E, Christensen R, Torp-Pedersen S, Bliddal H. Intra-articular treatment of hip osteo-
arthritis: a randomized trial of hyaluronic acid, corticosteroid, and isotonic saline. Osteoarthritis 
Cartilage 2006; 14: 163-170.
 18. Atchia I, Kane D, Reed MR, Isaacs JD, Birrell F. Efficacy of a single ultrasound-guided injection for 
the treatment of hip osteoarthritis. Ann Rheum Dis 2011; 70: 110-116.
 19. Kullenberg B, Runesson R, Tuvhag R, Olsson C, Resch S. Intraarticular corticosteroid injection: pain 
relief in osteoarthritis of the hip? J Rheumatol 2004; 31: 2265-2268.
 20. Lambert RG, Hutchings EJ, Grace MG, Jhangri GS, Conner-Spady B, Maksymowych WP. Steroid 
injection for osteoarthritis of the hip: a randomized, double-blind, placebo-controlled trial. 
Arthritis Rheum 2007; 56: 2278-2287.
 21. Posnett J, Dixit S, Oppenheimer B, Kili S, Mehin N. Patient preference and willingness to pay for 
knee osteoarthritis treatments. Patient preference and adherence 2015; 9: 733-744.
 22. Tamez-Perez HE, Quintanilla-Flores DL, Rodriguez-Gutierrez R, Gonzalez-Gonzalez JG, Tamez-
Pena AL. Steroid hyperglycemia: Prevalence, early detection and therapeutic recommendations: 
A narrative review. World journal of diabetes 2015; 6: 1073-1081.
 23. Juni P, Hari R, Rutjes AW, Fischer R, Silletta MG, Reichenbach S, et al. Intra-articular corticosteroid 
for knee osteoarthritis. Cochrane Database Syst Rev 2015; 10: CD005328.
 24. Kerkhof HJ, Bierma-Zeinstra SM, Castano-Betancourt MC, de Maat MP, Hofman A, Pols HA, et al. 
Serum C reactive protein levels and genetic variation in the CRP gene are not associated with the 
prevalence, incidence or progression of osteoarthritis independent of body mass index. Annals 
of the rheumatic diseases 2010; 69: 1976-1982.
 25. Sherman SL, James C, Stoker AM, Cook CR, Khazai RS, Flood DL, et al. In Vivo Toxicity of Local 
Anesthetics and Corticosteroids on Chondrocyte and Synoviocyte Viability and Metabolism. 
Cartilage 2015; 6: 106-112.
 26. Sherman SL, Khazai RS, James CH, Stoker AM, Flood DL, Cook JL. In Vitro Toxicity of Local Anes-
thetics and Corticosteroids on Chondrocyte and Synoviocyte Viability and Metabolism. Cartilage 
2015; 6: 233-240.
48
Appendix A Unadjusted results of the multivariable linear mixed model analysis with repeated measure-
ments regarding primary and secondary outcomes between the corticosteroid and placebo group.
Difference * (95% CI) p- value
Primary outcome
NRS (rest) (0-10) 2 w -1.3 (-2.2 to -0.3) 0.008
NRS (walking) (0-10) 2 w -0.8 (-1.7 to 0.2) 0.11
WOMAC (0-100) 2 w -4.6 (-11.4 to 2.2) 0.18
Secondary outcome
NRS pain (rest)
(0-10)
4 w -1.2 (-2.0 to -0.3) 0.01
6 w -1.4 (-2.4 to -0.5) 0.004
12 w -1.2 (-2.2 to -0.2) 0.02
NRS pain (walking)
(0-10)
4 w -1.0 (-1.9 to -0.1) 0.03
6 w -1.2 (-2.2 to -0.3) 0.008
12 w -1.1 (-2.1 to-0.1) 0.03
WOMAC pain
(0-100)
4 w -5.5 (-12.6 to 1.6) 0.13
6 w -8.5 (-15.9 to -1.0) 0.03
12 w -8.2 (-16.4 to 0.0) 0.05
WOMAC function
(0-100)
2 w -6.5 (-14.1 to 1.1) 0.09
4 w -8.4 (-16.1 to -0.6) 0.03
6 w -7.3 (-15.4 to 0.6) 0.07
12 w -8.2 (-16.9 to 0.5) 0.06
WOMAC stiffness
(0-100)
2 w -7.1 (-15.3 to 1.0) 0.09
4 w -9.4 (-18.3 to -0.6) 0.04
6 w -8.7 (-18.0 to 0.6) 0.07
12 w -9.7 (-19.7 to 0.2) 0.06
WOMAC total
(0-100)
2 w -6.2 (-13.2 to 0.9) 0.08
4 w -7.6 (-14.9 to -0.3) 0.04
6 w -7.8 (-15.5 to -0.0) 0.05
12 w -8.3 (-16.8 to 0.1) 0.05
HOOS pain
(0-100)
2 w 4.7 (-2.1 to 11.6) 0.18
4 w 4.5 (-2.4 to 11.4) 0.20
6 w 7.1 (-0.1 to 14.3) 0.05
12 w 6.8 (-1.1 to 14.8) 0.09
HOOS ADL
(0-100)
2 w 6.5 (-1.1 to 14.1) 0.09
4 w 8.4 (0.6 to 16.1) 0.03
6 w 7.4 (-0.6 to 15.4) 0.07
12 w 8.2 (-0.5 to 16.9) 0.06
ICOAP intermittent
(0-100)
2 w -7.5 (-15.2 to 0.1) 0.05
4 w -9.5 (-17.4 to -1.6) 0.02
6 w -12.7 (-20.8 to -4.6) 0.002
12 w -11.4 (-20.0 to -2.9) 0.009
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Appendix A Unadjusted results of the multivariable linear mixed model analysis with repeated measure-
ments regarding primary and secondary outcomes between the corticosteroid and placebo group. (con-
tinued)
Difference * (95% CI) p- value
ICOAP constant
(0100)
2 w -8.5 (-16.4 to -0.5) 0.04
4 w -9.2 (-17.5 to -0.8) 0.03
6 w -10.8 (-19.2 to -2.4) 0.01
12 w -11.1 (-19.5 to -2.8) 0.009
ICOAP total
(0-100)
2 w -8.0 (-15.1 to -0.8) 0.03
4 w -9.4 (-17.1 to -1.6) 0.02
6 w -11.9 (-19.7 to -4.0) 0.003
12 w -11.3 (-19.4 to -3.3) 0.006
quality of life
EQ-5D
2 w 0.061 (-0.007 to 0.129) 0.08
4 w 0.037 (-0.004 to 0.123) 0.39
6 w 0.071 (-0.002 to 0.144) 0.06
12 w 0.088 (-0.002 to 0.178) 0.06
* placebo group is reference group; SD = standard deviation; 95%CI = 95% confidence interval; WOMAC = 
Western Ontario and McMaster Universities Index (0 = no pain); NRS = Numerical Rating Scale (0 = no pain); 
HOOS = Hip disability and Osteoarthritis Outcome Score (0 = extreme problems); ICOAP = intermittent and 
constant osteoarthritis pain (0= no pain); EQ-5D = Euroqol; w = weeks
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Appendix B Co-interventions in the two study groups
Frequent pain medication use* Corticosteroid
(n= 52)
Placebo
(n= 54)
Acetaminophen, n (%) 2 w 19 (37) 25 (46)
4 w 21 (40) 26 (48)
6 w 19 (37) 24 (45)
12 w 19 (37) 25 (49)
NSAID, n (%) 2 w 13 (25) 11 (20)
4 w 12 (23) 13 (24)
6 w 9 (18) 12 (23)
12 w 12 (24) 11 (22)
Opiates, n (%) 2 w 8 (15) 8 (15)
4 w 7 (14) 8 (15)
6 w 6 (12) 7 (13)
12 w 5 (10) 6 (12)
Visited healthcare giver for hip OA, n (%)
General practitioner
Number of visits (median, range)
2 w 2 (4)
1 (1-1)
3 (6)
1 (1-2)
4 w 1 (2)
1 (1-1)
5 (9)
1 (1-2)
6 w 1 (2)
1 (1-1)
1 (2)
1 (1-1)
12 w 3 (6)
1 (1-2)
0
--
Physiotherapist
Number of visits (median, range)
2 w 9 (17)
2 (1-4)
7 (13)
1 (1-4)
4 w 8 (15)
1.5 (1-2)
8 (15)
1 (1-4)
6 w 10 (20)
1 (1-4)
8 (15)
1.5 (1-4)
12 w 7 (14)
2 (1-4)
9 (18)
1 (1-3)
Medical specialist
Number of visits (median, range)
2 w 2 (4)
1 (1)
2 (4)
1 (1)
4 w 0
--
1 (2)
1 (1)
6 w 2 (4)
1 (1)
3 (6)
1 (1)
12 w 2 (4)
1.5 (1-2)
2 (4)
1 (1)
* Frequent pain medication use = 3-5 times/week or daily use in the past 2 weeks; NSAID = non-steroidal 
anti-inflammatory drug; w = weeks
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A meta-analysis of case series.
DMJ Dorleijn, PAJ Luijsterburg, SMA Bierma-Zeinstra, 
PK Bos
Journal of Arthroplasty 2014, Jun 29(6) 1236-1242
54
Abstract
Background: To assess the diagnostic value of intra-articular anesthetic hip injection in 
patients with hip pain atypical for osteoarthritis (OA), literature was searched.
Methods: Included were studies assessing the diagnostic value of anesthetic hip injections 
in differentiating between pain caused by OA or another source. Pooled estimates of sensitiv-
ity and specificity with 95% confidence intervals (CI) were calculated.
Results: Of the 1387 potentially eligible articles, nine case series with high risk of bias could 
be included. The pooled sensitivity was 0.97 (95% CI 0.87 - 0.99). Specificity was 0.91 (95% CI 
0.83 - 0.95).
Conclusions: For clinical practice, no recommendation can be made regarding the use of 
hip injections for diagnosing hip OA. High quality, accurately reported studies are needed to 
provide better evidence on the diagnostic role of hip injection.
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Introduction
Pain in the hip region can arise from different sources, including intra-articular hip joint 
pathologies such as osteoarthritis (OA), synovitis, femoroacetabular impingement and 
labral pathology, as well as extra-articular causes such as greater trochanter pain syndrome, 
inguinal hernia, and referred pain or radicular pain from the lumbosacral spine and sacroiliac 
joints.
Although careful history taking and physical examination can often differentiate between 
hip OA and other sources, signs and symptoms are sometimes atypical, causing a diagnostic 
dilemma. Previous research provided evidence for an association between hip pain and disk 
space narrowing at disk level L1/L2 and L2/L3.[1] Moreover, the severity of radiographic hip 
OA does not always correlate with the symptoms.[2, 3]
Because therapy considered for end-stage hip OA includes total hip replacement (THR) 
surgery, it is essential to correctly evaluate the signs and symptoms.
Intra-articular anesthetic hip injection is an additional diagnostic tool to exclude or con-
firm an intra-articular source of hip pain.[4-8] Although this test is widely used in orthopaedic 
practice, the diagnostic value of this injection is not well established and most studies in-
cluded small numbers of participants.
The objective of this meta-analysis is to assess the diagnostic value of intra-articular anes-
thetic hip injection when differentiating between hip pain caused by hip OA or an alternative 
source in patients with hip pain atypical for OA.
Methods
Search strategy
A search was performed (1966 until end December 2011) in PubMed, Embase, PEDro, and the 
Cochrane Library (Cochrane database of systematic reviews, database of abstracts of reviews 
of effects, and Cochrane central register of controlled trials) to identify studies evaluating the 
diagnostic value of an anesthetic hip joint injection when differentiating between hip pain 
caused by OA, or a spinal source or another source, in patients with atypical hip pain. The 
databases were searched using a combination of different terms for the following items: “OA”, 
“hip”, “spine”, “diagnostic” and “intra-articular”. A detailed description of the full electronic 
search strategies is provided in Appendix A.
Eligibility criteria
We included all cohort studies, including randomized controlled trials and case series about 
adults with hip pain that was possibly caused by degenerative hip disease, and who had been 
given an anesthetic diagnostic injection in the hip joint. The study had to report original data 
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on a function score or pain score after the diagnostic injection, as well as a function score or 
pain score after further therapy, e.g. THR, spinal treatment.
Study selection
To identify potentially relevant studies, two authors (DD and PKB) independently evaluated 
the title and abstract on the basis of the eligibility criteria. Full-text articles were screened 
for eligibility and the reference lists of these articles were searched for additional articles. 
Disagreement was solved by discussion.
Data extraction
One author (DD) extracted the data using a standardized form. Extracted data were checked 
by a second author (PL). The following data were collected: demographic and clinical char-
acteristics (design, age and participant characteristics), how the anesthetic hip injection was 
given, the reference tests used, outcomes after consecutive therapy, and the duration of 
follow-up.
Assessment risk of bias
The included studies were assessed for their methodological quality by two authors (PL 
and SB), independently of each other, using the QUADAS2.[9] The QUADAS2 is a recently 
introduced improvement of the QUADAS[10] which was developed for quality assessment 
of diagnostic studies. The QUADAS2 consists of four domains covering the following items: 
patient selection, index test, reference standard, and flow and timing. Each item was scored 
for risk of bias (risk of bias indicated as low, high or unclear). If the answers to all signaling 
questions for a domain are “yes,” then risk of bias was judged as low. In the domain ‘patient 
selection’ the risk of bias was also judged as low if the first question was answered with “un-
clear” and the second and third questions with “yes”. If any signaling question was answered 
with “no,” the risk of bias was judged as high. Any other combination of answers to the signal-
ing questions for a domain was judged as unclear.
The items patient selection, index test, and reference standard were also scored for con-
cerns regarding applicability (low, high or unclear concern).[9] Disagreement was solved by 
discussion (Appendix B).
Outcomes and meta-analyses
Pain relief after THR was used as the main outcome measurement. Pain relief after other 
therapy (e.g. spinal treatment) was used as a secondary outcome. Diagnostic two-by-two 
tables were extracted or reconstructed using relevant data of the included studies. For each 
study, results are presented as sensitivity, specificity, positive predictive value and negative 
predictive value of the index test (intra-articular anesthetic hip injection).
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Depending on clinical homogeneity of the included studies, we calculated pooled esti-
mates of sensitivity, specificity, positive likelihood ratio and negative likelihood ratio with the 
95% confidence intervals (CI) of the diagnostic test (intra-articular anesthetic hip injection) 
for predicting pain relief after subsequent therapy including THR and for predicting pain 
relief after THR only.
Additionally, we performed a best-case and worst-case scenario analysis. In the best-case 
scenario, patients who reported pain relief after the diagnostic injection with no THR were 
considered true positive; and those who did not have pain relief after the diagnostic injection 
with unknown diagnosis were considered true negative. In the worst-case scenario, patients 
reporting pain relief after the diagnostic injection and no THR were considered false positive, 
and those with no pain relief after the diagnostic injection with unknown diagnosis were 
considered false negative. STATA version 12 was used to calculate pooled estimates.
Kappa statistics were used to calculate agreement between investigators for risk of bias of 
the selected studies (0–0.5 indicates a poor level of agreement, 0.5 to 0.7 indicates a moder-
ate level of agreement, 0.7 and above indicates a high level of agreement).
Results
Study selection
The literature search yielded 1387 potentially eligible studies. Finally, 9 articles representing 
556 patients with hip pain were included in the systematic review (Fig. 1).[4-8, 11-14]
Study characteristics
Table 1 presents the characteristics of the studies. Most studies included patients with 
concomitant hip and spine pathology or with inconclusive clinical and radiologic examina-
tions, resulting in a diagnostic dilemma. The intra-articular hip injection was often used as a 
discriminative diagnostic to decide whether the patient should receive a THR. Two studies 
had a prospective design.[7, 11] Three different anesthetic agents were used: bupivacaine, 
lidocaine and marcaine; three studies combined the anesthetic agent with a corticosteroid.
[5, 8, 13]
Pain relief after THR was scored with different measurement tools; only three studies used 
a validated scoring system for pain relief such as the Harris Hip Score (HHS) and a visual 
analogue scale (VAS).[6, 8, 14] None of the nine studies reported a validated measurement 
to evaluate pain relief following therapies for alternative diagnoses. Length of follow-up was 
not specified in three studies, and in the others ranged from 6 weeks to 65 months.
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!
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Embase n=890 
Pubmed n=949 
Cochrane Library n=11 
Pedro n=56 
 
Total n=1906 
Duplicates n=519 
Included from reference list n=1 
 
Full text assessed n=31 
Full text paper n=30 
Excluded n=22 
 
Exclusion  reaso ns 
6 narrative review, editorial, guideline or letter 
5 therapeutic trial 
2 hip osteoarthritis not in dierential diagnosis 
4 no total hip replacement 
2 index test no anesthetic injection 
1 cadaver study 
1 arthrography 
1 injection pertrochanteric 
Did not meet inclusion criteria n=1355 
Unable to obtain full text article n=1 
Congress abstract only n=1 
Included in review n=9 
 
Title / abstract n=1387 
Figure 1 Flowchart of the selection of included studies.
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Risk of bias
The quality assessment of the individual studies is presented in Table 2. Inter-observer agree-
ment for signaling questions was high (κ 0.72). Inter-observer agreement for each domain 
was moderate (κ 0.69). The reporting on whether the reference standard results were inter-
preted without knowledge of the results of the index test was poor in all studies. Because 
not all patients received the reference standard (THR), in all studies there was a high risk of 
verification bias.
Table 2 Risk of bias assessment.
Study Risk of bias Applicability concerns
Patient 
selection
Index 
test
Reference 
standard
Flow and 
timing
Patient 
selection
Index 
test
Reference 
standard
Ashok et al. [11] L L U H L H U
Crawford et al. [4] U U U H U L H
Faraj et al. [5] U H U H L U H
Illgen et al. [6] L L U H L H L
Kleiner et al. [7] U U U H H L H
Odoom et al. [12] U U U H H H H
Pateder et al. [8] L H U H H U L
Poiraudeau et al. [13] U L U H L H H
Yoong et al. [14] L U U H L H L
L = low; H = high; U = unclear
Outcome of the diagnostic test
Yoong et al used three different categories to rank the relief of pain after the diagnostic 
injection (complete relief, partial relief and no relief of pain); they also used these three cat-
egories to determine pain relief after subsequent therapy.[14] Odoom et al did not report the 
strategy for patients who did not have relief of pain after the diagnostic injection.[12] Neither 
of these two studies reported the sensitivity and specificity of the intra-articular anesthetic 
injection.[12, 14]
In the other studies,[4-8, 11, 13] the sensitivity of the intra-articular anesthetic hip injection 
to predict pain relief after THR ranged from 0.78 (95% CI 0.56 - 0.93) to 1.00 (95% CI 0.95 - 1.00) 
and specificity to predict pain relief after THR ranged from 0.67 (95% CI 0.22 - 0.96) to 1.00 
(95% CI 0.03 - 1.00) (Table 3). The positive predictive value ranged from 0.90 to 1.00 and the 
negative predictive value from 0.33 to 1.00.
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Table 3 Sensitivity, specificity and predictive values of the included studies for the intra-articular anesthetic 
hip injection to predict pain relief after THR.
Study Sensitivity (95% CI)* Specificity (95% CI) Positive predictive 
value
Negative predictive 
value
Ashok et al. [11] 0.97 (0.85 - 1.00) 0.91 (0.59 - 1.00) 0.97 0.91
Crawford et al. [4] 1.00 (0.89 - 1.00) 1.00 (0.66, 1.00) 1.00 1.00
Faraj et al. [5] 0.89 (0.71 - 0.98) 1.00 (0.80 - 1.00) 1.00 0.85
Illgen et al. [6] 0.95 (0.76 - 1.00) 0.88 (0.47 - 1.00) 0.95 0.88
Kleiner et al. [7] 0.88 (0.64 - 0.99) 1.00 (0.03 - 1.00) 1.00 0.33
Odoom et al. [12] NE NE 0.94 NE
Pateder et al. [3] 1.00 (0.95 - 1.00) 0.82 (0.48 - 0.98) 0.97 1.00
Poiraudeau et al. [13] 0.78 (0.56 - 0.93) 0.67 (0.22 - 0.96) 0.90 0.44
Yoong et al. [14] NE NE NE NE
* CI = confidence interval; NE = not estimable
Meta-analysis
The data of seven studies were pooled to calculate pooled estimates of sensitivity, specificity 
and likelihood ratios. Two studies were not included in the meta-analysis.[7, 12] The study of 
Odoom et al was excluded because it did not report the outcome pain relief of patients who 
responded negatively to diagnostic injection.[12] In the study of Kleiner et al, no patients 
with a false-positive response were reported;[7] also, as we could not calculate the specificity 
for this latter study, it was excluded from the meta-analysis.
Rather than reporting sensitivity and specificity, Yoong et al used three outcome categories 
after intra-articular injection and after surgery.[14] In order to use their data in the meta-
analysis, we dichotomized both outcomes by combining complete and partial within a single 
category. In the study of Crawford et al one patient died 10 days after THR;[4] thus, because 
the outcome after surgery is unknown this patient was also excluded from the meta-analysis.
Although 476 patients were available for the meta-analysis, data on pain relief after final 
therapy were missing for 125 patients: 75 patients who responded positively to the injection 
did not get a THR, and the diagnosis and treatment of 50 patients who responded negatively 
to the injection were unknown.
Therefore, a meta-analysis was performed with 351 patients with a pain outcome after THR, 
or after therapy for other diagnoses (Table 4).
A positive response to the diagnostic hip injection had pooled estimates of 0.97 (95% CI 
0.87 - 0.99) for sensitivity and of 0.91(95% CI 0.83 - 0.95) for specificity for predicting pain 
relief after subsequent therapy including THR. This corresponds to a positive likelihood ratio 
(LR+) of 10.6 (95% CI 5.6 - 20.1) and a negative likelihood ratio (LR−) of 0.04 (95% CI 0.01 - 
0.15). Fig. 2A shows the Receiver Operating Curve (ROC) of this meta-analysis.
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Additional analyses were performed for three different scenarios: a best-case scenario, a 
worst-case scenario and a THR-only scenario.
The best-case scenario included patients who responded positively to the injection that 
did not get a THR as true positive, and those who responded negatively to the injection with 
unknown diagnosis as true negative. The pooled estimates of sensitivity and specificity were 
0.97 (95% CI 0.91 - 0.99) and 0.93 (95% CI 0.87 - 0.97) for predicting pain relief after subse-
quent therapy including THR. This corresponds to an LR + of 14.7 (95% CI 7.3 - 29.8) and an 
LR− of 0.03 (95% CI 0.01 - 0.10).
The worst-case scenario included patients who responded positively to the injection that 
did not get a THR as false positive, and those who responded negatively to the injection 
with unknown diagnosis as false negative. The pooled estimates of sensitivity and specificity 
were 0.89 (95% CI 0.70 - 0.97) and 0.68 (95% CI 0.33 - 0.90) for predicting pain relief after 
subsequent therapy including THR. This corresponds to an LR + of 2.8 (95% CI 1.0 - 7.5) and 
an LR− of 0.16 (95% CI 0.04 - 0.57).
The THR-only scenario included patients who had received a THR and whose pain outcome 
was scored afterwards. These results are plotted in Fig. 2B. The pooled estimates of sensitivity 
and specificity for the intra-articular anesthetic injection were 0.96 (95% CI 0.87 - 0.99), and 
0.42 (95% CI 0.09 - 0.84) for predicting pain relief after THR. This corresponds to an LR + of 1.7 
(95% CI 0.7 - 3.8) and an LR− of 0.09 (95% CI 0.02 - 0.41).
Table 4 Meta-analysis of the included studies.
Pool Studies 
included
n Pooled 
sensitivity (95% 
CI)
Pooled 
specificity (95% 
CI)
Pooled positive 
likelihood ratio 
(95% CI)
Pooled negative 
likelihood ratio 
(95% CI)
All outcomes 7 351 0.97 (0.87 - 0.99) 0.91 (0.83 - 0.95) 10.6 (5.6 - 20.1) 0.04 (0.01 - 0.15)
Best case 7 476 0.97 (0.91 - 0.99) 0.93 (0.87 - 0.97) 14.7 (7.3 - 29.8) 0.03 (0.01 - 0.10)
Worst case 7 476 0.89 (0.70 - 0.97) 0.68 (0.33 - 0.90) 2.8 (1.0 - 7.5) 0.16 (0.04 - 0.57)
THR only 7 269 0.96 (0.87 - 0.99) 0.42 (0.09 - 0.84) 1.7 (0.7 - 3.8) 0.09 (0.02 - 0.41)
4 different analyses were conducted: All outcomes: this includes pain score after total hip replacement 
(THR) and pain score after other therapy; Best case: patients who responded positively to the injection that 
did not get a THR were categorized as true positive, and patients who responded negatively to the injection 
with unknown diagnosis were categorized as true negative; Worst case: patients who responded positively 
to the injection that did not get a THR were categorized as false positive, and patients who responded 
negatively to the injection with unknown diagnosis were categorized as false negative; THR only: patients 
who received a THR were analyzed
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Fig 2A Receiver Operating Curve (ROC) of pooled data; pain outcomes after total hip replacement and after 
other therapy.
HSROC = hierarchical summary receiver operating characteristic
Fig 2B Receiver Operating Curve (ROC) of pooled data; pain outcomes after total hip replacement.
HSROC = hierarchical summary receiver operating characteristic
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Discussion
This meta-analysis summarizes the available evidence on the diagnostic value of intra-
articular anesthetic hip injection in differentiating between hip pain caused by OA, spinal 
sources or other sources in adult patients with atypical hip pain.
Of the 1387 potentially eligible articles only 9 studies, with low-to-medium quality, met the 
inclusion criteria. The pooled results (of 7 studies) show that if the injection has a negative 
effect on pain relief, then this is predictive for no pain relief after THR (sensitivity of 0.97 (95% 
CI 0.87 - 0.99)). On the other hand the specificity ranged from 0.42 (95% CI 0.09 - 0.84) to 0.91 
(95% CI 0.83 - 0.95) and indicates that it is uncertain to predict pain relief after THR.
Strengths and weaknesses
An important problem of the included studies is the reference standard. All studies use THR 
as reference standard, but also had partial verification bias. For example, in our pooled analy-
ses, patients who responded positively to the diagnostic injection received a THR in 75% of 
the cases, whereas for patients who responded negatively to the injection only 15% received 
a THR. Similarly seven of the nine studies use pain outcomes after other therapy as a second 
gold standard; however, because these ‘other’ therapies are not well described, the outcomes 
are difficult to interpret. Also, low-back pain therapies might be less effective, even when 
the diagnosis is correct.[15, 16] Verification bias might lead to higher sensitivity and lower 
specificity, but our analyses show that both sensitivity and specificity increased.[17]
An important source of heterogeneity was the index test used (anesthetic injection). In 
three studies the anesthetic agent was combined with a corticosteroid.[5, 8, 13] Intra-articular 
corticosteroids have a beneficial effect on pain in hip OA and this effect is already present 
one week after injection.[18] Since two of three studies review the effect of the diagnostic 
injection on pain at two weeks follow-up, this might have increased the number of patients 
reporting pain relief.[5, 8] In sensitivity analysis, we excluded studies that combined the 
anesthetic agent with corticosteroids; this resulted in four included studies with a total of 
219 patients.[4, 6, 11, 14] The pooled estimates of sensitivity and specificity were 0.97 (95% CI 
0.87 - 0.99), and 0.92 (95% CI 0.81 - 0.97), respectively, which are similar to our results (Table 
4).
Another source of heterogeneity was the measurement of the outcome pain. Patients’ 
perceived pain after THR was measured at different time points during follow-up (ranging 
from 6 weeks to 65 months) and with various measuring instruments, such as a 5-point scale, 
patients’ satisfaction, and occurrence of complication. Only three studies used a validated 
instrument to measure pain (HHS, VAS).[6, 8, 14] We would recommend a follow-up after THR 
of at least 6 months.
Finally, a large percentage of data was missing in the meta-analysis. Perceived severity 
of hip pain after injection and after subsequent therapy was unclear for 125 (26%) of 476 
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patients. A positive response to the injection was reported for 75 of these 125 patients, but 
they did not receive a THR; although the authors provided two explanations for this, none of 
the studies recorded the reasons in a structured way. The explanations given were: patients’ 
refusal of surgery, and patients being too young to receive a THR. Of the 125 patients, 50 
(40%) responded negatively to the injection, but the final diagnosis and treatment were not 
described. Our analysis of the best-case scenario and worst-case scenario revealed the influ-
ence of these missing data.
There was a high inter-observer agreement in quality assessment of the included articles. 
Because the QUADAS2 was recently published, it has not been extensively used and compari-
son with other reviews using this second version is not yet possible. However, the interob-
server agreement presented by Whiting et al in their QUADAS2 article showed a considerable 
range (overall kappa for the four domains 0.00 to 1.00);[9] they did not assess the agreement 
for signaling questions.
Implications for clinical practice and research
An intra-articular anesthetic hip injection is a diagnostic test that is used in a patient group 
with atypical signs and symptoms when diagnosis of hip OA is difficult to establish. It is used 
in orthopaedic practice with significant implications for treatment strategy: including the 
decision for a THR.
This review indicates that there is little evidence available for the use of intra-articular in-
jections for the diagnosis of hip OA (9 out of 1387 studies). Moreover, the available evidence 
had a high risk of bias. Based on the available evidence, we can only very cautiously conclude 
that a negative effect on pain relief is predictive for no pain relief after THR. On the other hand 
with a positive effect on pain relief after injection it is uncertain to predict pain relief after 
THR. For clinical practice, no recommendation can be made regarding substantiated favoring 
or not favoring the use of intra-articular injections for the diagnosis of hip OA.
High quality and accurately reported diagnostic studies are needed to provide better 
evidence on the role of intra-articular anesthetic hip injection in differentiating between 
hip OA, spinal source and other sources of pain. Therefore, future studies, preferably a well-
designed large prospective cohort, should place more focus on the subsequent treatment 
and outcome(s) of patients who responded negatively to the diagnostic injection.
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Appendix A Description of the electronic search strategies.
PubMed (((osteoarthritis[tw] OR bursitis[tw] OR degenerative joint disease[tw] ) AND (hip[tiab] OR 
hip[mh] OR hip joint[mh] OR spine[tw] OR lumbar vertebrae[tw] )) OR Back pain*[tw] OR hip 
pain*[tw] OR backache*[tw] OR back-ache*[tw] OR Vertebrogenic Pain*[tw]) AND (Injections, 
Intra-Articular[tw] OR (injection*[tw] AND (anaesthetic[tw] OR anesthetic[tw] OR diagnostic[tw] 
OR back pain/diagnosis[mh] OR osteoarthritis/diagnosis[mh] OR bursitis/diagnosis[mh] OR 
intra-articular[tw] OR intraarticular[tw]))) NOT (editorial[pt] OR letter[pt]) NOT (animals[mh] NOT 
humans[mh])
Embase osteoarthritis:de,ab,ti OR bursitis:de,ab,ti OR ‘degenerative joint disease’:de,ab,ti AND 
(hip:de,ab,ti OR ‘hip joint’:de,ab,ti OR spine:de,ab,ti OR ‘lumbar vertebrae’:de,ab,ti) OR 
(back NEXT/1 pain*):de,ab,ti OR (hip NEXT/1 pain*):de,ab,ti OR backache*:de,ab,ti OR (back 
NEXT/1 ache*):de,ab,ti OR (vertebrogenic NEXT/1 pain*):de,ab,ti AND (‘intraarticular drug 
administration’/de OR ((injection* NEAR/5 (anaesthetic OR anesthetic OR diagnostic OR ‘intra 
articular’ OR intraarticular)):de,ab,ti OR ‘backache’/exp/dm_di OR ‘osteoarthritis’/exp/dm_di OR 
‘bursitis’/exp/dm_di AND injection*:de,ab,ti)) NOT (editorial:pt OR letter:pt) NOT ([animals]/lim 
NOT [humans]/lim)
Cochrane (“diagnos* in Title, Abstract or Keywords and hip in Title, Abstract or Keywords in Cochrane 
Database of Systematic Reviews”)
PEDro (diagnos* AND hip in Title, abstract)
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Appendix B Risk of bias assessment.
QUADAS2: Domains and signaling questions
Risk of bias
Domain
Patient selection Q: Could the selection of patients have introduced bias?
1 SQ: Was a consecutive or random sample of patients enrolled?
2 SQ: Was a case-control design avoided?
3 SQ: Did the study avoid inappropriate exclusions?
Index test Q: Could the conduct or interpretation of the index test have introduced bias?
1 SQ: Were the index test results without knowledge of the results of the reference 
standard?
2 SQ: If a threshold was used, was it pre-specified?
Reference standard Q: Could the reference standard, its conduct, or its interpretation have introduced 
bias?
1 SQ: Is the reference standard likely to correctly classify the target condition?
2 SQ: Were the reference standard results interpreted without knowledge of the 
results of the index test?
Flow and timing Q: Could the patient flow have introduced bias?
1 SQ: Was there an appropriate interval between the index test and the reference 
standard?*
2 SQ: Did all patients receive a reference standard?
3 SQ: Did patients receive the same reference standard?
4 SQ: Were all patients included in the analysis?
Applicability
Domain
Patient selection Q: Are there concerns that the included patients and setting do not match the 
review question?
Index test Q: Are there concerns that the index test, its conduct, or its interpretation differs 
from the review question?
Reference standard Q: Are there concerns that the target condition as defined by the reference 
standard does not match the question?
Q = question, SQ = signalling question
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Summary
Objectives: To assess associations between uCTX-II or uCIIM and severity of hip pain in pa-
tients with mild-moderate hip osteoarthritis (OA) over a 2-year period, and establish whether 
the level of these biomarkers at baseline could estimate a specific trajectory of hip pain.
Design: A cohort study with a 2-year follow-up and 6-monthly measurements of urinary 
biomarkers (uCTX-II and uCIIM) and symptom severity. Patients were recruited from general 
practices. The primary outcome was hip pain, measured with the Western Ontario and Mc-
Masters University Osteoarthritis Index (WOMAC) subscale and the Visual Analogue Scale 
(VAS). Associations between hip pain and biomarkers were assessed using linear mixed-
model analysis for repeated measurements. Five previously identified pain trajectories were 
used as outcome to investigate whether the level of biomarkers at baseline could estimate 
membership in one of the trajectories using multinomial regression analysis.
Results: LoguCTX-II and loguCIIM were not associated with WOMAC pain or VAS pain during 
the 2-year follow-up. Patients in the highly progressive pain trajectory and the moderate pain 
trajectory were more likely to have a higher loguCTX-II at baseline (OR 6.7; 95% CI 1.6-28.2 
and OR 4.8; 95% CI 1.0-22.8, respectively) than patients in the mild pain trajectory.
Conclusion: This study shows that in patients with mild-moderate hip OA the urinary bio-
chemical markers uCTX-II and uCIIM are not cross-sectionally associated with hip pain during 
the 2-year follow-up. Because the uCTX-II level estimated a progressive or moderate hip pain 
trajectory, this correlation needs to be confirmed in additional patients with hip OA.
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Introduction
Osteoarthritis (OA) is characterized by slowly progressive damage of synovial joint tissues, 
including cartilage destruction and alterations of the bone and synovial tissue. Signs and 
symptoms of OA include joint pain, stiffness and disability. Although radiography is used 
to confirm OA in clinical practice, specific OA signs (such as joint space narrowing) are only 
visible after significant cartilage degradation has taken place.[1]
Biochemical markers, or biomarkers, are defined as characteristics that are objectively mea-
sured and evaluated as an indicator of normal biological processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention.[2] The availability of biomarkers that 
can assist in diagnosing early-stage OA, predicting OA progression, and assessing therapeu-
tic responses could improve early diagnosis and help monitor the effect of OA treatment. In 
OA, biomarkers of interest originate from bone, synovial tissue, and the articular cartilage.[3]
The articular cartilage is composed of two primary matrix proteins: type II collagen and 
aggrecan. During cartilage erosion, type II collagen is sequentially degraded by enzymes, 
as matrix metalloproteinases (MMP). The resulting protein fragments, called neoepitopes, 
are released into the circulation and excreted in the urine; these fragments could serve as 
biomarkers. Two of these biomarkers of type II collagen metabolism are type II collagen C-
telopeptide (CTX-II) and MMP-derived CIIM. Urinary (u) CTX-II has been investigated most 
extensively and associations have been shown between uCTX-II and radiographic hip joint 
space narrowing, and between uCTX-II and hip pain.[4, 5] CIIM has recently been identified 
as a collagen type II neoepitope; serum CIIM levels are reported to be higher in individuals 
with knee OA than in those without knee OA.[6] Although CIIM was originally identified in 
urine by mass spectrometry, to date no study has clinically validated the marker in urine as 
a marker of OA.
Most previous studies have investigated the relationship between biomarkers and symp-
toms cross-sectionally,[5] or studied the relation between biomarkers and prediction of 
structural damage.[7] Moreover, because the performance of biochemical markers has been 
investigated more frequently in knee OA than in hip OA, our knowledge on the performance 
of biomarkers in hip OA is limited.[5]
Studying symptomatic progression requires repeated measurements and the ability to 
discriminate progressing disease from non-progressing disease. Latent class growth analysis 
(LCGA) has this ability and is a technique that finds clinically meaningful groups of people 
who are similar in their responses to measured variables, e.g., pain scores.[8] Recently, LCGA 
applied to a longitudinal dataset of patients with hip OA discriminated between five different 
pain trajectories over a 2-year period of follow-up, i.e., high pain, moderate pain, mild pain, 
regularly progressive pain and highly progressive pain.[8] If biomarkers could help in predict-
ing which group patients belong to, this could be of considerable clinical value.
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The objective of this study was to assess whether there is an association between uCTX-II 
or uCIIM and perceived hip pain of patients with mild-moderate hip OA, over a 2-year period 
with 6-monthly measurements of urinary biomarkers and hip pain. The secondary objective 
was to assess whether these biomarkers could help to estimate a specific trajectory of hip 
pain over the 2-year period.
Methods
Study population
The study population consisted of primary care patients diagnosed with hip OA (n= 222) who 
participated in a prospective randomized controlled trial that assessed the effect of glucos-
amine sulfate (the GOAL trial; ISRCTN54513166).[9-11] This trial recruited prevalent cases of 
patients with hip complaints from databases of general practices in the Netherlands. Patients 
were eligible if they met one of the American College of Rheumatology (ACR) criteria for hip 
OA.[12] Patients who had undergone or were awaiting total hip replacement (THR) surgery 
and patients with a Kellgren and Lawrence (KL) score of 4 were excluded.[13] Patients were 
also excluded if they had renal disease, liver disease, diabetes mellitus, or were already tak-
ing glucosamine. Also excluded were patients with a disabling comorbid disease that would 
make visits to the research center impossible, and those unable to complete questionnaires 
in Dutch.
Eligible patients were randomly assigned to receive either 1500 mg of oral glucosamine 
sulfate once daily or placebo over a period of 2 years. The Medical Ethics Committee of the 
Erasmus University Medical Center approved the study design, and all patients provided 
written informed consent. A detailed description of the study design and outcomes has been 
published elsewhere.[9-11] The GOAL trial showed that glucosamine sulfate was not superior 
to placebo in reducing symptoms and progression of hip OA. One of the secondary outcomes 
of this trial was biomarker level of CTX-II and a promising new marker CIIM assessed in urine 
samples.[10]
Biochemical markers
The biomarkers uCTX-II and uCIIM were measured in second morning void urine at five time 
points: at baseline, and at 6, 12, 18 and 24-months follow-up. The samples were stored at 
-80oC. The samples were collected from September 2003 until March 2006. The samples were 
analyzed in 2010. Prior to measurement the urine samples were thawed, vortexed and spun 
down to first mix the samples and pellet potential debris. Prolonged storage test of the assays 
for up to 12 years showed no effect of storage on the levels of the biomarkers. Urinary CTX-II 
was measured by the commercially available Cartilaps® ELISA (IDS Nordic, Herlev, Denmark). 
Urinary CIIM was measured by an in-house constructed EIA targeting the neo-epitope 
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RDGAAGY derived from MMP cleavage of type II collagen.[6, 14] For both assays, intra- and 
interassay variations were <8 and <12% for the urine measurement. Samples were run in 
duplicates and repeated if CV% was >15%. Both markers were normalized for the amount 
of creatinine (creat) in the urine. If the level of creat was below the lower limit of detection, 
then the level was set to the lowest detectable level (1 umol/mL creat). In our trial we did not 
measure CTX-II and CIIM in serum.
Clinical outcomes
The outcome was severity of hip pain reported by the patient. This was measured 3-monthly 
during the 2-year follow-up with two validated measuring instruments: the Western Ontario 
and McMasters University Osteoarthritis Index (WOMAC) subscale for hip pain and the Visual 
Analogue Scale (VAS; range 0-100, 0 indicates no pain, 100 indicates unbearable pain.[15] The 
WOMAC subscale was converted to a 0-100 score (0 indicates no symptoms, 100 indicates 
unbearable pain). The WOMAC is recommended by the Osteoarthritis Research Society 
International for use in clinical trials in patients with hip OA to measure pain severity. The 
WOMAC asks patients about their pain in the previous 2 days; the VAS pain was scored as the 
average hip pain during the previous 7 days. If patients had a THR during follow-up, available 
data were included in the analysis until surgery; data collected after surgery were assumed 
to be missing.
Pain trajectories
Recently, using the 3-monthly repeated pain measurements during 2-year follow-up, five dis-
tinct trajectories of hip pain were identified in the GOAL data.[8] The LCGA differentiated the 
following trajectories: mild pain (n=69), moderate pain (n= 31), high pain (n=31), regularly 
progressive pain (n= 48), and highly progressive pain (n= 42).
A more detailed description of the determination of these pain trajectories has already 
been published.[8] Three of these five trajectories started with low baseline pain scores; how-
ever, over time the trajectories show important differences. The ‘mild pain’ trajectory stayed 
at the same low pain level during the 2-year follow-up, the ‘moderate’ trajectory showed a 
moderate progression in pain score, and the ‘highly progressive’ trajectory showed a rapid 
progression in pain score.
Here, we used the pain trajectories as outcome to investigate whether the level of biomark-
ers at baseline could estimate membership in one of the trajectories.
Statistical analysis
Data were analyzed using multivariable linear mixed models for repeated measurement to 
assess the cross-sectional associations between patients’ perceived hip pain and uCTX-II and/
or uCIIM over the 2-year period. The linear mixed model adjusts for the within-patient cor-
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relation for the outcomes at different measurements in each patient and uses each outcome 
from each patient as a separate observation.
To obtain a normal distribution of uCTXII pg/umol creat and uCIIM pg/umol creat, the 
natural logarithm of both was taken. The unstructured covariance structure was used, since 
this yielded the lowest Akaike’s Information Criterium (AIC).
Covariates used in the model were: age, gender and body mass index (BMI). To minimise 
the bias in our estimation of the association between biomarker and pain we performed 
the 6-step approach by Pearl.[16] This yielded the following covariables: allocated treatment, 
duration of hip complaints (dichotomised to <3 years vs ≥3 years), presence of hand OA or 
knee OA and severity of radiologic hip OA. Knee OA and hand OA at baseline were defined as 
KL score ≥2 as seen on the X-ray. Radiologic hip OA was defined as OA of the index hip (KL ≥ 
2) vs no radiologic hip OA (KL < 2). All covariates were included in the model as fixed factors.
A subgroup analysis was performed with patients with minimal radiologic hip OA (KL < 2) 
and patients with definite radiologic hip OA (KL ≥2).
Multinomial regression analysis was used to assess if the baseline level of biomarkers 
estimates the probability of membership in one of the five trajectories of hip pain. Due to the 
division into five pain trajectories, the study population per trajectory was relatively small 
(n= 31 to n= 69). Therefore, in the multinomial analysis we did not adjust for other baseline 
variables. However, we studied other baseline variables also using univariate multinomial 
regression analysis. Since we were interested in the additional value of an imaging marker 
(radiography), we performed an explorative analysis for uCTX-II and uCIIM adjusted for base-
line radiographic hip OA. All analyses were conducted using SPSS version 20.0.
Results
Study population
The baseline characteristics of the 222 patients participating in the GOAL trial are presented 
in Table 1. The mean age was 63.4 (SD 9.0) years and 69.4% of patients were female. The mean 
WOMAC pain score was 34.2 (SD 23.1) and the mean VAS pain score was 32.4 (SD 25.9). The 
duration of hip complaints was ≥3 years in 119 (53.6%) patients; 108 (48.6%) patients had a 
minimum KL score of 2. Of all patients, 20 received a THR during follow-up.
Biochemical markers
The median uCIIM pg/umol creat was 61.7 (IQR 51.5) and the median uCTX-II pg/umol creat 
was 332 (IQR 355). At baseline, biomarkers for 197 (89%) patients were available for analysis, 
compared with 177 (80%) patients at 6-months follow-up, 190 (86%) at 12 months, 186 (84%) 
at 18 months and 187 (84%) patients at 24-months follow-up.
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Table 1 Patient characteristics at baseline.
Characteristic Patients (n=222)
Gender (n, %) Female 154 (69.4)
Age in years (mean, SD) 63.4 (9.0)
Body mass index (kg/m2) (mean, SD) 28.0 (4.7)
Duration of complaints (n, %) <3 years 103 (46.4)
≥3 years 119 (53.6)
Knee OA (KL ≥ 2) (n, %) 68 (30.6)
Hand OA (KL ≥ 2) (n, %) 116 (52.3)
Radiologic hip OA (n, %) KL<2 114 (51.4)
KL ≥ 2 108 (48.6)
uCIIM pg/umol creat (median, IQR) 61.7 (51.5)
uCTX-II pg/umol creat (median, IQR) 332 (355)
WOMAC pain (0-100) 34.2 (23.1)
WOMAC function (0-100) 35.1 (22.9)
WOMAC stiffness (0-100) 42.6 (25.2)
VAS hip pain (0-100) 32.4 (25.9)
KL = Kellgren & Lawrence grading of radiologic OA, uCIIM = type II collagen marker, uCTX-II = C-terminal 
telopeptides of type II collagen, creat = creatinine, WOMAC = Western Ontario and McMaster Universities 
(0 indicates no pain), VAS = Visual Analog Scale (0 indicates no pain), SD = standard deviation, IQR = inter-
quartile range
Associations between clinical outcomes and biochemical markers
The results of the multivariable adjusted mixed-model analysis are presented in Table 2a. 
Neither loguCTX-II nor loguCIIM were cross-sectionally associated with WOMAC pain or VAS 
pain during the 2-year follow-up. Covariates associated with WOMAC pain were: BMI (coef-
ficient 1.0; 95% CI 0.4-1.5), female gender (coefficient 8.1; 95% CI 2.4-13.8) and duration of 
complaints (coefficient 7.2; 95% CI 2.1-12.4). Covariates associated with VAS pain were: BMI 
(coefficient 1.1; 95% CI 0.5-1.7), female gender (coefficient 7.5; 95% CI 1.2-13.8), duration of 
complaints (coefficient 7.0; 95% CI 1.4-12.6) and radiologic hip OA (KL≥2) (coefficient 6.6; 95% 
CI 0.7-12.5). 
The subgroup analysis of patients with definite radiographic OA (KL≥2) at baseline (n =108) 
showed a significant association between loguCTX-II and VAS pain (coefficient 17.1; 95% CI 
7.7-26.5). The association between loguCTX-II and WOMAC pain was not significant in the 
definite radiographic OA group, nor were the associations between loguCIIM and WOMAC 
pain or VAS pain.
In the group with minimal radiographic OA at baseline (n= 114), no associations were 
found between loguCTX-II, loguCIIM and the pain scores (see Table 2b and c).
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Table 2a Results of multivariate linear mixed model analysis of biochemical markers and symptom severity 
during 2 years of follow-up with 6-monthly measurements.
Variable WOMAC pain (0-100) (n=213) VAS pain (0-100) (n=213)
Coefficient (95% CI) p-value Coefficient (95% CI) p-value
Gender (female) 8.1 (2.4 - 13.8) <0.01 7.5 (1.2 to 13.8) 0.02
Age (years) 0.0 (-0.3 to 0.3) 0.90 0.1 (-0.3 to 0.4) 0.68
Body mass index (kg/m2) 1.0 (0.4 - 1.5) <0.01 1.1 (0.5 - 1.7) <0.01
Duration of complaints (>3 years) 7.2 (2.1 - 12.4) <0.01 7.0 (1.4 - 12.6) 0.02
Concomitant knee OA 1.4 (-4.5 to 7.3) 0.64 -2.9 (-9.3 to 3.5) 0.37
Concomitant hand OA -3.4 (-9.1 to 2.3) 0.24 -2.7 (-8.9 to 3.5) 0.39
Radiologic hip OA (KL ≥ 2) 3.2 (-2.2 to 8.6) 0.24 6.6 (0.7 to 12.5) 0.03
Treatment (placebo) -2.9 (-7.9 to 2.1) 0.25 -2.0 (-7.4 to 3.5) 0.48
LoguCTX-II (pg/umol creat) 2.6 (-1.9 to 7.1) 0.26 4.3 (-1.2 to 9.9) 0.13
LoguCIIM (pg/umol creat) -1.6 (-5.7 to 2.5) 0.44 -0.7 (-5.8 to 4.3) 0.77
uCTX-II = C-terminal telopeptides of type II collagen, uCIIM = type II collagenmarker, creat = creatinine, CI = 
confidence interval, bold figures indicate p<0.05. The coefficient indicates the magnitude of change in pain 
score expected from a 1-unit change in the variable
Table 2b Results of multivariate linear mixed model analysis of biochemical markers and symptom severity 
during 2 years of follow-up with 6-monthly measurements; subgroup of patients with minimal radiologic 
hip OA (KL<2).
Variable WOMAC pain (0-100) (n=114) VAS pain (0-100) (n=114)
Coefficient (95% CI) p-value Coefficient (95% CI) p-value
Gender (female) 11.5 (2.2 to 20.8) 0.02 12.6 (2.4 to 22.8) 0.02
Age (years) 0.2 (-0.3 to 0.7) 0.35 0.3 (-0.2 to 0.9) 0.21
Body mass index (kg/m2) 1.2 (0.4 to 1.9) <0.01 1.2 (0.3 to 2.0 ) <0.01
Duration of complaints (>3 year) 3.2 (-4.1 to 10.5) 0.39 5.7 (-2.4 to 13.7) 0.17
Concomitant knee OA 1.7 (-7.1 to 10.5) 0.71 -1.7 (-11.3 to 8.0) 0.73
Concomitant hand OA -4.2 (-12.2 to 3.8) 0.30 -6.2 (-25.0 to 2.5) 0.16
Treatment (placebo) -0.7 (-8.0 to 6.7) 0.85 0.4 (-7.6 to 8.5) 0.91
LoguCTX-II (pg/umol creat) 1.3 (-4.0 to 6.4) 0.63 -3.4 (-9.9 to 3.0) 0.30
LoguCIIM (pg/umol creat) -2.0 (-7.4 to 3.4) 0.46 4.8 (-1.6 to 11.3) 0.14
uCTX-II = C-terminal telopeptides of type II collagen, uCIIM = type II collagen marker, creat = creatinine, CI 
= confidence interval, bold figures indicate p<0.05.
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Table 2c Results of multivariate linear mixed model analysis of biochemical markers and symptom severity 
during 2 years of follow-up with 6-monthly measurements; subgroup of patients with definite radiologic 
hip OA (KL≥2).
Variable WOMAC pain (0-100) (n=108) VAS pain (0-100) (n=108)
Coefficient (95% CI) p-value Coefficient (95% CI) p-value
Gender (female) 5.8 (-1.7 to 13.3) 0.13 3.0 (-5.0 to 11.1) 0.46
Age (years) -0.1 (-0.5 to 0.3) 0.67 -0.1 (-0.6 to 0.3) 0.54
Body mass index (kg/m2) 0.6 (-0.3 to 1.4) 0.20 1.0 (0.1 to 1.9) 0.03
Duration of complaints (>3 year) 10.7 (3.3 to 18.0) <0.01 9.7 (1.8 to 17.6) 0.02
Concomitant knee OA 1.9 (-6.0 to 9.9) 0.63 -1.7 (-10.1 to 6.7) 0.70
Concomitant hand OA -2.2 (-10.5 to 6.2) 0.61 2.2 (-6.8 to 11.1) 0.63
Treatment (placebo) -6.7 (-13.8 to 0.4) 0.06 -5.8 (-13.4 to 1.8) 0.13
LoguCTX-II (pg/umol creat) 6.0 (-1.8 to 13.8) 0.13 17.1 (7.7 to 26.5) <0.01
LoguCIIM (pg/umol creat) -0.4 (-6.7 to 5.8) 0.90 -6.3 (-14.1 to 1.5) 0.12
uCTX-II = C-terminal telopeptides of type II collagen, uCIIM = type II collagen marker, creat = creatinine, CI 
= confidence interval, bold figures indicate p<0.05
Multinomial regression analysis showed that, compared to patients in the mild pain trajec-
tory, patients in the highly progressive pain trajectory were more likely to have a higher 
loguCTX-II (OR 6.7; 95% CI 1.6-28.2) at baseline (Table 3). The odds ratio (OR) for loguCTX-II 
was higher than that for the duration of complaints or severity of radiologic OA. Patients in 
the moderate pain trajectory were also more likely to have a higher loguCTX-II at baseline 
(OR 4.8; 95% CI 1.0-22.8) compared to the mild pain trajectory.
After adjustment for the imaging marker (radiologic OA), patients in the highly progressive 
pain trajectory were more likely to have a higher loguCTX-II (OR 4.6; 95% CI 1.0-19.9; p 0.04) 
at baseline. LoguCTX-II explained 5% of the variance of the model and loguCIIM explained 
1% of the variance (Table 3).
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Table 3 Multinomial binary regression analysis for individual baseline variables for the four trajectories of 
hip pain (mild hip pain trajectory was used as reference group).
Moderate pain Always pain Regularly 
progressive 
pain traject
Highly 
progressive 
pain traject
explained 
variance 
by model
n=31 n=32 n=48 n=42
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Gender (female) 2.1 0.8 - 5.5 2.2 0.8 - 5.7 1.2 0.6 - 2.6 1.5 0.7 - 3.5 2%
Duration of hip complaints 
(≥3 years)
1.8 0.8 - 4.2 3.2 1.3 - 7.8 1.6 0.8 - 3.3 2.6 1.2 - 5.8 5%
Concomitant knee OA 2.3 0.9 - 6.0 2.5 1.0 - 6.5 3.4 1.5 - 7.9 2.6 1.1 - 6.4 5%
Concomitant hand OA 0.8 0.4 - 2.0 1.5 0.6 - 3.5 1.8 0.8 - 3.7 1.5 0.7 - 3.3 2%
Radiologic hip OA (KL ≥ 2) 1.9 0.8 - 4.4 3.3 1.4 - 8.0 2.0 0.9 - 4.3 3.3 1.5 - 7.2 6%
Age 1.0 0.9 - 1.0 1.0 1.0 - 1.1 1.0 1.0 - 1.1 1.0 1.0 - 1.1 2%
Body Mass Index* 1.1 1.0 - 1.3 1.2 1.1 - 1.4 1.1 1.0 - 1.2 1.2 1.1 - 1.3 9%
LoguCTX-II pg/umol creat** 4.8 1.0 - 22.8 4.1 0.9 -19.5 1.5 0.5 - 5.1 6.7 1.6 - 28.2 5%
LoguCIIM pg/umol creat** 2.3 0.5 - 11.9 1.5 0.3 - 7.4 0.9 0.2 - 3.4 1.7 0.4 - 7.2 1%
uCTX-II = C-terminal telopeptides of type II collagen, uCIIM = type II collagen marker, creat = creatinine, * 
n=220, ** n=197, bold figures indicate p<0.05.
Discussion
In patients with mild-moderate hip OA, urinary CTX-II and CIIM were not cross-sectionally 
associated with patients’ perceived severity of hip pain (measured with WOMAC pain and 
VAS pain) over the 2-year follow-up. Patients in the moderate pain trajectory and in the highly 
progressive pain trajectory were more likely to have a higher loguCTX-II at baseline than 
patients in the mild pain trajectory.
Results of earlier studies on the relationship between uCTX-II and patients’ perceived pain 
are conflicting. One cross-sectional study in patients with knee OA showed no association 
between uCTX-II and WOMAC total score, and uCTX-II and WOMAC pain score.[17] However, 
another study in patients with knee OA suggested that patients with a high level of uCTX-
II at baseline have a significant correlation with WOMAC scores, with a peak at 18-months 
follow-up.[18] In hip OA the correlation between uCTX-II and pain has also been shown to be 
cross-sectional.[4]
Urinary CIIM has not been investigated as extensively as uCTX-II. Although serum CIIM 
levels are reported to be higher in patients with radiographic knee OA than in those with-
out radiographic knee OA, its relationship with pain has not previously been investigated.
[6] Serum CIIM levels are reported to be somewhat predictive for structural progression in 
ankylosing spondylitis[19] and for treatment response in rheumatoid arthritis.[20]
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Although both CTX-II and CIIM are neoepitopes of type II collagen, clear histological 
differences have been observed which may explain differences in results between the two 
markers. CTX-II seems to be released from the eroded and fibrillated surface of the OA carti-
lage as well as the interface between the subchondral bone and the calcified cartilage.[21] 
In contrast, CIIM seems to be released from the articular cartilage.[6] In other words, CTX-II 
may be associated to a greater extent with the innervated bone tissue, whereas CIIM may be 
uniquely derived from the non-innervated articular cartilage. In our data uCIIM and uCTX-II 
were not correlated to each other.
The relationship between uCTX-II and radiographic OA has been reported previously in 
both knee and hip OA in cross-sectional designs.[4, 7, 22] Moreover, Reijman et al. showed 
that in patients with hip pain, the association between uCTX-II levels and radiographic OA 
was stronger (OR 20.4) than in patients without hip pain (OR 3.0).[7]
A strength of our study is the longitudinal design with five repeated follow-up measure-
ments of urinary biomarkers and pain scores during 2-year follow-up; this allowed to explore 
the relationship between biomarkers and pain over time. Although cross-sectional associa-
tions between biomarkers and clinical outcomes have previously been reported, longitudinal 
associations have not yet been extensively investigated. For clinical use, it would be interest-
ing to have biomarkers that are associated with future clinical outcomes of OA over a longer 
follow-up period. Then these biomarkers could be used to monitor disease progression or 
treatment effects over time. Another strength is that in our linear mixed models we were 
able to correct for some well-known covariables such as age, BMI and severity of radiologic 
hip OA.
The study also has some limitations. The first is that although we have information on knee 
OA and hand OA, we do not know whether knee OA or hand OA was unilateral of bilateral.
Urinary CTX-II and uCIIM are not specific markers for the hip, but are released in every joint. 
Therefore, it would be interesting to see whether the results are different when a weighted 
adjustment could be done, counting the number of joints affected by OA. In addition, it 
would also be interesting to adjust for lower back OA, since an association has been shown 
between CTXII and disc space narrowing.[23]
Another possible limitation is the use of glucosamine in half of the patients. Although the 
results of the GOAL trial showed that clinical symptoms and radiographic progression of hip 
OA did not differ between active treatment and placebo at any follow-up measurement,[9] 
other studies reported that glucosamine administration significantly decreased uCTX-II 
levels.[24] Therefore, a possible effect of glucosamine on uCTX-II levels cannot be ruled out. 
However, because analyses with and without adjustment for treatment yielded the same 
results, we believe that the contribution of a possible effect of glucosamine to the model is 
small.
In addition, we had no information on the menopausal status of the included women. This 
might have influenced the results, as it is reported that postmenopausal women show higher 
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levels of uCTXII than premenopausal women.[25] However, we believe that this would have 
little influence in the present study because the mean age of our population was 63 years 
(an age when most women have reached menopausal status). To further study the possible 
effect of the menopausal status, we analyzed men and women separately. In both groups no 
association was found between uCTX-II or uCIIM and severity of hip pain.
The GOAL study recruited prevalent cases of patients registered with hip OA or patients 
with symptoms associated with hip OA in the medical records of the general practices. These 
patients were contacted by their general practitioner (GP) and informed about the study. 
However, because a selection of patients might have responded to the GP’s invitation, there 
is a possibility of selection bias. Also, our results cannot be generalized to patients referred to 
secondary care for complaints of hip OA.
Finally, the results for the prediction of the course of pain were only analyzed bivari-
ately because the numbers of patients in the five pain trajectories were too small to perform 
multivariate analysis. A larger patient population would allow exploring the association 
between uCTX-II and progressive pain related to other variables such as BMI and duration of 
complaints to see whether some of the covariates could be confounders. It would also show 
whether uCTX-II has an additional value to predictors that are easily assessed during history 
taking and physical examination.
Implications for clinical practice and research
During the 2-year follow-up, no cross-sectional association was found between uCTX-II or 
uCIIM and severity of hip pain in patients with clinical hip OA according to the ACR criteria 
registered in the medical records of general practices. Baseline uCTX-II was related to progres-
sive pain trajectories during follow-up. Therefore, uCTX-II might help to identify patients at 
risk for a progressive pain trajectory. However, this needs further investigation and, although 
uCTX-II is commercially available, its value for the prognosis of an individual patient remains 
unclear. Further studies should also examine whether uCTX-II is a better predictor than other 
variables that are easier to assess by the GP (e.g., duration of complaints, gender), or variables 
already widely used in clinical practice (e.g., X-ray).
Based on this current work, we cannot recommend CIIM as a biomarker in hip OA in clinical 
practice.
Conclusion
This study shows that, over a 2-year period, the urinary biochemical markers uCTX-II and uCIIM 
were not cross-sectionally associated with perceived hip pain of patients with hip OA. However, 
uCTX-II might be helpful to estimate a progressive pain trajectory or a moderate pain trajectory 
over a 2-year period. This needs further evaluation in studies with a larger sample size.
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Abstract
Objectives: The goal of this study was to assess whether there is an association between am-
bient weather conditions and patients’ clinical symptoms in patients with hip osteoarthritis 
(OA).
Methods: The design was a cohort study with a 2-year follow-up and 3-monthly measure-
ments and prospectively collected data on weather variables. The study population consisted 
of 222 primary care patients with hip OA. Weather variables included temperature, wind 
speed, total amount of sun hours, precipitation, barometric pressure, and relative humid-
ity. The primary outcomes were severity of hip pain and hip disability as measured with the 
Western Ontario and McMasters University Osteoarthritis Index (WOMAC) pain and function 
subscales. Associations between hip pain and hip disability and the weather variables were 
assessed using crude and multivariate adjusted linear mixed-model analysis for repeated 
measurements.
Results: On the day of questionnaire completion, mean relative humidity was associated 
with WOMAC pain (estimate 0.1; 95% confidence interval 0.0–0.2; p 0.02). Relative humidity 
contributed <1% to the explained within-patient variance and between-patient variance of 
the WOMAC pain score. Mean barometric pressure was associated with WOMAC function 
(estimate 0.1; 95% confidence interval 0.0–0.1; p 0.02). Barometric pressure contributed <1% 
to the explained within-patient variance and between-patient variance of the WOMAC func-
tion score. The other weather variables were not associated with the WOMAC pain or function 
score.
Conclusion: Our results support the general opinion of OA patients that barometric pressure 
and relative humidity influence perceived OA symptoms. However, the contribution of these 
weather variables (<1%) to the severity of OA symptoms is not considered to be clinically 
relevant.
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Introduction
Patients with osteoarthritis (OA) often report that weather conditions (such as precipitation 
and temperature) influence their clinical symptoms such as pain and joint stiffness.[1] Up to 
62% of OA patients believe that they are weather sensitive and that, for example, tempera-
ture and precipitation aggravate their OA symptoms.[2]
Systematically searching the literature (PubMed, Embase, and the Cochrane Library from 
1966 until July 2012) on associations between weather conditions and OA yielded 11 articles 
describing 11 studies (Appendices A and B).
Patients included in these studies were diagnosed with rheumatoid arthritis (RA) or OA. 
The joints involved in OA were specified in 4 studies.[3-6] Although all these studies had a 
prospective design, only 3 covered all seasons of the year.[6-8] None of the meteorological 
variables showed a consistent correlation with patients’ pain in OA. An increase in tem-
perature was correlated with a decrease in pain in 4 studies and with an increase in pain in 
1 study, and was not correlated with pain in 5 studies. An increase in barometric pressure 
was correlated with a decrease in pain in 1 study and an increase in pain in 6 studies, and 
was not correlated with pain in 4 studies. Precipitation and relative humidity were positively 
correlated with pain in 3 studies and not correlated with pain in 5 studies (precipitation) 
and 6 studies (relative humidity). These differences could be caused by differences in the 
data collection. Some studies assessed pain and weather variables multiple times per day 
and used all of these measurements as different data points.[7] Others used the average of 
weather variables over 24 hours.[2, 5] The studies also used different techniques for analysis, 
varying from simple correlation to mixed model analysis.[5, 8] (see Appendix C for details 
on the characteristics of all 11 studies) Thus, studies have been unable to provide consistent 
evidence for a relationship between OA symptoms and weather conditions.[1, 3, 5-7, 9-11]
The present study investigates whether there is an association between ambient weather 
conditions (e.g. precipitation, temperature, barometric pressure) and patients’ hip pain and 
hip function, in primary care patients with hip OA. For this, we used a large prospective co-
hort study with 3-monthly measurements over 2 years of follow-up, with validated functional 
scoring systems and data of weather variables at all data points.
Methods
STROBE recommendations
When executing the study, the recommendations of the STrengthening the Reporting of 
OBservational studies in Epidemiology (STROBE) were followed.[12]
90
Study population
The study population consisted of primary care patients diagnosed with hip OA (n = 222) 
who participated in a prospective, randomized, controlled trial that assessed the effect of 
glucosamine sulphate (the GOAL trial: glucosamine sulphate in hip osteoarthritis).[13-15] The 
Medical Ethics Committee of the Erasmus MC approved the study design, and all patients 
provided written informed consent. This trial recruited patients with hip complaints from 
general practices in the Rotterdam area of the Netherlands. All patients were residing in the 
Rotterdam area. Patients were eligible if they met the clinical and/or radiological American 
College of Rheumatology criteria for hip OA.[16] Patients who had undergone or were await-
ing total hip replacement (THR) surgery and patients with a Kellgren & Lawrence (KL) score 
of 4 were excluded.[17] 
Patients were also excluded if they had renal disease, liver disease, or diabetes mellitus, 
or were already taking glucosamine. Also excluded were patients with a disabling comorbid 
disease that would make a visit to the research center impossible, and those unable to com-
plete questionnaires in the Dutch language. Patients were assessed every 3 months during 
a 2-year follow-up.
We considered the 222 participants as 1 cohort because the results of the GOAL trial showed 
that clinical symptoms and radiographic progression of hip OA did not differ between active 
treatment and placebo at any follow-up measurement.[13]
Clinical outcomes
The outcomes were severity of hip pain and hip function reported by the patient. These were 
assessed with a validated measuring instrument: the Western Ontario and McMasters Univer-
sity Osteoarthritis Index (WOMAC) subscale for hip pain and subscale for function.[18] The 
WOMAC subscales were converted to a score of 0 to 100, in which 0 indicated no pain or no 
disability. The WOMAC is recommended by the Osteoarthritis Research Society International 
for use in clinical trials in patients with hip OA to assess pain and disability.[18] In the WOMAC 
questionnaire, a self-administered questionnaire, patients’ symptoms during the last 2 days 
were scored. If patients had a THR during follow-up, available data were included in the 
analysis until surgery; data collected after surgery were not used in the analysis.
Patients filled in a questionnaire, which included the WOMAC questionnaire, every 3 
months. The baseline questionnaire and the 2-year questionnaire were completed at the 
research centre; the other 7 questionnaires were completed at home and sent to the re-
searchers by mail. This resulted in 9 recordings per patient in total (1 at baseline and 8 during 
follow-up). The date of completion was reported; however, the time of the day on completion 
of the questionnaire was unknown.
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Weather variables
Weather variables of the patients’ residences (weather station Rotterdam) were retrieved 
from the Royal Netherlands Meteorological Institute[19] and included the following: mean 
temperature (in degrees Celsius), mean wind speed (in meters/s), total amount of sun hours, 
total amount of precipitation (in millimeters), mean barometric pressure (hPa), and mean 
relative humidity (%).These variables were collected for the day of questionnaire completion 
of each patient.
Statistical analysis
Crude and adjusted linear mixed-model analysis for repeated measurements were used to 
assess associations between patients’ severity of hip pain and hip joint disability and the 
weather variables of interest. This technique adjusts for the within-patient correlation for the 
outcomes in each patient and uses each outcome from each patient as a separate observa-
tion.
In the mixed-model analyses, the weather variables were included as fixed factors. The 
compound structured covariance structure was used, assuming that the within-subject and 
between-subject variance is a constant. Weather variables that showed a significance level 
of p < 0.15 with the outcome in the binary linear mixed-model analysis were entered in the 
multivariate, adjusted linear mixed-model analysis. Covariates that were associated with 1 
of the outcomes (WOMAC function or WOMAC pain; p < 0.15) in the binary analysis were 
included in the adjusted models as fixed factors to be adjusted for.
We were also interested in whether associations between weather variables and hip OA 
were more prominent in patients with definite radiologic hip OA (KL≥2) versus patients 
with early radiologic OA (KL< 2). Therefore, a subgroup analysis was performed for patients 
with a KL score of 2/3. Between-patient and within-patient variances were calculated for the 
intercept-only model, the crude model, and the multivariate adjusted model. All analyses 
were performed using SPSS version 20.0.
Results
Study population
A total of 222 patients participated in the GOAL trial; Table 1 shows the baseline character-
istics of these patients. The mean age was 63.4 years (standard deviation [SD] 9.0 years), and 
69.4% of patients were female. At baseline, the mean WOMAC pain score was 34.2 (SD 23.1), 
and the mean WOMAC function score was 35.1 (SD 22.9). Because of patients undergoing 
a THR during the 2-year follow-up and patients lost to follow-up, the number of patients 
with available data ranged from 217 patients (98%) at the 3-month follow-up to 188 patients 
(84.7%) at the 2-year follow-up.[13]
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Table 1 Baseline characteristics of the 222 primary care patients with hip OA.
Characteristic Patients
(n=222)
Gender Female 154 (69.4)
Age in years 63.4 (9.0)
Body mass index (kg/m2) 28.0 (4.7)
Duration of complaints <1 year 26 (11.7)
1-3 years 77 (34.7)
>3 years 119 (53.6)
OA Localised* 85 (38.3)
Generalised 137 (61.7)
Radiologic hip OA KL 1 114 (51.4)
KL ≥ 2 108 (48.6)
Pain medication users 112 (50.5)
WOMAC pain (0-100) 34.2 (23.1)
WOMAC function (0-100) 35.1 (22.9)
WOMAC stiffness (0-100) 42.6 (25.2)
VAS hip pain (0-100) 32.4 (25.9)
Categorical data are presented as number (%); continuous data as mean (standard deviation) KL = Kellgren 
& Lawrence grading of radiologic OA; OA = Osteoarthritis; VAS = Visual Analogue Scale; WOMAC = Western 
Ontario and McMaster Universities. * Localised = only hip OA; Generalised = OA in hips, hands and/or knees
Clinical outcomes
The mean WOMAC subscores showed little variation over the study period. The WOMAC pain 
score decreased from 34.2 (SD 23.1) at baseline to 32.1 (SD 23.5) at 2-year follow-up. The 
WOMAC function score improved from 35.1 (SD 22.9) at baseline to 33.3 (SD 23.8) at 2-year 
follow-up.
Weather
On the days of questionnaire completion, the mean barometric pressure was 1016.1 (SD 9.6) 
hPa and the mean relative humidity was 82.5% (SD 7.6). The range of barometric pressure was 
980.4 to 1041.7, and the range of relative humidity was 49% to 99%. The mean temperature 
was 10.1°C (SD 6.1°C). The median wind speed was 3.9 m/s (25%–75% interquartile range 
[IQR] 2.8–5.5 m/s), and the median precipitation was 0.1 mm (25%–75% IQR 0.0–2.4 mm). The 
median hours of sun per day were 3.8 (25%–75% IQR 1.1–7.5).
Associations among clinical outcomes, individual characteristics, disease aspects, and 
weather
The results of the binary linear mixed model analysis on the day of questionnaire completion 
are presented in Table 2. Six covariates were associated (p < 0.15) with WOMAC pain and/or 
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WOMAC function: gender, body mass index (BMI), duration of OA complaints, localised versus 
generalised OA, unilateral versus bilateral OA, and severity of radiologic OA (KL 1 vs KL≥2). 
Relative humidity was associated with WOMAC pain (estimate 0.1; 95% confidence interval 
[CI] 0.0–0.2), and barometric pressure was associated with WOMAC function (estimate 0.1; 
95% CI 0.0–0.1).
Table 2 Results of binary linear mixed model analysis of weather variables and clinical outcomes on the day 
of questionnaire completion during 2 years of follow-up with 3-monthly measurements.
Variable WOMAC pain (0-100) WOMAC function (0-100)
Estimate* (95% CI) p value Estimate (95% CI) p value
Gender (female) 8.8 (3.3 to 14.4) <0.01 6.8 (0.7 to 12.8) 0.03
Body mass index (kg/m2) 1.3 (0.7 to 1.8) <0.01 1.6 (1.0 to 2.2) <0.01
Duration of complaints
< 6 months -22.6 (-35.5 to -9.7) <0.01 -20.6 (-34.6 to -6.5) <0.01
6 to 12 months -3.3 (-13.1 to 6.5) 0.51 -6.0 (-16.7 to 4.6) 0.27
1 to 3 years -7.7 (-13.2 to -2.1) <0.01 -9.1 (-15.1 to -3.1) <0.01
>3 years reference reference
Localised vs generalised OA (localised) -4.5 (-9.8 to 0.8) 0.10 -6.3 (-12.0 to -0..5) 0.03
Severity radiologic OA (KL< 2) -3.8 (-9.1 to 1.3) 0.14 -7.3 (-12.9 to -1.8) 0.01
Unilateral vs bilateral OA (unilateral) -3.7 (-8.9 to 1.5) 0.16 -5.5 (-11.1 to 0.1) 0.06
Precipitation (mm) 0.0 (-0.1 to 0.1) 0.89 -0.1 (-0.2 to 0.0) 0.15
Sun hours (per day) -0.1 (-0.3 to 0.1) 0.27 -0.0 (-0.1 to 0.1) 0.88
Temperature (degrees Celsius) 0.0 (-0.1 to 0.1) 0.84 -0.0 (-0.1 to 0.1) 0.61
Wind speed (m/sec) -0.2 (-0.5 to 0.1) 0.19 -0.2 (-0.5 to 0.0) 0.09
Barometric pressure (hPa) 0.0 (-0.0 to 0.1) 0.51 0.1 (0.0 to 0.1) <0.01
Relative humidity (%) 0.1 (0.0 to 0.2) 0.03 0.0 (-0.0 to 0.1) 0.16
CI = confidence interval; OA = osteoarthritis; SD = standard deviation: WOMAC = Western Ontario and Mc-
Master Universities. * Estimate indicates the magnitude of change in pain or function score expected from 
a 1-unit change in the variable of interest. 
In the multivariate adjusted mixed-model analysis, relative humidity was associated with 
WOMAC pain (estimate 0.1; 95% CI 0.0–0.2), and barometric pressure was associated with 
WOMAC function (estimate 0.1; 95% CI 0.0–0.1) (Table 3).
The estimate indicates the magnitude of change in pain score or function score expected 
from a 1-unit change in the weather variable. Thus, for each increase of 10% in relative 
humidity, the WOMAC pain score increased by 1.0 on a scale of 0 to 100. For each 10-hPA 
increase in barometric pressure, the WOMAC function score deteriorated by 1.0 point (scale, 
0–100). In a sensitivity subgroup analysis performed in patients with a KL score of 2/3, similar 
results were found.
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Table 3 Results of multivariate adjusted linear mixed model analysis of weather variables and clinical out-
comes on the day of questionnaire completion during 2 years of follow-up with 3-monthly measurements.
Variable WOMAC pain (0-100) WOMAC function (0-100)
Estimate (95% CI) p value Estimate (95% CI) p value
Gender (female) 7.3 (1.8 to 12.8) 0.01 5.2 (-0.6 to 11.0) 0.08
Body mass index (kg/m2) 1.1 (0.5 to 1.6) <0.01 1.4 (0.8 to 2.0) <0.01
Duration of complaints
< 6 months -20.2 (-32.6 to -7.9) <0.01 -18.0 (-31.0 to -4.9) <0.01
6 to 12 months -2.2 (-11.8 to 7.3) 0.65 -5.1 (-15.2 to 5.0) 0.32
1 to 3 years -6.1 (-11.4 to -0.7) 0.03 -6.5 (-12.2 to -0.9) 0.02
> 3 years reference reference
Localised vs generalised OA (localised) -1.8 (-7.8 to 3.4) 0.49 -2.8 (-8.2 to 2.7) 0.32
Severity radiologic OA (KL<2) -4.4 (-9.6 to 0.7) 0.09 -6.8 (-12.3 to -1.4) 0.02
Unilateral vs bilateral OA (unilateral) -2.2 (-7.1 to 2.6) 0.37 -3.7 (-8.8 to 1.5) 0.16
Relative humidity (%) 0.1 (0.0 to 0.2) 0.02 not included in model
Wind speed (m/sec) not included in model -0.1 (-0.4 to 0.2) 0.42
Barometric pressure (hPa) not included in model 0.1 (0.0 to 0.1) 0.02
CI = confidence interval; OA = osteoarthritis; WOMAC = Western Ontario and McMaster Universities. * Es-
timate indicates the magnitude of change in pain or function score expected from a 1-unit change in the 
weather variable. 
Table 4 shows the between-patient and within-patient variances for WOMAC function 
regarding barometric pressure and for WOMAC pain regarding relative humidity. Barometric 
pressure contributed <1% to the explained within-patient and between-patient variance of 
the WOMAC function score. Also, relative humidity contributed 61% to the explained within-
patient and between-patient variance of the WOMAC pain score.
Additional analysis
In an additional analysis, we calculated the means of the weather variables for the 2 days pre-
ceding the day of questionnaire completion, and analysed whether these means of weather 
variables were associated with WOMAC pain and/or WOMAC function. In the adjusted linear 
mixed-model analysis, only average precipitation over the 2 days preceding the day of ques-
tionnaire completion was associated with WOMAC function (estimate-0.2; 95% CI -0.3 to -0.0; p 
0.02). This indicates that for each 10-mm average increase in precipitation in the 2 days preced-
ing questionnaire completion, the WOMAC function (scale, 0–100) improved by 2 points.
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Table 4 Patient variances for WOMAC pain and relative humidity, and for WOMAC function and barometric 
pressure.
Variable WOMAC function WOMAC pain
bP (% explained) wP (% explained) bP (% explained) wP (% explained)
IC only 436 113 363 164
IC + barometric pressure 435 (<1) 112 (<1) -- --
IC + relative humidity -- -- 363 (<1) 163 (<1)
IC + wind speed 436 (<1) 112 (<1) -- --
IC + gender 428 (2) -- 348 (4) --
IC + duration of OA 413 (5) -- 341 (6) --
IC + BMI 387 (11) -- 333 (8) --
IC + severity of radiologic OA 425 (3) -- 362 (<1) --
IC + covariates 354 (19) 113 (<1) 303 (17) 164 (<1)
IC + covariates + wind speed + 
barometric pressure
352 (19) 112 (<1) -- --
IC + covariates + relative humidity -- -- 304 (16) 164 (<1)
BMI = body mass index; bP = between patient variance; IC = intercept; OA = osteoarthritis; WOMAC = West-
ern Ontario and McMaster Universities; wP = within patient variance. Covariates are gender, duration of OA, 
BMI, localised vs generalized OA, unilateral vs bilateral OA and severity of radiologic OA.
Discussion
This study shows that, in patients with hip OA, there was an association between relative hu-
midity and patients’ severity of hip pain (estimate 0.1; 95% CI 0.0–0.2) and between barometric 
pressure and patients’ hip function (estimate 0.1; 95% CI 0.0–0.1). However, the contribution 
of these weather variables in the pain score or function score was small. An increase of 10% in 
relative humidity increased the WOMAC pain score by 1 on a scale of 0 to 100. In addition to 
this, the range of relative humidity in our database was 49% to 99%, which corresponds to a 
maximum change in pain score of 5 on a scale of 0 to100. Similarly, for each 10-hPa increase in 
barometric pressure, the WOMAC function score deteriorates by 1 point on a scale of 0 to 100. 
The range of barometric pressure in our database was 980.4 to 1041.7, resulting in a maximum 
change in function score of 6.1 on a scale of 0 to 100. Pham et al. defined a clinically relevant 
moderate improvement in pain or function as an absolute change of ≥10 in pain of function 
score on a scale of 0 to 100 or an improvement of 20% in pain or function score.[20] Our results 
for both WOMAC pain and WOMAC function are therefore not clinically relevant. Second, rela-
tive humidity and barometric pressure explained only a very small part (<1%) of the within-
patient and between-patient variances of patients’ severity of hip pain and hip function.
A possible cause of these small associations could be that weather data were measured very 
precisely, whereas the pain data were assessed on a less precise level. Another explanation could 
be that there is no relationship between weather and OA symptoms, but that people tend to 
perceive patterns. One study has shown that people believe that arthritis symptoms are related 
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to barometric pressure, temperature, or humidity, but the investigators found no correlations 
between these weather-related variables and pain, joint tenderness, or functional status.[21]
The underlying mechanism as to why weather variables could affect pain or disability on 
OA is not well understood. Several hypotheses have been formulated. Fluctuations in atmo-
spheric pressure could lead to synovial fluid being forced into the subchondral bone, which 
can aggravate pain and disability. However, Brennan et al.[3] did not find evidence to support 
this in their study. A cadaver study by Wingstrand et al.[22] demonstrated that the stability 
of the hip is maintained primarily by atmospheric pressure. Changes in atmospheric pressure 
could change hip stability and lead to subluxation of the hip.
Strengths and limitations
Our study used a relatively large dataset of 222 hip OA patients whose symptoms were as-
sessed with questionnaires every 3 months over a 2-year follow-up period. Therefore, we were 
able to include weather variables during all seasons of the year. As there is a clear 4-season 
climate in the Netherlands, we believe that this is an important strength of the study. Also, 
this study used an appropriate statistical method (linear mixed models) for analyzing the 
associations between weather and symptoms of hip OA.
This study also has some limitations. First, the weather variables were all averaged over 24 
hours; it was not possible to retrieve the changes in weather variables for each hour of the 24 
hours of the day. The change in a weather variable from hour to hour potentially could be of 
more importance to a patient’s clinical symptoms than a daily average. Furthermore, as we 
were also unaware of the time of day that the questionnaire was completed, the influence 
of time of day could not be assessed in this study. In addition, because we did not have 
data on psychological variables in the patients, we were unable to examine or correct for 
psychological factors in our analysis. In addition, although up to 62% of patients with OA 
have been reported to believe that weather can change their OA symptoms,[2] we lacked 
information on our patients’ weather sensitivity. Outcomes might differ between patients 
who believe that they are weather sensitive and patients who do not.
Another important point is the fact that we were unaware of the time that patients spent 
indoors and outdoors. Compared to outdoors, staying indoors could less affect people re-
garding temperature and precipitation. However, barometric pressure is a weather variable 
that remains equal indoors and outdoors.[9]
A final important point is the selection of the study population. Patients were excluded 
from the GOAL study if they had severe radiographic OA (KL 4). The effects of weather could 
be more troublesome to patients with severe OA than to patients with mild to moderate OA.
Comparison with literature
Our study shows that higher relative humidity is associated with more hip pain in OA patients. 
Although this is in accordance with 3 earlier studies, those studies included patients with OA, 
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RA, and knee OA, not only hip OA.[4, 7, 8] Six studies reported no correlation between humid-
ity and OA.[1, 2, 5, 9-11] The contribution that our study makes to this accrued evidence is 
that the magnitude of this association is small and clinically not relevant.
Although the correlation between barometric pressure and OA is mainly positive in previ-
ous studies,[3-7, 10] the correlation between barometric pressure and hip function has been 
studied only once.[12] Verges et al. reported a significant correlation between humidity and 
functional incapacity as measured with the Health Assessment Questionnaire (odds ratio 
0.99; 95% CI 0.98–0.99; p 0.037).[11] Because this outcome showed only a borderline change, 
the authors reported that the correlation could not be conclusive from a clinical point of 
view. Our study agrees with their conclusion that the association between barometric pres-
sure and hip function, albeit significant, was small in magnitude and clinically not relevant.
Only 1 study reporting on knee OA and weather variables showed the magnitude of the 
associations; however, for both temperature and pressure changes, the magnitude of the 
associations was small.[5] This latter study also examined the change in weather variables 
between the day before each pain report and the actual day of the pain report. In the mul-
tivariate analysis, although barometric pressure was correlated with the WOMAC pain score, 
the magnitude of this association was small.[5]
In neuropathic rats, lowering barometric pressure in a pressure chamber, within the range 
of natural weather, results in more sensitivity to pain.[23] Perhaps patients with neuropathic 
pain are also more weather sensitive than other patients. In our study, we were unaware of 
whether patients had neuropathic pain.
Recall bias
In the WOMAC questionnaire, patients scored their symptoms during the previous 2 days. 
Therefore, we hypothesized that the means of the different weather variables of the 2 days 
preceding questionnaire completion would correlate with these WOMAC pain scores. How-
ever, no such correlation was found in our data; on the contrary, there was a small associa-
tion between the WOMAC pain score and the means of the weather variables on the day of 
questionnaire completion. It is known that there is a recall bias in pain questionnaires that 
address the means of pain during a previous time period; patients tend to rate their mean 
pain higher if their recent pain level is high and lower if their recent pain level is low.[24] This 
phenomenon might explain the influence of weather on hip symptoms over a short period 
of time (1 day) but not over a longer period of time (≥2 days).
Conclusion
In conclusion, our results support the general opinion of OA patients that barometric 
pressure and relative humidity influence OA symptoms (pain and disability). However, the 
contribution of these weather variables to the severity of OA symptoms is not considered to 
be clinically relevant.
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Appendix A Search terms for articles reporting on OA and weather influences.
PubMed (osteoarthritis[tw] OR (degenerative joint disease[tw])) AND (weather[tw] OR precipitation[tw] 
OR sunshine[tw] OR temperature[tw] OR (barometric pressure[tw]) OR (wind speed[tw]) OR 
(relative humidity[tw])) NOT (editorial[pt] OR letter[pt]) NOT (animals[mh] NOT humans[mh])
Embase (osteoarthritis:de,ab,ti OR ‘degenerative joint disease’:de,ab,ti) AND (weather:de,ab,ti 
OR precipitation:de,ti,ab OR sunshine:de,ti,ab OR temperature:de,ti,ab OR ‘barometric 
pressure’:de,ti,ab OR ‘wind speed’:de,ti,ab OR ‘relative humidity’:de,ti,ab) NOT (editorial:pt OR 
letter:pt) NOT ([animals]/lim NOT [humans]/lim)
Cochrane “osteoarthritis in Title, Abstract or Keywords and weather in Title, Abstract or Keywords in 
Cochrane Central Register of Controlled Trials”
6101
 
!
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Embase n=405 
Pubmed n=300 
Cochrane Library n=2 
 
Total n=707 
Duplicates n=189 
Included from reference list n=0 
 
Full text assessed n=21 
Full text paper n=21 
Excluded n=10 
 
Exclusion  reaso ns 
5 Editorial or (narrative) review 
1 Summary of previous research 
4 No pain measurements 
Did not meet inclusion criteria n=492 
Unable to obtain full text article n=3 
Congress abstract only n=1 
Double presentation n=1 
Included in review  n=11 
 
Title / abstract n=518 
Appendix B Study selection fl ow chart.
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Greater trochanter pain syndrome: 
prevalence and influence on hip 
pain severity in patients with hip 
osteoarthritis in a cohort study
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Abstract
Introduction: Patients with symptomatic osteoarthritis often show fluctuating pain levels, 
but the cause remains largely unclear. Although bursal and tendon pathology can cause pain 
in patients with osteoarthritis, little is known about an association between fluctuating pain 
and bursal and tendon pathology. Greater trochanteric pain syndrome (GTPS) consists of a 
tendinitis of the insertion of the gluteus medius or minimus muscle and/or a trochanteric 
bursitis. This study investigates the prevalence of GTPS in patients with hip osteoarthritis and 
whether the co-existence of GTPS is associated with the severity of perceived pain in these 
patients.
Methods: In this prospective study, patients with hip osteoarthritis recruited from general 
practices were followed for 2 years. GTPS was diagnosed as tenderness at or around the 
greater trochanter, recognition of this tenderness as one of the complaints, and a painful 
resisted hip abduction. Pain severity was measured with the Western Ontario and McMasters 
University Osteoarthritis Index (WOMAC) subscale for hip pain (0-100) and the Visual Ana-
logue Scale (VAS) (0-100). Associations between patients’ perceived hip pain and presence of 
GTPS were assessed using linear mixed model analysis for repeated measurements.
Results: GTPS was present in 32/205 (16%) patients at baseline and in 26/184 (14%) patients 
at two-year follow-up. Eight (4%) patients had GTPS at both baseline and follow-up. Presence 
of GTPS at one of the measurements was associated with more severe WOMAC pain (estimate 
10.2, 95% CI 4.3-16.1; p=0.001) and more severe VAS pain (estimate 13.8, 95% CI 7.0-20.6; 
p<0.001).
Conclusion: In this cohort, one in seven patients with hip osteoarthritis had concurrent 
GTPS. Patients with hip osteoarthritis and GTPS at one of the measurements showed clinically 
significant higher pain scores at all measurements than those with hip osteoarthritis without 
GTPS at any of the measurements.
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Introduction
Osteoarthritis (OA) of hip and knee is the most disabling type of OA and affects about 5-10% 
of the elderly population.[1] Until now, the development of disease-modifying OA drugs 
remains largely unsuccessful.[2] Therefore, mainly symptomatic treatment for OA is applied, 
but with only minor to moderate effectiveness.[3] Lack of treatment options to stop or re-
verse OA may result in joint replacement surgery.
Improvement of symptomatic therapy might be possible with better understanding of the 
perceived pain in OA. Patients with symptomatic OA often show fluctuating pain levels, i.e. 
periods with pain flares alternated with periods with much less, or even absence of, pain.[4, 
5] Although this fluctuating pain pattern in OA patients is common, little is know about the 
mechanism behind these fluctuations.[6]
Bursal and tendon pathology are possible causes of pain in patients with OA. In radiologi-
cal knee OA, patients reporting knee pain more frequently showed peri-articular lesions on 
magnetic resonance imaging than patients not reporting knee pain.[7]
In hip OA, few data are available on an association between the fluctuating pain patterns 
and bursal and tendon pathology.[4] Greater trochanter pain syndrome (GTPS) is a well-
known tendinitis in the hip region with an incidence in primary care of 1.8 patients per 1000 
per year.[8] Although there is continuing debate on how to define GTPS, it is generally seen 
as a tendinitis of the insertion of the gluteus medius or minimus muscle, or a trochanteric 
bursitis, or a combination of both.[9, 10] About 25% of patients with low-back pain have 
GTPS[11] and about 30% of patients with GTPS also have low-back pain or hip OA (defined as 
clinical hip OA by the American College of Rheumatology).[12]
Methods
Study design
For the present study, data were used from a randomized controlled trial that assessed the 
effectiveness of glucosamine sulfate on progression of OA (the GOAL trial).[13-15] In that 
study, eligible patients with hip OA were randomly assigned to receive either 1500 mg of oral 
glucosamine sulfate or placebo over a period of 2 years.
The Medical Ethics Committee of Erasmus MC approved the study design, and all patients 
provided written informed consent. A detailed description of the study design and outcomes 
are available elsewhere.[13-15] The original study showed that glucosamine sulfate was no 
better than placebo in reducing symptoms and progression of hip OA.
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Setting and participants
The trial recruited prevalent cases of patients with hip complaints from medical records 
of general practices located in the south-west of the Netherlands. Patients were eligible if 
they met the American College of Rheumatology criteria for hip OA.[16] Patients who had 
undergone or were awaiting hip replacement surgery were not eligible. Also excluded from 
the study were patients who had a Kellgren & Lawrence (KL) score of 4 of the hip[17], renal 
disease, liver disease, diabetes mellitus, or a disabling co-morbid condition that would make 
visits to the research center impossible, as well as patients already receiving glucosamine 
sulfate and those unable to complete questionnaires in the Dutch language. Patients who 
violated the study protocol were encouraged to complete the data collection in order to limit 
the loss to follow-up.
Outcomes and follow-up
Using a baseline questionnaire we assessed patient characteristics, disease characteristics, 
and co-morbidity. Back pain severity was assessed with the question: ‘In the past three months 
did you have osteoarthritis of your back, or pain in your back’. At baseline, radiography of the 
knees was performed to record the presence of radiographic OA according to the KL grading 
(≥ 2). Also, radiography of the hip was performed to assess radiographic severity of hip OA 
according to the KL grading scale (0-4).[17]
At baseline and at 2-year follow-up, patients visited the research center for a physical ex-
amination that included range of motion of the hip and painful involvement of extra-articular 
tissues at the hip. The greater trochanter region was assessed for tenderness at the top of 
the greater trochanter, as well as just above, dorsal and beneath the trochanter. In case of 
tenderness, patients were asked if they recognized the pain as one of their complaints.[18] In 
addition, we assessed whether resisted hip abduction in the extended position was painful.
GTPS was defined as the presence of tenderness at the side of the greater trochanter (on 
the top, or just above, dorsal or beneath) in combination with patients’ recognition of this 
tenderness as one of the complaints, and with a painful resisted hip abduction at the ipsilat-
eral side. Co-existence of GTPS was defined as GTPS at the site of the symptomatic hip; the 
symptomatic hip was designated as that with hip OA. Patients with bilateral hip symptoms 
were asked to indicate which hip was most affected. For patients unable to decide, the hip 
with the highest KL score, or the smallest internal rotation during physical examination, was 
used.
Severity of hip pain was measured with two validated measurement instruments: the West-
ern Ontario and McMasters University Osteoarthritis Index (WOMAC) subscale for hip pain 
and the Visual Analogue Scale (VAS). The WOMAC subscale is presented as a standardized 
score (0-100, where 0 indicates no symptoms and 100 indicates unbearable pain). The VAS 
has a 0-100 score (where 0 indicates no pain and 100 indicates unbearable pain).[19-21] If 
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patients had a total hip replacement during follow-up, available data were included in the 
analysis until surgery; data collected after surgery were assumed to be missing.
Statistical analysis
Data were analyzed using multivariate linear mixed models for repeated measurement to 
assess associations between patients’ perceived hip pain and presence of GTPS (with a 2-year 
period between). This technique adjusts for the within-patient correlation for the outcomes 
at diff erent measurements in each patient, and uses each outcome from each patient as a 
separate observation, and it therefore also allowed us to identify the between-patient vari-
ance and within-patient variance due to the presence of GTPS. The compound symmetry 
covariance structure was used since this yields the lowest Akaike’s Information Criterium 
(AIC). The estimate calculated from this model is a coeffi  cient.
Covariates used for adjustment were based on previous studies[13, 22, 23] and included: 
age, gender, body mass index (BMI), allocated treatment (glucosamine sulfate or placebo), 
and duration of hip complaints (<3 years or ≥ 3 year). We also adjusted for presence of knee 
OA at baseline (KL ≥ 2 in one of the knees), presence of low-back pain at baseline, and severity 
of radiologic hip OA at baseline (KL ≥ 2 in one of the hips). All covariates were included in the 
model as fi xed factors. A p-value ≤ 0.05 was considered statistically signifi cant. All analyses 
were conducted using SPSS version 20.0.
Results
The GOAL trial included and randomized 222 patients; of these, 111 received glucosamine 
sulfate and 111 received a placebo during the 2-year follow-up. The GTPS assessment was 
missing for 17 patients at baseline and for 18 patients at follow-up. Another 20 patients had 
undergone total hip replacement surgery during the follow-up period (Figure 1).
 
 222 patients included in the GOAL study 
n=32 
GTPS 
n=8 
GTPS 
n=15 
no GTPS 
n=4 missing 
n=5 THR 
n=17 
missing 
n=17 
no GTPS 
n=173 
no GTPS 
n=18 
GTPS 
n=126 
no GTPS 
n=14 missing 
n=15 THR 
Figure 1 Flowchart of the included patients.
GTPS = greater trochanter pain syndrome, THR = Total Hip Replacement
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Of the 205 patients, 32 (16%) with hip OA and GTPS assessment at baseline had symptomatic 
GTPS. Table 1 presents the characteristics of patients with and without GTPS at baseline. 
Patients with GTPS more often had a lower KL score (<2) than patients without GTPS. Ra-
diographic knee OA was more frequently present in patients without GTPS (36%) than in 
patients with GTPS (19%). Low-back pain was present in about 2/3 of the patients both with 
and without GTPS.
Table 1 Baseline characteristics and symptom severity in patients with hip osteoarthritis with and without 
greater trochanteric pain syndrome.
Hip OA with GTPS
n=32
Hip OA without GTPS
n=173
Female (n, %) 29 (91) 116 (67)
Age in years (mean, SD) 62.0 (8.2) 64.1 (8.5)
BMI (mean, SD) 28.5 (4.9) 27.8 (4.7)
Duration of hip complaints ≥3 years (n, %) 18 (56) 91 (53)
Radiographic severity of hip OA (n, %)
- Kellgren&Lawrence <2
- Kellgren&Lawrence ≥2
20 (62.5)
12 (37.5)
89 (51)
84 (49)
Presence of low back pain (n, %) 23 (72) 113 (65)
Radiographic knee OA (n, %) 6 (19) 62 (36)
Radiographic hand OA (n, %) 15 (47) 95 (55)
Symptom severity
WOMAC pain (0-100) (mean, SD) 45.9 (21.9) 32.6 (22.8)
WOMAC function (0-100) (mean, SD) 44.8 (21.2) 33.2 (22.2)
WOMAC stiffness (0-100) (mean, SD) 54.3 (23.9) 40.5 (24.1)
VAS hip pain (mean, SD) 49.0 (28.2) 29.6 (24.3)
OA = osteoarthritis; GTPS = greater trochanteric pain syndrome; BMI = body mass index; WOMAC = Western 
Ontario and McMasters University Osteoarthritis Index (higher score means more pain); VAS = Visual Ana-
logue Scale (higher score means more pain), SD= standard deviation
Of the 184 patients, at follow-up 26 (14%) had GTPS. Despite a comparable prevalence of 
GTPS in patients with hip OA at baseline (16%) and at follow-up (14%), only 8 (4%) had GTPS 
at both baseline and follow-up (Figure 2).
Associations between GTPS and symptom severity
Table 2 presents the results of the multivariate linear mixed-model analysis. GTPS was sig-
nificantly associated with WOMAC pain score (estimate 10.2, 95% CI 4.3-16.1; p=0.001). The 
estimate indicates that, when GTPS is present, the WOMAC pain score is 10.2 points higher 
(on a 0-100 scale). For VAS pain, GTPS was also significantly associated with an estimate of 
13.8 (95% CI 7.0-20.6; p<0.001).
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 Figure 2 Distribution of the greater trochanteric pain syndrome (GTPS) at baseline and at 2-year follow-up 
and overlap between them.
Total n=167
Striped area GTPS at baseline (n=15); Dotted area GTPS at 2-year follow-up (n=18); Black area GTPS at base-
line and at 2-year follow-up (n=8); Excluded were persons with total hip replacement during follow-up, or 
missing the GTPS examination at baseline or at 2-year follow-up.
Table 3 presents the explained variances of the covariates included in the linear mixed model. 
GTPS explains 7% of the between-patient variance for WOMAC pain; however, GTPS explains 
<1% of the within-patient variance for WOMAC pain. The total model explains 36% of the 
between-patient variance for WOMAC pain; with 7% (20% of the models explained between-
patient variance) GTPS is an important factor in this model.
In the model for VAS pain, GTPS explains 16% of the between-patient variance and 2.7% of 
the within-patient variance. The total model explains 39% of the between-patient variance 
for VAS pain; with 16% (41% of the models explained between-patient variance) GTPS is also 
an important factor in this model. The small within-patient variance in both models indicates 
that patients with hip OA that have or had GTPS at one of the measurements have more pain 
than patients with hip OA that did not have GTPS at one of two measurements.
Table 2 Results of multivariable linear mixed model analysis for GTPS and perceived severity of pain at base-
line and 2-year follow-up (n=220).
WOMAC pain VAS hip pain
Estimate 95% CI p-value Estimate 95% CI p-value
GTPS (at baseline and at 2-year FU) 10.2 4.3 – 16.1 0.001 13.8 7.0 – 20.6 <0.001
Knee OA at baseline (KL≥2) 1.3 -4.3 – 6.9 0.65 0.3 -5.9 – 6.5 0.92
Back pain at baseline 13.7 8.4 – 19.0 <0.001 11.9 6.1 – 17.7 <0.001
Hip OA at baseline (KL≥2) 6.7 1.6 – 11.8 0.010 9.2 3.6 – 14.8 0.001
Analysis adjusted for baseline variables gender, age (years), body mass index (kg/m2), allocated treatment 
(glucosamine sulfate or placebo), and duration of complaints (<3 years or ≥3 years). FU = follow-up; WOMAC 
= Western Ontario and Mc Masters University Osteoarthritis Index; VAS = Visual Analogue Scale; OA = os-
teoarthritis; KL = Kellgren & Lawrence grading of radiologic OA; GTPS = greater trochanter pain syndrome
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Table 3 Between-patient and within-patient variances for GTPS and pain at baseline and at 2-year follow-up 
(n=220).
WOMAC pain VAS hip pain
bP (% explained) wP (% explained) bP (% explained) wP (% explained)
IC only 263 281 268 413
IC + adjustments* 220 (16%) 225 (16%)
IC + knee OA at baseline (KL≥2) 259 (2%) 266 (1%)
IC + back pain at baseline 207 (21%) 221 (16%)
IC + hip OA at baseline (KL≥2) 262 (0%) 260 (3%)
IC + GTPS (at baseline and FU) 245 (7%) 280 (<1%) 226 (16%) 424 (2,7%)
Total model** 168 (36%) 164 (39%)
FU = follow-up; WOMAC = Western Ontario and McMaster Universities, VAS = Visual Analogue Scale, bP = 
between-patient variance, wP = within-patient variance, IC = intercept, OA = osteoarthritis, GTPS = greater 
trochanter pain syndrome * Adjusted for for baseline variables gender, age (years), body mass index (kg/
m2), allocated treatment (glucosamine sulfate or placebo), duration of complaints (<3 years or ≥3 years). 
** In the total model all variables and adjustments are included: GTPS, gender, age (years), body mass in-
dex (kg/m2), allocated treatment (glucosamine sulfate or placebo), duration of complaints (<3 years or ≥3 
years), knee OA, back pain and severity of radiologic OA.
Discussion
In this primary care cohort, one in seven patients with hip OA had concurrent GTPS. Patients 
with hip OA and GTPS showed clinically significant higher pain scores than patients with hip 
OA without GTPS.[24]
To our knowledge this is the first study to report the incidence and analysis of GTPS in 
hip OA patients. In a population aged 50-79 years with knee OA or at risk for knee OA, Segal 
et al. found a prevalence of GTPS of 17.6% (based on tenderness at physical examination) 
and found that GTPS was related to the presence of ipsilateral knee OA.[25] In the present 
longitudinal study with measurements at baseline and 2-year follow-up, data were analyzed 
using linear mixed model analysis. An earlier study, included in a PhD thesis[26] assessed 
in the same data whether the co-existence of GTPS was associated with more pain, using a 
linear regression model with backward selection. However, we believe that use of a linear 
mixed model with repeated measurements is more appropriate since this technique adjusts 
for the within-patient correlation for the symptom severity scores at different measurement 
points, and also clearly shows both the within-patient variance and between-patient vari-
ance due to GTPS. 
Based on these analyses, it showed that more between-patient variance was explained 
by GTPS than within-patient variance. This implies that patients with hip OA who had GTPS 
at one of the measurements have more pain even when GTPS is absent than patients who 
did not have GTPS at one of the occasions. It also implies that patients with GTPS may have 
factors in common that correlate with reported pain ranging from biomechanical factors like 
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a disturbed walking pattern to the presence of sensitized pain pattern. However, because of 
the omission of such factors in our study we were not able to study any causal mechanism 
behind the association between GTPS and increased pain.
About two thirds of our hip OA patients reported low-back pain. The presence of low-back 
pain aggravated the severity of symptoms in hip OA even more than the presence of GTPS. 
Musculoskeletal co-morbidity is known to influence the severity of symptoms in OA.[27, 
28] Co-existent low-back pain is also known to predict future pain in those with clinical hip 
OA.[29] The presence of co-existent low-back or buttock pain, often in combination with 
spine OA, may also be a cause of persisting pain at that location after total hip replacement 
and may lead to dissatisfaction with the surgery.[30]
At present, no data are available on the influence of co-existent GTPS on the outcome of 
any treatment for hip OA. On the other hand, the influence of co-existent hip OA or low-back 
pain was studied in a trial using local corticosteroid injection in patients with GTPS.[12, 31] 
There was a significant short-term effect of local corticosteroid injection in the total group, 
but also to a similar or even greater degree in the subgroup of patients with co-existent 
low-back pain or hip OA.[12] This implies that the subgroup of patients with co-morbidity 
benefits as much from injection therapy as the total group.
A limitation of the present study is the lack of consensus on the diagnostic criteria for GTPS. 
Related to this, few data are available on the validity or reliability of diagnostic criteria for this 
condition (although we did not evaluate these properties in the present study). Although 
some studies mentioned trochanteric tenderness and recognition of the pain as diagnostic 
criteria[18, 32-34], others report on additional diagnostic tests such as a positive Trendelen-
burg sign, painful resisted abduction, painful resisted internal rotation, and a painful FABER 
test (flexion, abduction, external rotation).[10, 35, 36] The present study used trochanteric 
tenderness, patients’ recognition of the pain, and resisted painful abduction, as diagnostic 
criteria. When analyzing our data using a less stringent diagnosis of GTPS (trochanteric 
tenderness and recognition of the pain only) the prevalence of GTPS was higher but the as-
sociation with perceived pain in hip OA remained about the same.
In our study patients were selected from databases of general practitioners (GPs) who 
diagnosed patients with hip OA. Because these patients were contacted by their GP, this 
study used prevalent cases of hip OA in general practice. Therefore, these results should be 
interpreted with caution and cannot be directly extrapolated to patients with hip OA visiting 
their GP for pain and patients with hip OA visiting secondary caregivers.
In clinical practice it is important to identify in patients with hip OA, the concurrent GTPS 
or other musculoskeletal co-morbidity since these patients often show more pain. Treat-
ment should be aimed at both the musculoskeletal co-morbidity and the hip OA, but also, 
when known at the causal mechanisms behind it. It has been shown that patient with GTPS 
demonstrate significant weakness of the hip abductor muscles, even bilaterally, compared to 
healthy individuals.[37] It is not clear whether GTPS precedes hip abductor weakness or vice 
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versa, however this could be a future point-of-action for therapy. An ongoing trial is, at this 
moment, studying treatment of GTPS comparing wait-and-see to corticosteroid injection to 
physiotherapy.[38] New research should also assess whether pain sensitization mechanisms 
are present in case of musculoskeletal co-morbidity, and search for subsequent adequate 
treatment.
Conclusions
In this cohort study, one in seven patients with hip osteoarthritis had concurrent GTPS. Pa-
tients with hip OA and GTPS at one of the measurements showed clinically significant higher 
pain scores than patients with hip OA without GTPS at any of the measurements.
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CHAPTER 8
General discussion
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The aim of the work presented in this thesis was to assess the effectiveness of intramuscular 
corticosteroid injection in patients with painful hip osteoarthritis (OA), to gain insight into 
diagnosing hip OA, and into the course of pain and comorbidities influencing complaints in 
patients with hip OA.
First, we conducted a randomized controlled trial (RCT) that assessed the effectiveness of 
an intramuscular corticosteroid injection compared to an intramuscular placebo injection in 
patients with painful hip OA. In a systematic review we then studied the value of anesthetic 
hip joint injection in diagnosing hip OA. We also examined associations between clinical 
symptoms in patients with hip OA and biomarkers. A systematic review was made of the 
available literature and associations were assessed between patients’ symptoms due to hip 
OA and weather conditions. Finally, we focused on the influence of the greater trochanter 
pain syndrome (GTPS) on hip pain severity in patients with hip OA.
This chapter presents the main findings of our work in relation to existing evidence and 
addresses some methodological challenges. The chapter closes by presenting some implica-
tions for daily practice and ideas for future research.
Non-operative treatment of hip OA
Several international guidelines are available for non-operative treatment of hip OA and 
many of the recommendations are generally agreed upon.[1-4] The current Dutch guideline 
for the diagnosis and treatment hip OA has a multidisciplinary design and is supported by 
both primary care providers and secondary care providers.[3] This guideline (dating from 
2007) is under currently revision; an updated guideline is expected in due course.
Treatment of symptomatic OA begins with non-pharmacological management including 
education, exercise, weight loss, and assistive devices.[4] These therapies can be combined 
with pain medication. Acetaminophen is still the first-line treatment, followed by non-
steroidal anti-inflammatory agents (NSAIDs) and opiates (tramadol). Another possibility is 
an intra-articular corticosteroid injection; most international guidelines recommend this 
treatment option for knee OA and hip OA.[1-4] However, because the hip joint cannot be 
palpated and is adjacent to important neurovascular structures, hip joint injection is best 
performed under fluoroscopic or ultrasound guidance. In clinical practice this often results 
in delay or refraining from this type of treatment, because an appointment at the radiology 
department has to be planned. In contrast, an intramuscular corticosteroid injection can be 
given immediately.
In Chapter 3 we show that an intramuscular corticosteroid injection has a systemic effect 
on hip pain reduction in patients with hip OA during a 12-week follow-up period. This non-
operative alternative treatment might lengthen the non-operative management of patients 
with hip OA in primary care, or postpone surgical treatment in secondary care.
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It was interesting that the effect of the intramuscular corticosteroid injection was main-
tained during the entire 12-week follow-up period. The mid-term (±3 months) effect of 
intra-articular corticosteroid compared to placebo has been demonstrated in a meta-analysis 
using individual patient data from patients with hip OA, from two hip OA trials with medium 
to low risk of bias. At mid-term follow-up (3 months) the pooled mean difference (MD) for 
intra-articular injection was 13.6 (95% CI 3.5 to 23.6) (scale 0-100); this result was similar to 
the effect of intramuscular injection in our trial, i.e. MD -1.2 (95% CI -2.3 to -0.2) (scale 0-10).
[5] On the other hand, a recent systematic review (including 5 studies) did not find this mid-
term effect of intra-articular corticosteroids in patients with hip OA.[6] Moreover, a recent 
Cochrane review (including 27 trials with 1767 participants) on knee OA and intra-articular 
corticosteroid injection, also found no mid-term effect on pain reduction.[7]
In clinical practice, repeated intra-articular corticosteroid injection is under debate because 
of the assumed risk of progression of OA due to chondrotoxicity. In basic science literature 
intra-articular corticosteroid treatment has been associated with toxicity to chondrocytes.[8]
A recent systematic review on the effect of intra-articular corticosteroids on articular 
cartilage identified only one clinical trial in humans. All other studies were in vitro human 
chondrocyte studies or in vivo animal studies.[8] The one human clinical trial studied the 
effect of 40 mg triamcinolone acetate injection in patients with knee OA by administering 
injections every 3 months for a 2-year period; the results show no difference in radiographic 
narrowing in the corticosteroid group or the placebo group, suggesting that multiple intra-
articular corticosteroid injections can safely be given with regard to structural progression.[9]
Another important point is the assumed increased risk of prosthesis infection after intra-
articular injection with corticosteroids. An intra-articular hip injection in the year preceding 
hip replacement increases the risk of prosthesis infection (3.3% versus 2.4% for patients who 
did not receive intra-articular injection) in a retrospective cohort study.[10] This increased 
risk of prosthesis injection has also been shown in a retrospective cohort study for systemic 
corticosteroid treatment for more than 1 week (OR 2.19 corticosteroid treatment versus no 
corticosteroid treatment).[11] For a single intramuscular injection no literature is available on 
the assessed risk of prosthesis infection. A recent systematic review on this subject included 
9 nine studies with important methodological flaws.[12] 8 of the 9 studies were retrospective 
and confounding factors were poorly addressed. This systematic review concludes that there 
is insufficient evidence to conclude that intra-articular corticosteroid injection increases the 
risk of prosthesis infection.
According to a predefined subgroup analysis, the effects of hip pain reduction in the corti-
costeroid group were larger for patients from secondary care than for patients from primary 
care: Numerical Rating Scale (NRS) in rest at 2-week follow-up: between-group difference 
-2.3 (95% CI -4.4 to -0.2); between-group difference in primary care -0.9 (95% CI -2.0 to 0.2). 
These effects were present despite the relatively small group of patients from secondary care 
(n=26) compared to the group recruited from primary care (n=80). This suggests that, even 
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after referral to secondary care, non-operative treatment can be effective in pain reduction 
and that total hip replacement (THR) should not be offered immediately.
A challenge we experienced was recruiting patients to participate in our placebo-con-
trolled trial. Although we assessed 422 patients with hip OA for eligibility, we were unable to 
include our pre-calculated sample size of 128 patients. Of the 422 assessed patients, 92 (22%) 
declined to participate, mostly because they did not want to risk receiving a placebo. Of the 
334 patients that did not immediately refuse, 30% (n=101) did not use any pain medication 
despite moderate to severe pain (NRS ≥3; scale 0-10). In clinical practice, patients consider 
the effect of pain medications such as acetaminophen and NSAIDs to be too small. In a cohort 
of patients with knee OA, 74% of patients used over-the-counter pain medication; however, 
only 47% rated this treatment as very effective.[13] Patients with severe knee OA used less 
over-the-counter pain medication (67%) compared to those with mild and moderate knee 
OA, i.e. 72.9% and 77.2%, respectively.[13] Because clinical practice shows that not all pa-
tients with OA with moderate to severe pain take pain medication, future clinical research 
should set less stringent inclusion criteria on this item.
Diagnosis in hip pain
Hip pain can arise from different sources, both intra-articular and extra-articular. It is impor-
tant to correctly classify the disease that is the source of hip pain, especially when treatment 
includes surgery (such as THR). Careful history taking and physical examination can often 
differentiate between hip OA and other sources of symptoms.[14] However, in some cases 
presentation is nonspecific and the diagnosis remains challenging. Although the presence 
of limping, groin pain, and limited internal rotation of the hip are more predictive for hip 
disorders, these symptoms are also seen in patients with spine disease, or both hip disease 
and spine disease.[15] Additional radiographic examination will not always be helpful 
to diagnose hip OA. For example, in two large epidemiological studies, Kim et al. showed 
that many people with painful hips do not have radiographic evidence of hip OA and many 
patients with radiographic OA do not have hip pain.[16] Moreover, hip pain is also associated 
with disc space narrowing at level L1-2 (men OR = 2.0, and women OR = 1.7) and at L2-3 
(women OR = 1.6).[17]
To differentiate between hip pain originating from the hip joint and other pathology (e.g. 
spinal disease), an anesthetic hip joint injection is used in orthopaedic practice. However, in 
our systematic review (Chapter 4) we conclude that, based on the available evidence, no rec-
ommendation can be made regarding the use of hip injection for diagnosing hip OA because 
of the high risk of bias of the included studies. The available evidence consisted of 9 studies 
(with a total of 556 patients) with medium to high risk of bias. Although all studies used THR 
as reference standard, there was considerable verification bias. In our pooled results, 75% of 
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the patients that had reduction in pain after injection received a THR, whereas in patients 
that did not have pain reduction after injection only 15% received a THR.
To check the data we found in the published studies from abroad, we performed an 
explorative retrospective cohort study in patients that received a diagnostic hip injection 
between January 2009 and December 2010 in two Dutch hospitals (Erasmus Medical Centre 
Rotterdam and Elisabeth Hospital Tilburg). We identified 103 patients that had a diagnostic 
hip injection. However, in this retrospective setting, pain scores after diagnostic injection 
were missing for most patients. Moreover, although a final diagnosis was made in 99 patients, 
for 30 of these patients we could not retrieve their level of satisfaction or pain relief after final 
treatment. These data are in accordance with other retrospective studies on the diagnostic 
value of anesthetic hip joint injection and did not result in new insights.[18-23] However, 
based on lacking data in such retrospective studies, we emphasize the importance of routine 
collecting of standardized patient-reported outcome measures in clinical practice.
So far, the value of intra-articular diagnostic hip injection remains under debate. Based on 
the available evidence we cannot recommend its use in clinical practice.
Course of pain in hip OA
Patients diagnosed with hip OA often ask their healthcare providers about the prognosis of 
their complaints, i.e. they would like to know about the progression of OA and related com-
plaints. For healthcare providers this is a difficult question because the available knowledge 
and data are mainly on the group level. It is reported, on group level, that pain and functional 
status deteriorate slowly over time for hip OA.[24] Beside this slow progression, symptoms 
can also vary greatly on a time (e.g. days/weeks) basis. These flairs in pain are associated with 
disability, poorer sleep quality, productivity losses, reduced quality of life, and higher health-
care resource use.[25] It also is known that some patients are fast progressors and some slow 
progressors; however, this is difficult to predict for the individual patient. If physicians are 
able to identify patients at high risk of fast progression of OA, we could tailor our advice to 
the individual patient and adjust treatment accordingly. Prognostic factors to predict the 
course of hip pain due to OA are limited.[26] To identify possible trajectories of pain in hip OA 
over time, latent class growth analysis (LCGA) can be used. This statistical technique attempts 
to group people who are similar in their response to measured variables or growth trajec-
tories. This method allows to discriminate between progressive trajectory disease and non-
progressive disease,[27, 28] and is applied to repeated measurement data. Previously, these 
trajectories were difficult to identify due to the lack of repeated measurements. For example, 
when only one follow-up moment was used, the patient could be defined as a progressor or 
non-progressor depending on their temporary flair or non-flair period, whereas their overall 
symptomatic progression over several time points might show a different pattern.
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LCGA has been used in patients with hip OA with 3-monthly measurements of pain dur-
ing a 2-year follow-up study. LCGA was able to discriminate five distinct trajectories of pain: 
i.e. mild pain, moderate pain, always (severe) pain, regularly progressive pain, and highly 
progressive pain.[28] In another cohort of patients with early symptomatic hip OA and a 
5-year follow-up, four different pain trajectories were found using LCGA: mild pain, moder-
ate decrease, moderate progression, and severe pain. Factors associated with more severe 
pain trajectories were lower education, higher activity limitation scores, frequent use of pain 
reinterpretation as coping strategy, and painful internal hip rotation.[29]
In the future, when a risk assessment score for individual patients can be made and 
validated for the trajectory of progression in hip pain, patients can be educated and treated 
according to their individual risk.
Biomarkers are defined as characteristics that are objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes, or pharmacologic responses 
to a therapeutic intervention.[30] However, OA-specific biomarkers are not joint specific 
when assessed in serum or urine. If such biomarkers could predict progression of hip pain or 
hip OA in individual patients, this would be of substantial clinical value. However, until now, 
again few publications are available on biomarkers and the prediction of OA progression.[31] 
Most studies present association data on group level, and no discriminative areas under the 
curve or predictive values.
In Chapter 5 we assessed the association between cartilage biomarkers (uCTXII and uCIIM) 
and clinical symptoms in patients with hip OA using the previously defined pain trajectories 
based on LCGA. Both these markers are derivatives of type II collagen and degraded by en-
zymes during cartilage erosion and excreted in urine. CTXII has been studied extensively in 
knee as well as hip OA.[31] Our study showed that in patients with mild to moderate hip OA, 
uCTX-II and uCIIM were not cross-sectionally associated with hip pain at 6-monthly intervals 
during the 2-year follow-up. However, patients in the moderate pain trajectory and in the 
highly progressive pain trajectory were more likely to have a higher loguCTX-II at baseline 
than patients in the mild pain trajectory.
A recent prediction model for knee OA shows that ‘questionnaire-based’ risk factors, age/
gender/BMI, a genetic risk score, or uCTX-II levels alone are not good predictors of incident 
radiographic knee OA.[32] Also, a combination of these risk factors has a relatively low 
predictive value for knee OA. However, a model that includes doubtful minor radiographic 
degeneration reached good predictive value and is applicable in clinical practice. A recent 
systematic review on the use of biomarkers for risk assessment shows that limited data are 
available on hip OA.[31] If, in the future, biomarkers, together with other variables, could be 
included in a risk assessment score for individual patients for hip OA, then biomarkers could 
be used in clinical practice. However, at the moment, biomarkers show no or only small as-
sociations and offer no additional value over variables that are easily assessed, e.g. reported 
morning stiffness, painful internal rotation, etc.
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As mentioned previously, patients with OA show daily or weekly fluctuations in pain 
symptoms.[25, 28] Because patients often report that weather conditions influence their 
symptoms, this could be a contributing factor.[33] In Chapter 6 it is shown that in patients 
with hip OA, barometric pressure and relative humidity influence OA pain and disability. 
However, the contribution of these weather variables to the severity of OA symptoms is not 
considered to be clinically relevant.
The effect of weather variables has also been studied in low back pain; in this case, the 
speed of wind and wind gusts showed an association with back pain; however, the magni-
tude of the increase was, again, not considered to be clinically relevant.[34]
Previous studies on hip OA and weather show no consistent correlation with patients’ pain. 
This inconsistency might be caused by differences in the methods of data collection and 
statistical analyses. Based on our findings, as well as the inconsistency of previous studies 
on hip OA and weather and the findings related to low back pain, we suggest that no new 
studies should focus on musculoskeletal disorders and weather variables. In clinical practice, 
patients can be informed that the weather has practically no influence on symptoms related 
to hip OA.
Hip OA and comorbidities
The onset of musculoskeletal comorbidity, e.g. low back pain or tendinopathy, can cause an 
increase in pain in patients with hip OA. Parvizi et al. reported that in patients with hip OA and 
pre-operative low back pain, this back pain does not resolve after THR in one third of patients; 
[35] this might lead to dissatisfaction after THR.
Another comorbidity is greater trochanter pain syndrome (GTPS), which is a trochanteric 
bursitis and/or a tendinitis of the insertion of the gluteus medius or gluteus minimus muscle. 
In Chapter 7 we concluded that one in seven patients with hip OA had concomitant GTPS. 
Moreover, patients with concomitant GTPS reported significantly higher scores for hip pain 
than patients with hip OA alone.
In patients with hip OA, it is important to identify concurrent GTPS or other musculoskel-
etal co-morbidity, since these patients often report more pain. The treatment of patients with 
hip OA and GTPS should be aimed at both conditions. GTPS can be treated by wait-and-see, 
physiotherapy (hip abductor weakness), analgesics, and a local corticosteroid injection. Even, 
in patients with GTPS and comorbidities, such as low back pain and/or hip OA, the effect of 
a corticosteroid injection in the trochanteric bursa is greater (58% recovered) compared to 
patients with GTPS alone (32% recovered).[36]
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Implications for clinical practice and future research
This thesis shows that although diagnostic anesthetic hip injection is frequently used, evi-
dence for the diagnostic value of this test is limited and there is a lack of studies, which have 
a low risk of bias. Therefore, future research should preferably consist of an observational 
prospective cohort of patients with hip pain atypical for hip OA, or patients with hip OA and 
concomitant lumbar spine OA visiting the orthopaedic outpatient clinic. In this cohort, sever-
ity of pain and patients’ satisfaction should be measured using validated questionnaires at 
pre-injection, post-injection, and after subsequent treatment, e.g. THR.
Such studies should help establish: i) the diagnostic value of intra-articular anesthetic hip 
injection in patients with atypical hip pain who consult an orthopaedic surgeon; ii) the effect 
of intra-articular anesthetic hip injection on atypical hip pain; iii) the type/effect of therapies 
given to these patients; iv) outcomes after the selected therapies; v) and clinical differences 
between patients with atypical hip pain and a final treatment for hip OA (THR) compared 
with patients with atypical hip pain and a different type of final treatment.
This thesis also shows that, based on the results of our blinded RCT evaluating the effective-
ness of an intramuscular corticosteroid injection versus an intramuscular placebo injection, 
there is a pain-reducing effect in patients with painful hip OA for at least 12 weeks.
This information could change the treatment strategy for hip OA, because this means an 
additional treatment option is available for patients with painful hip OA. Since this intramus-
cular injection can be given in both primary and secondary care, general practitioners will be 
able to treat patients with hip OA for a longer period of time in primary care. However, since 
this is the first trial assessing the effect of intramuscular corticosteroid injection for painful 
hip OA, our findings need to be confirmed in additional trials. Moreover, cost-effectiveness 
compared to usual care and compared to intra-articular injection is lacking. Our results need 
to be validated in a study with a longer follow-up period, assessing multiple injections and 
including patients from both primary and secondary care.
Finally, our study did not assess the effect of intramuscular corticosteroid injection com-
pared to intra-articular injection. If future research shows at least a similar effect of intra-
muscular and intra-articular injection, or shows effective mid-term or even long-term effects, 
then intramuscular injection could replace intra-articular injection. However, this should 
(preferably) be investigated in a blinded randomized controlled inferiority trial comparing 
the two types of corticosteroid injection. The aim of all these studies is to further improve the 
diagnosis and treatment of patients with painful hip osteoarthritis.
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Summary
The aim of the research described in this thesis was to assess the effectiveness of intramuscu-
lar corticosteroid injection in patients with painful hip osteoarthritis (OA), and to gain insight 
in the course of pain and comorbidities influencing hip complaints in patients with hip OA.
In chapter 2 the study protocol of our double-blinded, randomized controlled trial (RCT) 
is presented. We enrolled patients (aged > 40 years) with painful hip OA scoring ≥3 on an 
11-point numerical rating scale (NRS:0-10;0=no hip pain) despite the use of oral analgesics. 
Patients were screened for eligibility by general practitioners and orthopaedic surgeons. 
Patients were randomized to receive either 40mg of triamcinolone acetate or placebo (saline) 
with an intramuscular injection into the ipsilateral gluteus muscle.
Randomization was stratified for setting (primary care versus secondary care). To assure 
blinding an independent pharmacy assistant allocated each included patient based on 
a computerized randomization list. After randomization the vials for the injections were 
prepared, packed and sealed in an identical way for both groups by the pharmacy assistant. 
An independent trial nurse not involved with follow-up measurements prepared and admin-
istered the injection out of sight of the patient, assessors, treating doctors, and researchers.
The primary outcome was severity of hip pain at 2 weeks, measured with an 11-point 
numerical rating scale (NRS: 0-10, where 0=no pain) in rest and on walking, and with the 
Western Ontario and McMaster University Osteoarthritis Index pain subscale (WOMAC pain: 
0 to 100, where 0 equals no symptoms). Secondary outcomes were the primary outcomes 
at 4, 6, and 12 weeks follow-up. Additional secondary outcome measures were WOMAC 
function, stiffness and total, quality of life (EQ-5D), Intermittent and Constant Osteoarthritis 
Pain (ICOAP), and patients’ perceived recovery, using a 7-point Likert scale. Statistical analysis 
was based on the intention-to-treat principle. Linear mixed models with repeated measures 
were used for continuous outcomes. Generalized estimating equations analyses (GEE) with 
repeated measures were done for dichotomous outcomes.
In chapter 3 the results of this performed RCT are shown. 107 patients were randomized 
of which 106 patients could be analyzed; 52 patients in the corticosteroid group and 54 pa-
tients in the placebo group. At 2 weeks follow-up, the corticosteroid injection was statistically 
significant and clinically relevant associated with hip pain reduction at rest (difference -1.3, 
95%CI -2.3 to -0.3) compared to the placebo injection. At 4, 6 and 12 weeks the corticosteroid 
injection was also associated with statistically significant and clinically relevant hip pain 
reduction at rest as well as during walking. Moreover, at almost all follow-up measurements 
the estimates showed statistically significant and clinically relevant differences in favor of the 
corticosteroid injection on WOMAC function, stiffness, and total, and ICOAP. No significant 
differences between groups were found for side effects and quality of life. At 2 weeks follow-
up perceived improvement and the OMERACT-OARSI responders showed a significant effect 
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in favor of corticosteroid injection, OR 2.8 (95%CI 1.3 to 6.4 and OR 3.9 (95% CI 1.2 to 7.2) 
respectively.
We conclude that an intramuscular corticosteroid injection compared to placebo showed 
clinical effectiveness in patients with painful hip OA for at least 12 weeks of follow-up.
Chapter 4 systematically outlines the diagnostic value of intra-articular anesthetic hip 
injection in patients with hip pain atypical for OA. A systematic literature search was con-
ducted until end December 2011. Studies assessing the diagnostic value of anesthetic hip 
injections in differentiating between pain caused by OA or another source were included and 
a meta-analysis was performed. Of the 1387 potentially eligible articles, nine case series with 
high risk of bias were included. The data of seven studies (351 participants) could be pooled 
to calculate pooled estimates of sensitivity, specificity, and likelihood ratios. The pooled 
sensitivity was 0.97 (95% CI 0.87 - 0.99). Pooled specificity was 0.91 (95% CI 0.83 - 0.95). The 
positive likelihood ratio was 10.6 (95% CI 5.6 - 20.1) and the negative likelihood ratio was 0.04 
(95% CI 0.01 - 0.15).
Although all studies used total hip replacement (THR) as reference standard, all studies had 
partial verification bias. In our pooled analyses, 75% of patients that had a good response to 
the diagnostic injection received a THR, compared to 15% of patients that had a negative 
response to the diagnostic injection. We conclude therefore that for clinical practice, no rec-
ommendation can be made regarding the use of hip injections for diagnosing hip OA. High 
quality, accurately reported studies are needed to provide better evidence on the diagnostic 
role of hip injection.
In chapter 5 a cohort study assessing the association between two cartilage biomarker 
and clinical symptoms in patients with hip OA using pain trajectories defined by Latent Class 
Growth Analysis (LCGA) is reported. LCGA is a statistical technique that has the ability to find 
groups of people who are similar in their responses to measured variables, e.g., pain scores. 
We used a longitudinal dataset of patients with hip OA (n=222) where LCGA was applied. 
This resulted in five different pain trajectories over a 2-year period of follow-up, i.e., high 
pain, moderate pain, mild pain, regularly progressive pain and highly progressive pain. We 
selected two biomarkers of interest: uCTXII and uCIIM. Both these markers are derivates of 
type II collagen and degraded by enzymes during cartilage erosion and are excreted in urine.
The objective was to assess associations between uCTX-II or uCIIM and severity of hip pain 
in patients with mild or moderate hip OA over a 2-year period, and establish whether the 
level of these biomarkers at baseline could estimate a specific trajectory of hip pain. Urinary 
biomarkers and symptom severity were measured 6-monthly with a 2-year follow-up. Pa-
tients were recruited from general practices. The primary outcome was hip pain, measured 
with the WOMAC subscale and the Visual Analogue Scale (VAS). LoguCTX-II and loguCIIM 
were not associated with WOMAC pain or VAS pain during the 2-year follow-up. Patients in 
the highly progressive pain trajectory and the moderate pain trajectory were more likely to 
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have a higher loguCTX-II at baseline (OR 6.7; 95% CI 1.6-28.2 and OR 4.8; 95% CI 1.0-22.8, 
respectively) than patients in the mild pain trajectory.
In conclusion in patients with mild or moderate pain due to hip OA the urinary biochemical 
markers uCTX-II and uCIIM are not cross-sectionally associated with hip pain at 6 month-
intervals during the 2-year follow-up.
Chapter 6 starts with a systematic outline of available literature on associations between 
weather conditions and pain in OA. This resulted in 11 studies assessing different weather 
variables, e.g. temperature, barometric pressure, precipitation and relative humidity. None of 
the meteorological variables showed a consistent correlation with patients’ pain in OA. 
Secondly we assessed whether there is an association between ambient weather condi-
tions and patients’ clinical symptoms in patients with hip OA. We used a cohort study with a 
2-year follow-up and 3-monthly measurements and prospectively collected data on weather 
variables. The study population consisted of 222 primary care patients with hip OA. Weather 
variables included temperature, wind speed, total amount of sun hours, precipitation, baro-
metric pressure, and relative humidity. The primary outcomes were severity of hip pain and 
hip disability as measured with the WOMAC pain and function subscales. On the day of ques-
tionnaire completion, mean relative humidity was associated with WOMAC pain (estimate 
0.1; 95% CI 0.0–0.2; p 0.02). Mean barometric pressure was associated with WOMAC function 
(estimate 0.1; 95% CI 0.0–0.1; p 0.02). The other weather variables were not associated with 
the WOMAC pain or function score. However, the contribution of these weather variables in 
the pain score or function score was small. An increase of 10% in relative humidity increased 
the WOMAC pain score by 1 on a scale of 0 to 100. In addition to this, the range of relative 
humidity in our database was 49% to 99%, which corresponds to a maximum change in pain 
score of 5 on a scale of 0 to100. Similarly, for each 10-hPa increase in barometric pressure, the 
WOMAC function score deteriorates by 1 point on a scale of 0 to 100. The range of barometric 
pressure in our database was 980.4 to 1041.7, resulting in a maximum change in function 
score of 6.1 on a scale of 0 to 100. Relative humidity contributed <1% to the explained 
within-patient variance and between-patient variance of the WOMAC pain score. Barometric 
pressure contributed <1% to the explained within-patient variance and between-patient 
variance of the WOMAC function score.
Our results support the general opinion of OA patients that barometric pressure and rela-
tive humidity influence perceived OA symptoms. However, the contribution of these weather 
variables to the severity of OA symptoms was not clinically relevant.
In chapter 7 we investigated the prevalence of Greater Trochanter Pain Syndrome (GTPS) 
in patients with hip OA and whether the co-existence of GTPS is associated with perceived 
hip pain in these patients.
Here we used a cohort of 222 patients with hip OA recruited from general practices with 
a follow-up of 2 year. GTPS was diagnosed by physical examination at baseline and at 2-year 
follow-up. GTPS was defined as tenderness at or around the greater trochanter, recognition 
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of this tenderness as one of the complaints, and a painful resisted hip abduction. Primary 
outcome was hip pain severity measured with the WOMAC subscale for hip pain (0-100; 0 
equals no pain,) and the VAS (0-100; 0 equals no pain). GTPS was present in 32/205 (16%) 
patients at baseline and in 26/184 (14%) patients at follow-up. Eight (4%) patients had GTPS 
at both baseline and follow-up. GTPS was associated with WOMAC pain (estimate 10.2, 95% 
CI 4.3-16.1; p=0.001) and VAS pain (estimate 13.8, 95% CI 7.0-20.6; p<0.001).
In conclusion, one in seven patients with hip OA had concurrent GTPS. Patients with hip OA 
and GTPS showed clinically significant higher hip pain scores than those with hip OA without 
GTPS.
Chapter 8 presents the main findings of this thesis in relation to existing evidence and 
their additional clinical value. Besides we reflect in this chapter on study limitations and their 
implications for daily clinical practice and future research.

Samenvatting (Dutch summary)
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Samenvatting (Dutch summary)
Het doel van het onderzoek beschreven in dit proefschrift was de effectiviteit van een in-
tramusculaire corticosteroïdinjectie bij patiënten met pijnlijke heupartrose te onderzoeken. 
Daarnaast wilden we inzicht krijgen in het pijnbeloop en comorbiditeiten die heupklachten 
beïnvloeden bij patiënten met heupartrose.
In hoofdstuk 2 presenteren wij het studieprotocol van onze dubbelblinde, gerandomi-
seerde, gecontroleerde trial (RCT). Patiënten (> 40 jaar) werden geworven voor ons onder-
zoek als zij pijnlijke heupartrose hadden ondanks gebruik van orale analgetica met een score 
van ≥3 op een 11-punts Numerical Rating Scale (NRS:0-10;0=geen pijn). Patiënten werden 
gescreend op geschiktheid door huisartsen en orthopaedisch chirurgen. Vervolgens werden 
patiënten gerandomiseerd om ofwel 40mg triamcinolonacetaat ofwel placebo (zoutoplos-
sing) te ontvangen via een intramusculaire injectie in de ipsilaterale bilmusculatuur.
De randomisatie was gestratificeerd voor setting (eerstelijn versus tweede lijn). Om zeker 
te zijn van blindering werd iedere patiënt een behandeling toegewezen door een onafhan-
kelijke apothekersmedewerker met behulp van een geautomatiseerde randomisatielijst. Na 
randomisatie werden de flacons voorbereid, verpakt en verzegeld op identieke wijze voor 
beide groepen door de apothekersmedewerker. Een onafhankelijke onderzoekmedewerker, 
die verder niet betrokken was bij de vervolgmetingen, maakte de injecties klaar en diende 
deze toe, buiten het zicht van patiënt, behandeld artsen en onderzoekers.
De primaire uitkomst was ernst van heuppijn na 2 weken, gemeten met een 11-punts 
Numerical Rating Scale (NRS:0-10;0=geen pijn) in rust en tijdens lopen, en met de Western 
Ontario and McMaster University Osteoarthritis Index pijn subschaal (WOMAC pijn: 0-100, 
0=geen pijn). De secundaire uitkomstmaten zijn de primaire uitkomstmaten na 4, 6 en 12 
weken. Andere secundaire uitkomstmaten zijn WOMAC functie, stijfheid en totaalscore, kwa-
liteit van leven (EQ-5D), intermitterende en constante artrose pijn (Intermittent and Constant 
Osteoarthritis Pain (ICOAP)) en het door de patiënt ervaren herstel, gemeten met een 7-punts 
Likert schaal. Statistische analyse was gebaseerd op het intention-to-treat principe. Continue 
uitkomsten werden geanalyseerd met linear mixed models met herhaalde metingen. Dicho-
tome uitkomsten werden geanalyseerd met generalized estimating equations analyses (GEE) 
met herhaalde metingen.
In hoofdstuk 3 laten we de resultaten van bovengenoemde RCT zien. Er werden 107 
patiënten gerandomiseerd, waarvan wij 106 patiënten konden analyseren. De corticosteroïd-
groep bestond uit 52 patiënten, de placebo-groep uit 54 patiënten. Na 2 weken was de 
corticosteroïdinjectie statistisch significant en klinisch relevant geassocieerd met verminde-
ring van heuppijn in rust (verschil -1,3; 95% betrouwbaarheidsinterval (BI) -2,3 tot -0,3) in 
vergelijking met de placebo-injectie. Na 4, 6 en 12 weken was de corticosteroïdinjectie ook 
statistisch significant en klinisch relevant geassocieerd met vermindering van heuppijn in 
rust en tijdens lopen. Bovendien toonde de corticosteroïdinjectie op bijna alle vervolgmo-
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menten een statistisch significant en klinisch relevant verschil voor WOMAC functie, stijfheid, 
totaal en ICOAP. Er werden geen significante verschillen gevonden tussen de groepen voor 
bijwerkingen en kwaliteit van leven. Na 2 weken toonde het ervaren herstel en de OMERACT-
OARSI responders een significant effect ten faveure van corticosteroïdinjectie (OR 2,8 (95%BI 
1,3 tot 6,4 respectievelijk OR 3,9 (95%BI 1,2 tot 7,2).
We concluderen dat een intramusculaire corticosteroïdinjectie vergeleken met een 
placebo-injectie klinisch effectief is voor patiënten met pijnlijke heupartrose gedurende 
minimaal 12 weken.
In Hoofdstuk 4 bekeken we met een systematisch literatuur overzicht de diagnostische 
waarde van intra-articulaire heupmarcaïnisatie voor patiënten met heuppijn die atypisch 
is voor artrose. Literatuur werd systematisch doorzocht tot eind december 2011. We inclu-
deerden artikelen van studies die de diagnostische waarde van intra-articulaire heupmar-
caïnisatie onderzochten en voerden een meta-analyse uit. Van de 1387 potentieel geschikte 
artikelen werden 9 artikelen geïncludeerd die 9 case series met hoog risico op vertekening 
beschreven. De gegevens van 7 onderzoeken met in totaal 351 patiënten konden worden 
samengevoegd om gepoolde schatters van sensitiviteit, specificiteit en likelihood ratios te 
berekenen. De gepoolde sensitiviteit was 0.97 (95%BI 0.87 tot 0.99). De gepoolde specificiteit 
was 0.91 (95%BI 0.83 tot 0.95). De positieve likelihood ratio was 10.6 (95%BI 5.6 tot 20.1) en 
de negatieve likelihood ratio 0.04 (95%BI 0.01 tot 0.15).
Hoewel alle onderzoeken totale heupprothese (THP) als referentie standaard gebruikten, 
hadden alle onderzoeken gedeeltelijke verificatie bias. In onze gepoolde analyses kreeg 75% 
van de patiënten met een goede respons op de diagnostische injectie een THP, vergeleken 
met 15% van de patiënten met een negatieve respons op de diagnostische injectie. We 
concluderen daarom dat er voor de klinische praktijk geen aanbeveling gedaan kan worden 
over het gebruik van heupmarcaïnisatie om heupartrose te diagnosticeren. Onderzoek met 
een laag risico op vertekening is nodig om de diagnostische rol van heupmarcaïnisatie nader 
te bepalen.
In hoofdstuk 5 wordt een cohortonderzoek besproken waarin de associatie tussen 2 
kraakbeen biomarkers en klinische symptomen van patiënten met heupartrose is bestu-
deerd. Hiervoor werd gebruik gemaakt van pijntrajecten gedefinieerd door een Latent Class 
Growth Analysis (LCGA). Dit is een statistische techniek die groepen maakt van mensen die 
gelijk zijn in hun respons op gemeten variabelen, bijvoorbeeld pijnscores. We hebben een 
longitudinale dataset van patiënten met heupartrose (n=222) gebruikt waarop LCGA was 
toegepast. Dit resulteerde in 5 verschillende pijntrajecten gedurende een periode van 2 
jaar follow-up. Het betreft: veel pijn, matige pijn, milde pijn, geleidelijk toenemende pijn 
en snel toenemende pijn. Beide onderzochte kraakbeen biomarkers, uCTXII en uCIIM, zijn 
afbraakproducten van type II collageen en worden enzymatisch afgebroken tijdens kraak-
beenslijtage. Beiden worden uitgescheiden via de urine.
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Het doel van dit onderzoek was de associatie te onderzoeken tussen uCTX-II of uCIIM en 
de ernst van heuppijn bij patiënten met milde tot matige heupartrose gedurende 2 jaar 
follow-up. Daarnaast onderzochten wij of de hoogte van deze biomarkers aan het begin van 
het onderzoek een specifiek pijntraject kon voorspellen. Biomarkers gemeten in de urine 
en ernst van de symptomen werd elke 6 maanden gemeten gedurende 2 jaar. Patiënten 
werden geworven via huisartspraktijken. De primaire uitkomst was heuppijn, gemeten met 
de WOMAC pijnschaal en de Visual Analogue Scale (VAS).
LoguCTX-II en loguCIIM waren niet geassocieerd met WOMAC pijn of VAS tijdens de 2 jaar 
follow-up. Patiënten in het snel toenemende pijntraject en patiënten in het matige pijntra-
ject hadden vaker een hoge loguCTX-II aan het begin van het onderzoek OR 6.7; 95%BI 1.6 
tot 28.2 en OR 4.8; 95%BI 1.0 tot 22.8, respectievelijk) dan patiënten in het milde pijntraject.
Concluderend, bij patiënten met milde tot matige pijn door heupartrose zijn de biomarkers 
uCTX-II en uCIIM niet cross-sectioneel geassocieerd met heuppijn gedurende 2 jaar follow-
up met intervallen van 6 maanden.
Hoofdstuk 6 begint met een systematische samenvatting van de literatuur over associa-
ties tussen weercondities en pijn bij patiënten met artrose. Dit resulteert in 11 onderzoeken 
die verschillende weersvariabelen bestuderen zoals temperatuur, barometerdruk, neerslag 
en relatieve luchtvochtigheid. Geen enkele van deze meteorologische variabelen laat een 
consistente correlatie zien met pijn bij artrosepatiënten. 
Vervolgens hebben we gekeken of er een associatie is tussen weersvariabelen en klini-
sche symptomen van patiënten met heupartrose. Hiervoor gebruikten we een cohort met 
2 jaar follow-up en 3-maandelijkse metingen en prospectief verzamelde gegevens over 
weersvariabelen. De studiepopulatie bestond uit 222 eerstelijns-patiënten met heupartrose. 
De bestudeerde weersvariabelen waren temperatuur, windsnelheid, totale hoeveelheid zon-
uren, neerslag, barometerdruk en relatieve luchtvochtigheid. De primaire uitkomsten waren 
de ernst van heuppijn en de heupfunctie gemeten met de WOMAC pijn en WOMAC functie 
vragenlijsten. Op de dag van invullen van de vragenlijst was WOMAC pijn geassocieerd met 
relatieve luchtvochtigheid (schatter 0.1; 95%BI 0.0 tot 0.2; P .02). De bijdrage van de weersva-
riabele aan de pijnscore was echter klein. Een toename van 10% in relatieve luchtvochtigheid 
gaf een toename van de WOMAC pijnscore van 1 op een schaal van 0 tot 100. Bovendien, was 
de range van relatieve luchtvochtigheid in onze data tussen de 49% en 99%, wat overeen-
komt met een maximum verschil in pijnscore van 5 op en schaal van 0 tot 100.
Gemiddelde barometerdruk was geassocieerd met WOMAC functie (schatter 0.1; 95%BI 0.0 
tot 0.1; P .02). Ook voor barometerdruk geldt dit kleine verschil. Voor elke 10 hPa toename in 
barometerdruk, verslechtert de WOMAC functiescore met 1 punt op een schaal van 1 tot 100. 
De range van barometerdruk in ons databestand was 980.4 tot 1041.7, wat resulteert in een 
maximum verschil in functiescore van 6.1 op een schaal van 0 tot 100.
Relatieve luchtvochtigheid droeg <1% bij aan de verklaarde binnen-patiënt variantie en 
tussen-patiënt variantie voor de WOMAC pijnscore. Barometerdruk droeg <1% bij aan de ver-
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klaarde binnen-patiënt variantie en tussen-patiënt variantie voor de WOMAC functiescore. 
De andere weersvariabelen waren niet geassocieerd met WOMAC pijn of WOMAC functie.
Onze resultaten ondersteunen de algemene opinie van patiënten met artrose dat baro-
meterdruk en relatieve luchtvochtigheid de symptomen van artrose beïnvloeden. Maar de 
bijdrage van deze weersvariabelen aan de ernst van symptomen van artrose was klinisch 
niet relevant.
In hoofdstuk 7 onderzochten we de prevalentie van het Trochanter Major Pijn Syndroom 
(ook wel Greater Trochanter Pain Syndrome (GTPS) genoemd) bij patiënten met heupartrose. 
Daarnaast bestudeerden we of aanwezigheid van GTPS geassocieerd is met heuppijn bij 
patiënten met heupartrose.
Hiervoor gebruikten we een cohort van 222 patiënten met heupartrose die geworven 
waren in de huisartsenpraktijk. Deze patiënten werden 2 jaar gevolgd. GTPS werd gediagnos-
ticeerd door lichamelijk onderzoek aan het begin van het onderzoek en na 2 jaar follow-up. 
GTPS werd gedefinieerd als gevoeligheid op of rond het trochanter major, herkenning van de 
gevoeligheid als een van de klachten en pijnlijke heupadbuctie tegen weerstand in. Primaire 
uitkomst was ernst van de heuppijn gemeten met de WOMAC pijn subschaal (0-100; 0 = geen 
pijn) en de VAS (0-100; 0 = geen pijn).
GTPS was aanwezig in 32/205 (16%) patiënten bij het begin van het onderzoek en in 
26/184 (14%) van de patiënten na 2 jaar follow-up. Acht (4%) patiënten hadden GTPS zowel 
bij begin van het onderzoek als na 2 jaar. GTPS was geassocieerd met WOMAC pijn (schatter 
10,2; 95%BI 4.3 tot 16.1; p 0.001) en VAS pijn (schatter 13.8, 95%BI 7.0 tot 20.6; p<0.001).
Concluderend, één op de zeven patiënten met heupartrose had tegelijkertijd GTPS. Pati-
enten met heupartrose en GTPS hadden klinisch significant hogere pijnscores dan patiënten 
met heupartrose zonder GTPS.
In hoofdstuk 8 zijn de belangrijkste bevindingen van dit proefschrift uiteengezet in relatie 
tot de bestaande literatuur en hun toegevoegde waarde hierop. Daarnaast wordt er in dit 
hoofdstuk gereflecteerd op de beperkingen van het onderzoek en de implicaties voor de 
praktijk en toekomstig wetenschappelijk onderzoek.
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Dankwoord
Onderzoek doe je niet alleen en ik heb de afgelopen jaren met veel mensen mogen samen-
werken. Graag wil ik iedereen bedanken die een bijdrage heeft geleverd aan dit proefschrift. 
Een aantal mensen wil ik in het bijzonder bedanken.
Mijn promotor, prof. dr. SMA Bierma-Zeinstra. Beste Sita, dank dat je mij, met destijds vooral 
klinische ervaring, op dit onderzoeksproject durfde aan te nemen. Jij hebt mij laten zien dat 
onderzoek doen ongelofelijk leuk is. Dankzij jouw voortvarende aanpak lagen er na 2,5 jaar 
4 manuscripten. Dank ook dat je me de tijd hebt gegeven voor het afronden van HOCI naast 
mijn opleiding.
Mijn copromotoren, dr. PAJ Luisterburg en dr. PK Bos.
Beste Pim, dank voor je begeleiding van mijn promotietraject. Je hebt mij de ruimte ge-
geven tijdens mijn onderzoek, maar daarnaast was je laagdrempelig beschikbaar als ik vast 
liep. Je nuchtere adviezen zorgden altijd weer voor genoeg voortgang in het geheel. Dank 
ook dat je de laatste 3 jaar zoveel ‘over de mail’ hebt willen doen. Ik heb onze samenwerking 
als zeer prettig ervaren.
Beste Koen, grote dank voor je klinische blik. Fijn dat jij in je commentaar op mijn ma-
nuscripten altijd weer vroeg: ‘maar wat heeft de clinicus hier nu aan’. Dit heeft de artikelen 
beter leesbaar en praktischer toepasbaar gemaakt. Dank ook voor het tussen de bedrijven 
door scoren van alle röntgenfoto’s voor HOCI. Ik hoop dat we in de toekomst nog een mooi 
hip-spine cohort kunnen opzetten.
Collega’s van de afdeling huisartsgeneeskunde; een grote groep onderzoekers, onder-
zoeksmedewerkers en AIOTHO’s. Dank voor de gezelligheid, de maandag-lunch-haal-
wandelingen naar de Appie, de vele koffie- en zelfgebakken taart-momenten, de ijsjes op het 
Westzeedijkbalkon en de mooie nevenactiviteiten tijdens congressen.
Speciale dank aan Rianne R. voor het gebruik van de GOAL data en je altijd snelle antwoord 
op mijn vragen over GOAL. Ook dank aan Rianne vd H. voor het waarnemen van de honneurs 
tijdens mijn verlof.
Marlous, Saskia, Jantine en Pauline, jullie onderzoeken liepen al toen ik begon. Dank voor 
alle voorbeelden die ik van jullie mocht lenen: van METC-aanvraag tot query voor internet-
vragenlijst.
Mijn kamergenoten straatzijde van de eerste kamer van de WZD: Marienke, Gijs en Marijke, 
dank voor de gezellige breaks tijdens het onderzoek doen.
Marlies, dank voor je secretariële ondersteuning tijdens mijn project. Jan, dank voor je tijd 
en uitleg over internetvragenlijsten, datasystemen, databeheer en query’s.
Mariet, dank voor je inzet voor het HOCI-project. Includeren bij huisartsen, dubbel-blinde 
injecties toedienen, administratie of het controleren van steekproeven, als er een SOPje van 
was, ging jij aan de slag. Fijn ook dat je samen met Metthilde het HOCI project zo goed hebt 
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voorgezet na mijn vertrek. Dank ook voor je interesse in het thuisfront. Geniet van je (pre)
pensioen samen met Dre.
Beste prof. Verhaar, dank dat ik wekelijks een deel van mijn onderzoekstijd mocht door-
brengen bij de klinisch onderzoekers orthopaedie. Dit is de voortgang van het HOCI-project 
zeker ten goede gekomen. Dank ook voor suggesties en kritische blik op mijn manuscripten.
Collega’s van de afdeling klinisch onderzoek orthopaedie. Belle, Vincent, Eline, Max, Guus, 
Tijs, Job, Maaike, dank voor jullie gastvrijheid in HS-104 en het ortho-biebje. Ik heb het enorm 
naar mijn zin gehad op mijn woensdag ortho-dag. Hard werken werd bij jullie afgewisseld 
met de nodige humor, voetbal-weetjes, gezellige etentjes en sportieve uitjes.
Belle, fijn dat je nu helemaal op je plek bent bij de sportgeneeskunde. Naast een harde 
werker ben je zeer sociaal en altijd bereid om te helpen.
Vincent, lotgenoot als het gaat om tegenvallende inclusies. Dank voor je gezelligheid, 
goede koffie en relativeringsvermogen (‘kaftje erom en klaar’). Mijn kaftje zit erom, hopelijk 
volgt die van jou ook snel.
Eline, dank voor je hulp bij logistieke zaken. Jouw kennis van de juiste wegen op de polikli-
niek orthopaedie zorgde ervoor dat ik op de goede plek mijn HOCI-bakje kreeg.
Guus, ik was er meestal als jij er niet was. Dus vooral dank voor het gebruik maken van je 
bureau.
Tijs, Job en Maaike, dank voor de gezelligheid. Max, dank voor je adviezen over multicenter 
onderzoek en je kritische blik op het HOCI-onderzoek.
Orthopaeden Isala Zwolle: dr. Verheijen, dr. Zuurmond, dr. Tulp, dr. Mostert, dr. Janus, dr. 
Ettema, drs. van Solinge en drs. van Egmond. Dank voor jullie interesse in mijn promotietra-
ject en de tijd die ik voor de afronding hiervan heb gekregen. Dank ook voor het prettige 
opleidingsklimaat.
Orthopaedie collega’s Zwolle: Arjan, Arina, Chris, Edwin, Erwin, Frank, Jelle, Jeroen, Nienke, 
Maurits, Marije, Patricia, Paul, Rob, Stefan, Thomas, Wybren, Wouter, Wietse. Een mooie en 
gezellige groep. Dank voor jullie interesse, support, tips om mijn presentaties te verbeteren 
en luisterende oren. Arina, dank voor de tip voor de voorkant van dit boekje.
Dit proefschrift kan niet verdedigd worden zonder de steun van mijn paranimfen.
Metthilde, dank voor al het werk dat je hebt verzet voor het HOCI-project. Ik besef goed dat 
ik het enorm getroffen heb met een ervaren onderzoeksassistente. Dankzij jou kon ik al snel 
de administratie rondom HOCI los laten en gaan werken aan andere dingen. Fantastisch hoe 
jij en Mariet het project zo hebben voortgezet na mijn vertrek. Dank ook voor je gezelligheid, 
nuchtere kijk en ‘moederlijke’ adviezen over van alles. Fijn dat je naast me wilt staan tijdens 
mijn promotie. De stellingen zijn in het Nederlands, dus maak je daarover geen zorgen!
Jeroen, mijn ‘kleine’ broer. Dank voor alle kopjes thee die je in Breda na het tennissen kwam 
halen. Dank ook voor je rust als ik weer eens doordraaf. Ik vind het mooi hoe je samen met 
Nienke je toekomst uitstippelt. Hoewel we tegenwoordig wat verder uit elkaar wonen blijven 
we elkaar hopelijk vaak zien.
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Pap en mam, jullie hebben me alle mogelijkheden en vrijheid gegeven met te ontwikkelen. 
Bedankt voor jullie steun bij mijn keuzes. Mam, dank voor het tijdelijke, gezellige, onderdak 
en het oppassen op Annemarijn tijdens mijn laatste maanden in Rotterdam. Sietske, mijn 
kleine zusje, fantastisch dat jij de grote reizen, waar ik stiekem van droom, gewoon maakt.
Henk en Nel, ik heb geluk met schoonouders zoals jullie. Dank voor de oppasdagen op de 
kleintjes, zodat ik meters kon maken.
Alle (schoon)familie en vrienden, gelukkig is er meer dan alleen onderzoek doen. Dank 
voor de nodige afleiding en gezelligheid.
Maarten, dank voor je onvoorwaardelijke steun, liefde, humor en relativeringsvermogen. 
Dank ook dat je af en toe op de rem trapt. Ik geniet van elk moment samen. Piu bella cosa.
Annemarijn, mamma vindt het heel gezellig als jij op zolder komt kleuren of spelen terwijl 
ik druk ben op de ‘konkjoeter’. Floris, jouw vrolijkheid is aanstekelijk. Lieve Annemarijn en 
Floris, mamma’s boek is natuurlijk ongelofelijk saai: veel tekst, weinig plaatjes. Misschien 
lezen jullie het later eens, als jullie groot zijn. Vanavond lees ik jullie gewoon weer voor uit 
Kikker, Pluk of Floddertje.
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Curriculum Vitae
Desirée Maria Johanna Dorleijn is op 16 juli 1982 geboren in Vlissingen. Na het behalen van 
haar gymnasium diploma aan de Christelijke Scholengemeenschap Walcheren in Middelburg 
begon zij in 2000 met de studie geneeskunde aan de Universiteit Utrecht.
Na afronding van haar studie in 2006 werkte zij als arts-assistent op de spoedeisende hulp 
en bij de chirurgie en orthopaedie in verschillende ziekenhuizen (Beatrixziekenhuis, UMC St 
Radboud, Tweesteden Ziekenhuis, IJssellandziekenhuis).
In januari 2011 begon zij als promovendus aan het Erasmus Medisch Centrum onder su-
pervisie van prof. dr. S.M.A. Bierma-Zeinstra. Zij werkte aan de in dit proefschrift beschreven 
projecten over heupartrose, waaronder het HOCI-onderzoek. Dit is een gerandomiseerd, 
gecontroleerd onderzoek bij patiënten met heupartrose naar het systemisch effect van 
corticosteroïden op pijnklachten.
In oktober 2013 startte zij haar vooropleiding chirurgie in de Isala te Zwolle (opleider dr. 
S.H. van Helden). Sinds oktober 2015 werkt zij als AIOS orthopaedie in Isala (opleider dr. 
C.C.P.M. Verheijen, Isala; prof. dr. S.J. Bulstra, UMC Groningen). Zij vervolgt haar opleiding per 
januari 2017 in het Medisch Centrum Leeuwarden (opleider dr. P.C. Rijk).
Daarnaast is zij sinds januari 2016 lid van de ledenraad van de ANWB. Desirée is getrouwd 
met Maarten Kiel en samen hebben zij 2 kinderen: Annemarijn en Floris.
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Summary of PhD training and teaching
Name PhD student: Desirée Dorleijn
Erasmus MC Department: General Practice
Research school:  NIHES
PhD period:   2011-2016
Supervisor:   Prof.dr. S.M.A. Bierma-Zeinstra
Co-supervisors:   Dr. P.A.J. Luijsterburg
   Dr. P.K. Bos
PhD Training Year Workload
Hours / ECTS
Courses
Course Endnote, Erasmus MC Library 2011 2 hours
Course systematic literature search, Erasmus MC Library 2011 2 hours
Good Clinical Practice (BROK) 2011 30 hours
Introduction to clinical research, NIHES 2012 0.9 ECTS
Biostatistics for clinicians, NIHES 2012 1.0 ECTS
Regression analysis for clinicians, NIHES 2012 1.9 ECTS
Courses for the quantitative researcher, NIHES 2012 1.4 ECTS
Repeated Measurement, NIHES 2012 1.4 ECTS
Biomedical English Writing and Communication 2012 4.0 ECTS
Recertification Good Clinical Practice 2015 4 hours
Seminars and workshops
Minisymposium ‘Methodologie van patiëntgebonden onderzoek en 
voorbereiding van subsidieaanvragen’
2011 8 hours
PhDay: Get the best out of your PhD 2011 4 hours
Presentations
Oral
NOF, 56th Northern Orthopaedic Federation Congress, Tallinn, Estland 2012 20 hours
ROGO-dag Rotterdam, Rotterdam 2012 10 hours
NOF, 58th Northern Orthopaedic Federation Congress, Linkoeping, Sweden 2016 20 hours
Dutch Orthopaedic Association ‘NOV’ najaarsvergadering, Veldhoven 2016 20 hours
Poster
OARSI, world congress on Osteoarthritis, San Diego, USA 2011 16 hours
OARSI, world congress on Osteoarthritis, Philadelphia, USA 2013 16 hours
OARSI, world congress on Osteoarthritis, Amsterdam, the Netherlands 2016 16 hours
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Supervising ‘critical appraisal of biomedical article for medical students’ (3 times) 2012, 2013 9 hours
Supervising medical student writing letter-to-the-editor 2012 2 hours
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Hip OsteOartHritis
Heupartrose is een veelvoorkomende, chronisch ziekte die 
vooral voorkomt bij oudere patiënten. Vaak treden pijn 
en stijfheid van de heup op. Omdat heupartrose nog niet 
te genezen is, bestaat de behandeling uit bestrijden van 
symptomen. In dit proefschrift wordt de effectiviteit van 
een corticosteroïdinjectie in vergelijking tot een placebo-
injectie in de bilspier beschreven bij patiënten met pijnlijke 
heupartrose. Daarnaast wordt er inzicht gegeven in het 
pijnbeloop en comorbiditeiten die heupklachten beïnvloe-
den bij patiënten met heupartrose.
Desirée Dorleijn werd geboren op 16 juli 1982 
te Vlissingen. De studie geneeskunde volgde 
zij aan de Universiteit Utrecht. Na het beha-
len van haar arts-examen werkte zij als arts-
assistent op de afdelingen spoedeisende hulp, 
chirurgie en orthopaedie. In 2011 startte zij aan 
het Erasmus Medisch Centrum met onderzoek 
onder patiënten met heupartrose afkomstig 
van huisartsen en orthopaeden. In een geblin-
deerde gerandomiseerde studie onderzocht zij 
of een corticosteroïdinjectie in de bilspier een vermindering van 
pijn geeft bij deze patiënten. Dit onderzoek vormde de basis van 
dit proefschrift. Zij is vanaf 2013 in opleiding tot orthopaedisch 
chirurg in het Isala ziekenhuis te Zwolle.
